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ABSTRACT 
The NADPH oxidase homolog, dual oxidase 1 (DUOX1), is an H2O2 producing 
transmembrane enzyme highly expressed in the airway epithelium. DUOX1-dependent 
redox signaling has been characterized to regulate many homeostatic processes in the lung 
epithelium, such as host defense, wound healing, and type II immune responses. 
Intriguingly, DUOX1 has been found to be suppressed in many epithelial cancers, 
including lung cancer, by hypermethylation of its promoter. Epigenetic silencing of 
DUOX1 in cancer is paradoxical to the understanding that tumors harbor elevated levels 
of reactive oxygen species (ROS), suggesting that DUOX1 may be a tumor suppressor.  
Since DUOX1 loss occurs in many forms of lung cancer, we aimed to characterize 
the functional importance of DUOX1 suppression. RNAi-mediated knockdown of DUOX1 
in lung epithelial cells induced features of the epithelial-to-mesenchymal transition (EMT), 
a characteristic of aggressive or invasive tumor cells. Indeed, DUOX1 suppression 
promoted the acquisition of molecular signatures associated with EMT, such as the loss of 
E-cadherin, and induced expression of vimentin and smooth muscle actin. Additionally, 
we find that DUOX1 suppression promotes the acquisition of other EMT-related features, 
such as enhanced levels of cancer stem cell molecular markers, cellular invasiveness, and 
critically, resistance to epidermal growth factor receptor (EGFR) inhibition. Importantly, 
overexpression of DUOX1 in DUOX1-lacking lung cancer cells promoted the recovery of 
epithelial characteristics, pinning DUOX1 as a critical mediator of the epithelial phenotype.  
 Based on prior studies demonstrating DUOX1 as an important regulator of EGFR 
signaling in the lung epithelium, we hypothesized that DUOX1 loss in lung cancer may 
impact EGFR regulation.  EGFR belongs to a larger family of ErbB receptor tyrosine 
kinases, which are often overexpressed or mutated in many forms of lung cancer. 
Surprisingly, we find that lung cancer cells lacking DUOX1 have significantly altered 
EGFR redox regulation, specifically, kinetically enhanced cysteine oxidation-reduction 
dynamics. Additionally, our results demonstrate DUOX1-lacking cancer cells have altered 
intracellular EGFR trafficking with enhanced nuclear targeting. Indeed, we observe many 
oncogenic features of nuclear EGFR e.g. enhanced migratory capacity, resistance to EGFR 
blocking antibodies. Finally, we have uncovered that EGFR cysteine redox dynamics may 
regulate intracellular trafficking and/or nuclear transport, offering potentially novel 
avenues in the design of therapeutics. 
 Proper DUOX1 localization and enzymatic function in the plasma membrane 
requires partnership with its maturation factor, dual oxidase maturation factor 1 
(DUOXA1). Preliminary findings from a newly designed DUOX1-DUOXA1 co-
expression system suggests that following enzymatic activation of DUOX1, DUOXA1 
dissociates from DUOX1 and potentially translocates to the nucleus, a feature not 
previously described in lung epithelial or cancer cells. While these preliminary results 
require additional experimentation, this could be a unique regulatory feature of DUOX1 
and a novel role for DUOXA1.  
 Collectively, the research demonstrated in this dissertation characterizes the 
functional and mechanistic importance of DUOX1 suppression in cancer. Indeed, loss of 
DUOX1 expression may be an indicator of tumor aggressiveness and responsiveness to 
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1 
CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
1.1. Lung Cancer 
Lung cancer is the leading cause of cancer-related mortalities in both men and women in 
the United States, and worldwide(Siegel, Miller and Jemal; Ferlay et al.). Approximately 
150-160,000 Americans will succumb to lung cancer each year, accounting for nearly 27 
percent of all cancer deaths(Siegel, Miller and Jemal). Today, roughly 415,000 Americans 
currently live with a diagnosed form of lung cancer, and each year, approximately 225,000 
new cases will be detected(Siegel, Miller and Jemal). Lung cancer, like many other forms 
of cancer, is a disease of the elderly, with nearly 80 percent of lung cancer patients over 
the age of 60(Ferlay et al.; Siegel, Miller and Jemal; Torre, Siegel and Jemal). Older age 
of diagnosed patients undoubtedly contributes to the mortality of lung cancer, despite this 
more than half of people with lung cancer will die within one year of diagnosis. 
Additionally, the five-year survival rate of lung cancer is abysmally low, around 17 
percent, compared to much higher numbers in cancers of other tissues e.g. colon (64 
percent), breast (90 percent) and prostate (99 percent)(Siegel, Miller and Jemal; Torre, 
Siegel and Jemal). These statistics are independent of smoking status, which remains as 
the primary cause of small cell (SCLC) and non-small cell (NSCLC) lung cancers. 
Astoundingly, smoking is currently considered to directly cause nearly 90 percent of lung 
cancer related deaths, claiming approximately 130,000 lives each year(Alberg, Shopland 
and Cummings). Men who smoke have a greater than 20 percent chance, and women, 
greater than 10 percent chance of developing lung cancer than their non-smoking 
counterparts(Alberg, Shopland and Cummings). Smoking is not the only environmental 
hazard known to be a causative agent in the development of lung cancer, as occupational 
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exposure to radon, asbestos, and elevated levels of outdoor air pollution, have shown to 
significantly enhance incidence of lung cancer(Alberg and Samet; Siegel, Miller and 
Jemal; Torre, Siegel and Jemal) 
Non-small cell lung cancer comprises nearly 85 percent of all lung cancers, thus 
many studies have been performed in attempt to better understand the molecular 
mechanism that drive progression of the disease(Z. Chen et al.). NSCLC can be further 
subtyped into adenocarcinoma (ADC) and squamous cell carcinoma (SCC) based on their 
histological makeup and distinct molecular markers (e.g. cytokeratin 5/6 for SCC; thyroid 
transcription factor 1, keratin 7 for ADC), comprising roughly 50 and 40 percent of all 
NSCLCs, respectively(Z. Chen et al.; Errico). Additionally, genetic mutations and 
significant genomic alterations accompany each subtype of NSCLC, lending to its vast 
heterogeneous molecular composition (Fig. 1.1). Of the common genetic abnormalities in 
lung tumors are mutations or alterations to receptor tyrosine kinases e.g. epidermal growth 
factor receptor (EGFR) or fibroblast growth factor receptor 1 (FGFR1), signaling pathways 
associated with cell survival or growth e.g. KRAS, and/or tumor suppressor genes e.g. 
TP53(Z. Chen et al.; Errico; J. Zhang et al.). Heterogeneity not only exists in the tumor 
cells themselves, but also in the tumor microenvironment, a diverse landscape of 
interacting cells, blood vessels, and components of the extracellular matrix (ECM)(Z. Chen 
et al.; Murdoch et al.). Collectively, diversity and heterogeneity across the various subsets 







Figure 1.1 - The molecular signatures of lung cancers are diverse and 
heterogeneous. Among the three most common forms of lung cancer, various 
molecular abnormalities can occur (top panel - copy number alterations; bottom 




1.1.1 Lung Cancer Staging 
Treatment regiments for lung cancer are largely dependent on tumor staging and the 
molecular subtype of the tumor. Early stage lung tumors (e.g. stage 0/I/II) often undergo 
surgical resection, in nearly 70 percent of patients(Miller et al.). Although in early stage 
lung cancer patients that are at a higher risk of tumor resurgence, which is primarily 
dependent on location, size, and/or molecular signatures, surgery can be coupled to 
regiments of adjuvant chemotherapy(Howington et al.; Miller et al.). As lung tumors 
advance in staging, surgery as a primary treatment option becomes less and less applicable. 
Stage III lung cancers are divided into two separate classes, stage IIIA and IIIB, with the 
primary difference between the two being the size, location, and potential for surgery. 
Stage IIIA tumors are classified as having spread to nearby lymph nodes, usually on the 
same side of the chest, and can sometimes be targeted for surgery, often combined with 
radiation and chemotherapy. Stage IIIB lung tumors have spread to the lymph nodes on the 
opposing side of the chest and is more advanced than stage IIIA, and are not suitable for 
surgery. Treatment options for stage IIIB tumors are chemotherapy and radiation, and/or 
targeted therapies against ‘driver’ oncoproteins. Stage IV lung tumors are the most difficult 
to treat, as they have metastasized to other regions of the body, including but not limited 
to the bone, brain, breast, or liver. Treatment of stage IV lung cancer includes surgery, 
chemotherapy, targeted therapies, immunotherapies, and radiation. While these treatments 
are aimed to either improve quality of life, or prolong life, they offer little promise in fully 




Low five-year survival rates for lung cancer, compared to other cancers, speaks to the lack 
of available, effective therapeutics. Poor efficacy in treatment of lung cancer is primarily 
due to the fact that lung cancers are generally not diagnosed in their early stages, as early 
stage lung tumors are often asymptomatic(Miller et al.). As patients start to present with 
features of lung cancer, e.g. blood in cough, chest pain, etc, they are diagnosed with a later 
stage (e.g. III/IV) lung tumor, limiting treatment options. This speaks to the need and 
importance of preventative screening, as five-year survival rates for early stage lung cancer 
are drastically better than their late stage counterparts, roughly 55 percent for localized 
disease versus 4 percent in distant stage disease(Miller et al.). Regardless, many patients 
will still present with late stage lung cancer, and the fact remains that effective treatment 
options are limited. This is largely due to the vastly heterogeneous molecular landscape of 
human lung tumors, making targeted therapeutics extremely challenging.  
 
1.1.2  Molecular Mutations and Targeted Treatments in Lung Cancer 
Patients that harbor proteins with oncogenic ‘driver’ mutations (e.g. EGFR; TP53: ALK) 
also called activating mutations, can be treated with inhibitors that specifically target these 
proteins (Gridelli et al.).  Interestingly, treatment of lung cancer patients with EGFR 
tyrosine kinase inhibitors (TKIs) in 2003(Fukuoka et al.), predated our knowledge of these 
activating mutations(Siegelin and Borczuk). Despite this, treatment of unselected patient 
populations with the EGFR-TKI, gefitinib, still resulted in a nearly 20 percent positive 
response rate, suggesting a subpopulation of patients were suitable for EGFR-TKI 
therapies(Siegelin and Borczuk). This led to studies in 2004 which uncovered that certain 
EGFR mutations rendered patients sensitive to EGFR-TKIs, specifically gefitinib(Lynch 
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et al.). This seminal report defined three unique point mutations (e.g. G719C, L858R and 
L861Q) and in-frame deletions in exon 19 (ΔE747-A750, ΔL747-T751inS, and ΔL747-
P753inS) which occurred in a heterozygous fashion, significantly associated with 
sensitivity to EGFR-TKI(Lynch et al.). The eventually led to patients with EGFR activating 
mutations being prescribed first generation EGFR-TKIs erlotinib/gefitinib, as a second line 
therapy following standard chemotherapy(Camidge, Pao and Sequist; Gridelli et al.). 
Although, there are some reports which suggest utilization of EGFR TKIs for prospective 
patients as a first line treatment are superior to standard platinum-based 
chemotherapy(Mok, Yang and Lam). Patients that are placed on EGFR-TKIs usually 
experience a positive tumor response rate, at times as high as 86 percent, prolonged 
survival, and overall improved quality of life(Camidge, Pao and Sequist; Gridelli et al.). 
Despite these encouraging statistics, most patients will develop resistance to EGFR TKIs, 
primarily due to an acquired mutation (T790M) in the EGFR kinase domain, changing the 
binding affinity for ATP and diminishes its sensitivity to competitive inhibition (Camidge, 
Pao and Sequist; Neel and Bivona). The EGFR T790M mutation has been aptly named the 
‘gatekeeper mutation’ due to its prevalence in patients with acquired resistance, responsible 
for nearly 60 percent of all EGFR-TKI acquired resistance mechanisms(Neel and Bivona). 
These primary findings in 2005 ignited the design of second generation irreversible EGFR 
inhibitors (e.g. afatinib, dacomitinib, neratinib) which in addition to targeting EGFR 
activating mutations, now recognized EGFR T790M+ tumors, which first were introduced 
in 2009 (Sullivan and Planchard; Chong and Janne). These second-generation inhibitors 
offered significant promise in a laboratory setting, although clinically, was not as effective 
against T790M+ and harbored higher levels of cytotoxicity(Lecia V. Sequist et al.; 
 
7 
Reckamp et al.). The consensus from these and other clinical trials defined the need for 
more specific inhibition of T790+ tumors. This has led to the design of third generation 
EGFR-TKIs, with two therapies currently approved for clinical use (osimertinib and 
olmutinib) and several others in development and/or in clinical phase trials(Sullivan and 
Planchard). While secondary mutations in EGFR gene are the primary mode of acquired 
resistance to EGFR-TKIs, other mechanisms have been defined over the past ~12 years. 
For instance, oncogenic mutations found in KRAS have been found to promote resistance 
to erlotinib(Pao et al.). Other resistance mechanisms exist such as MET 
amplification(Gridelli et al.; Neel and Bivona) and the epithelial-to-mesenchymal 
transition (EMT)(Singh and Settleman; Thomson, Buck, et al.), which is discussed in 
greater detail later in section 1.3. 
 
1.2. The Epidermal Growth Factor Receptor 
EGFR is a member of the ErbB (HER) family of receptor tyrosine kinases, which are 
transmembrane proteins that are activated via its interaction with their cognate ligands to 
induce homo- or hetero-dimerization, thereby activate intrinsic tyrosine kinase activity and 
a range of signaling cascades that regulate a diverse array of cellular functions, such as 
differentiation, cytoskeletal arrangement, and cell migration(Lemmon, Schlessinger and 
Ferguson). Although the EGFR family is mostly considered in the context of cancer, they 
are broadly expressed(Yarden and Sliwkowski) and play significant roles in a vast number 
of normal physiological regulatory pathways(Lemmon, Schlessinger and Ferguson). This 
is supported by the fact that many of the ErbB knockouts in mouse models are embryonic 
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lethal (Sibilia et al.). Detailed below are the basics of EGFR biology, structure, and 
function, and how some of these properties are altered in cancer.   
 
1.2.1. Basic Aspects of EGFR Biology 
EGFR is primarily regulated by at least seven activating ligands in humans(Lemmon, 
Schlessinger and Ferguson); EGF, transforming growth factor α (TGF-α), heparin-binding 
EGF-like growth factor (HB-EGF), amphiregulin (ARG), epiregulin (EPR) and epigen 
(EGN)(Schneider and Wolf). Each of these ligands are synthesized as membrane-bound 
precursors, expressed on the extracellular side of the plasma membrane, and proteolytically 
cleaved to liberate them from the cell surface, rendering them available to bind the 
extracellular receptor domain(Adrain and Freeman).  The EGF family of receptors have 
rather large extracellular ligand binding domains, around 620 amino acids, further 
categorized in to four domains(Adrain and Freeman). Domains I and III are quite similar 
and serve as the primary site of ligand binding, while domains II and IV are cysteine-rich 
containing many disulfide linked molecules(Ward, Hoyne and Flegg). A single 
transmembrane domain connects the ~540AA intracellular region which contains a kinase 
domain, as well as a C-terminal ~230AA tail. Binding of the EGFR or ErbB4 to activation 
ligands strongly induces receptor homodimerization(Ferguson et al.), although, other 
members of the family e.g. ErbB2/3 do not form homodimers and only can achieve 
signaling through receptor heterodimerization(Yarden and Sliwkowski). Following 
receptor activation, several intracellular tyrosines localized on the C-terminal tail become 
autophosphorylated(Honegger et al.), and serve as “docking” sites for SH2 and PTB 
domains(Wagner et al.). These sites vary among the different EGFR family members 
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which serve to provide unique but compensatory responses(Jones et al.; Yarden and 
Sliwkowski).  
Crystallographic studies of EGFR tyrosine kinase domain (TKD) revealed that 
the ErbB receptors are structurally unique in their activation versus other receptor tyrosine 
kinases (RTK) whereas they do not require activation-loop phosphorylation to adopt an 
active-like structure(Stamos, Sliwkowski and Eigenbrot; Gotoh et al.; Burgess et al.). The 
probable EGFR TKD activation mechanism was elegantly described in 2006, as EGFR 
dimerizes in an asymmetric fashion, permitting one carboxy-lobe of the EGFR TKD 
(activator) to actively phosphorylate the amino lobe of the other EGFR monomer 
(receiver), inducing structural changes and thereby activating it(X. Zhang et al.). These and 
other studies have confirmed that EGFR TKD activation is mediated allosterically, rather 
than via activation-loop phosphorylation(Yarden and Sliwkowski; Lemmon, Schlessinger 
and Ferguson).  
 
1.2.2. EGFR Recycling and Regulation 
Shortly following ligand binding and signal transduction, EGFR is endocytosed and further 
processed to a variety of fates (Goh and Sorkin; Madshus and Stang). This is primarily a 
cellular response to attenuate EGFR signaling, forcing turnover, and ultimate 
downregulation of the signal(Goh and Sorkin), achieved through the endocytic sorting of 
internalized EGFR to late endosomes and/or lysosomes for proteolytic degradation(Goh 
and Sorkin). Studies have supported this notion by showing enhanced EGF-stimulated 
signaling and proliferation in a mutant form of EGFR that cannot internalized(Goh et al.) 
or a dynamin-mutant cell model that blocks clathrin mediated endocytosis (CME)(Vieira, 
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Lamaze and Schmid). Defining the cellular mechanisms that mediate EGFR endocytosis 
and endosomal processing have been somewhat controversial, due to studies displaying 
that EGFR internalization can be mediated by a variety of confounding molecular factors, 
comprehensively reviewed here(Goh and Sorkin; A. Tomas, C. E. Futter and E. R. Eden; 
Tan et al.). Regardless, clathrin-mediated endocytosis is the main mode of ligand-induced 
EGFR internalization, with endocytic rates far higher than clathrin-independent 
mechanisms (CIE)(Goh and Sorkin). Although, kinetic analysis of CME EGFR reveal as 
concentrations of EGFR activating ligand increase, available cell surface receptors become 
saturated, and CME rates decline(Wiley). In parallel, a slower, clathrin-independent 
mechanism contributes to EGFR internalization, suggesting dynamic modes of endocytic 
processing dependent of local ligand concentration(Wiley; Sigismund, Woelk, et al.). 
Bimodal RTK endocytosis like EGFR have also been described for the insulin-like growth 
factor 1 receptor (IGF-1R) (Backer et al.; Prager et al.), fibroblast growth factor receptor 
(FGFR)(Wiedlocha and Sorensen), and vascular endothelial growth factor receptor 
(VEGFR)(Lanahan et al.; Haugsten et al.). There are various mechanisms which have been 
proposed to mediate CIE, such as cytoskeletal rearrangements and membrane 
ruffling(Haigler, McKanna and Cohen; Orth et al.), caveolae-mediated or associated(Salani 
et al.; Sigismund, Woelk, et al.), or a recently described role for the endoplasmic reticulum 
in a calcium-dependent fashion(Giusi Caldieri et al.). While CME is well characterized, 
mechanisms that govern or associate with CIE are poorly understood, and further study is 
needed to enhance our understanding of EGFR endocytic regulation in attempt to exploit 
them therapeutically.   
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1.2.3. EGFR Signaling and Function in Lung Biology 
In the lung, ErbB1 (HER1 or EGFR) is the predominantly expressed isoform and 
interestingly has low basal levels of expression, although is transiently expressed during 
epithelial repair(Korfhagen et al.). Regardless, activation of EGFR signaling has been 
described over the last 25 years to be a crucial mediator of many homeostatic features of 
lung biology. The importance of EGFR in the lung is supported by the fact that mice 
lacking EGFR (HER1) have significant developmental defects in the lung and often 
perish in utero(Miettinen et al.). EGFR signaling has also contributed to many other lung 
related functions, such as (but not limited to), alveolar type II cell maturation(Plopper et 
al.), mitigating acute lung injury(J. H. Finigan, G. P. Downey and J. A. Kern), lung 
developmental processes(Patel et al.), epithelial proliferation and differentiation(W. Liu 
et al.; LeSimple et al.), surfactant production(Zscheppang et al.).  
 EGFR signaling is also an important regulator of resolving lung epithelial 
wounds(James H. Finigan, Gregory P. Downey and Jeffrey A. Kern). Injury to the lung 
can occur in a variety of formats e.g. bacterial/viral infections, inflammation, allergic 
responses, environmental exposures, among others. Confirming earlier 
studies(Korfhagen et al.), EGFR was shown to be transiently upregulated within 1 to 2 
days following epithelial wounding, in the bronchioles of mice(Van Winkle, Isaac and 
Plopper), with resolution of its expression occurring 4 to 7 days post injury. Indeed, 
mitigation of epithelial wounding is supported by both cell proliferation and migration, 
and a seminal report in 1994 by Kheradmand and colleagues highlighted the critical 
importance of EGFR signaling to this process(Kheradmand et al.). Supporting these cell-
based findings, it was later discovered that patients with acute lung injury (ALI) were 
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found to have high levels of the EGFR ligand, TGF-α, in their pulmonary edema 
fluid(Chesnutt et al.). Additionally, supplementation with edema fluid from ALI patients 
greatly enhanced wound closure on A549 lung cell monolayers(Geiser et al.).  
Indeed, many of our previous studies have aimed to understand the mechanisms 
that regulate EGFR signaling in lung epithelial wound and allergic responses. Prior 
studies have reported that a wounded epithelial monolayer releases both EGF ligand and 
ATP to re-epithelialize and promote repair (Yin et al.). Our studies have demonstrated 
that ATP-dependent activation of dual oxidase 1 (DUOX1) is a crucial step in regulating 
EGFR-dependent wound repair in the airway epithelium(Wesley et al.; Gorissen et al.; 
Sham et al.). Additionally, we have uncovered that DUOX1 mediates EGFR-dependent 
type II allergic responses(Danyal et al.; Habibovic et al.; Hristova et al.). These studies 
have connected DUOX1 as an important regulator of EGFR signaling in airway epithelial 
biology, and mechanisms of redox regulation of EGFR is covered in more detail in 
section 1.4.2. 
 
1.2.4. EGFR Signaling and Function in Lung Cancer 
EGFR signaling has long been appreciated for its role in cancer biology, primarily because 
of its ability to promote cellular events related to oncogenic cellular behavior, such as 
proliferation, cell cycle progression, and migration(Citri and Yarden; Yarden and Pines; 
Singh and Settleman). EGFR is frequently overexpressed, dysregulated, or mutated in 
various human carcinomas, such as head and neck, bladder, breast, ovarian, renal, colon, 
and lung cancer(Yewale et al.; Herbst and Shin). Cancers that rely on the overexpression 
of growth factors and their receptors to promote cell growth, such as EGF and the EGFR, 
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are often classified to have “oncogene addiction”. This has made EGFR an attractive target 
in the design of cancer therapeutics, especially in patients harboring activating mutations, 
which is discussed in greater detail in section 1.1.2. Dysregulated EGFR signaling can 
promote enhanced or prolonged signals that can lead to persistent activation of downstream 
effectors such as the MAPK and PI3K/Akt pathways, promoting oncogenic 
outcomes(Chong and Janne). While there are many factors that contribute to irregular 
EGFR signaling in cancer, one critical abnormality is that endocytic homeostasis has been 
reported to be dysregulated(Tan et al.), leading to aberrant trafficking to intracellular 
organelles (e.g. mitochondria in NSCLC, (T. F. Che et al.)), specifically the nucleus(T. M. 
Brand, M. Iida, N. Luthar, et al.; T. M. Brand, M. Iida, C. Li, et al.; Lo and Hung; Abella 
and Park). Recently, nuclear EGFR (nEGFR) has been associated with resistance to EGFR 
targeted therapies(T. M. Brand, M. Iida, N. Luthar, et al.; Wheeler et al.), radio-
resistance(T. M. Brand, M. Iida, C. Li, et al.), cell cycle progression(T. M. Brand, M. Iida, 
C. Li, et al.), and poor overall survival in NSCLC(Traynor et al.). Nuclear EGFR is 
considered to act as a transcriptional enhancer by its binding to AT rich regions within the 
promotors of cyclin D1, B-Myb, iNOS and Aurora-A(Y. N. Wang et al.; T. M. Brand, M. 
Iida, C. Li, et al.; H.-P. Kim et al.). Furthermore, nuclear EGFR can enhance gene 
transcription by the physical interaction of transcription factors such as a STAT3/5 and 
E2F1(Y. N. Wang et al.; T. M. Brand, M. Iida, C. Li, et al.),  lending to drive cell 
proliferation and promote transcriptional programs consistent with oncogenic behavior. 
Mechanisms of nuclear translocation of EGFR have largely been considered to be mediated 
by its ability to form complexes with importin α/β or importin-β alone, which recognize 
the putative EGFR nuclear localization signal (NLS)(S.-C. Wang et al.; H. W. Lo et al.) 
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allowing its transport from cytosolic endosomes to the nucleus(Y. N. Wang et al.; Madshus 
and Stang; Goh and Sorkin). Additionally, recent reports have identified EGFR tyrosine 
1101 as a critical mediator of EGFR nuclear transport(Iida et al.), a molecular substrate of 
the Src family kinases (SFKs)(Biscardi et al.; T. M. Brand, M. Iida, N. Luthar, et al.), and 
EGFR-Y1101 phosphorylation is required for nuclear entry. Recently, Wheeler and 
colleagues have defined the AXL kinase mediates cetuximab resistance by persistent 
activation of EGFR and enhanced nuclear translocation, physically sequestering EGFR 
from the cell surface and subsequent antibody based inhibition(Toni M. Brand et al.). 
Future studies should aim to critically evaluate subcellular trafficking and localization of 
growth factors, including but not limited to the EGFR, as this may provide further insights 
to patient responsiveness to chemotherapies, tumor aggressiveness, and clinical outcome.  
 
 
1.3. The Epithelial-to-Mesenchymal Transition 
EMT is defined as the gradual loss of epithelial cell characteristics, such as cell-cell 
contacts, epithelial polarization, and detachment from the epithelial cell basement 
membrane, and the acquisition of mesenchymal cell features e.g. spindle cell morphology, 
migratory phenotype. Completion of EMT is signified by the degradation of the epithelial 
cell basement membrane, such that the newly transformed cell may migrate away from the 
epithelial layer it once resided (Raghu Kalluri and Robert A. Weinberg). EMT was first 
described in developing tissues, and originated from the idea that as cells and tissues mature 
from a single cellular origin (J. M. Lee et al.). As progenitor cells differentiate to their 
epithelial lineages, generally in a tissue specific manner, they can in fact de-differentiate 
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back to a mesenchymal state, performing this process in waves to fully generate/populate 
a developing tissue. Indeed, coordination of epithelial to mesenchymal cell plasticity is an 
imperative aspect of development, tissue repair, and other pathological stresses(Raghu 
Kalluri and Robert A. Weinberg). Discussed in the following subsections are the various 
classifications of EMT as well as some of the critical molecular features and/or regulators. 
Additionally, some of the functional features of EMT are covered e.g. enhanced cancer 
stem cell characteristics and acquired drug resistance, and finally some discussion 
regarding the existing links between EMT and EGFR signaling.   
 
1.3.1. EMT Classification 
Generally, EMT can be classified into three types; developmental (type 1), fibrotic (type 
2), and metastatic(type 3)(Raghu Kalluri and Robert A. Weinberg). Type 1 EMTs are 
widely considered to be, a tightly controlled, initial mechanisms during implantation, 
embryogenesis, and organ development, with minimal off target fibrotic or invasive 
phenotypes(Raghu Kalluri and Robert A. Weinberg; Zeisberg and Neilson). Type 2 EMTs 
are more closely related to tissue repair and fibrotic remodeling, as this usually begins as a 
normal physiological response to damage and generates fibroblasts and other related cell 
types to aid in healing(Raghu Kalluri and Robert A. Weinberg).  Since these EMTs are 
generally coupled to inflammatory responses, they often subside once inflammation is 
resolved, and wound healing is complete(Raghu Kalluri and Robert A. Weinberg). In the 
setting of fibrosis, the ability to ‘turn off’ the type 2 EMT is dysregulated, creating fibrotic 
remodeling and additional layers of tissue deposition, leading to elevated levels of scarring 
or tissue hardening(Lamouille, Xu and Derynck; Zeisberg and Neilson). Type 3 EMT is 
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associated with the critical step where tumor cells, which still retain some or much of their 
epithelial characteristics, acquire a dramatically more invasive phenotype, and obtain the 
capacity to escape a primary tumor site and metastasize distant tissues(Raghu Kalluri and 
Robert A. Weinberg; Heerboth et al.; Thiery).  Understandably, defining the molecular 
mechanisms which govern or are associated with type 3 EMT, are critically important in 
the attempt to design therapeutics to target this pathway.   
 
1.3.2. Molecular Regulation of EMT 
While there are vast molecular mechanisms that contribute to the various forms of EMT, a 
commonality among them is the loss of the adherins and cell-cell tight junction proteins 
e.g. E-cadherin, claudin, and occludin(Lamouille, Xu and Derynck). This is widely 
considered to be the initial step in cellular transformation, and genetic and epigenetic 
control of this process, has been comprehensively studied(Lamouille, Xu and Derynck). E-
cadherin destabilization is a complex process, requiring coordination of several genetic, 
epigenetic, and post-translational regulatory elements. For instance, there are many various 
families of transcriptional regulators of E-cadherin, e.g. SNAIL/ZEB/bHLH, that bind 
regions of the E-cadherin promotor and suppress its expression(Lamouille, Xu and 
Derynck). These transcription factors can be regulated in several fashions, either 
epigenetically (e.g. E-cadherin promoter methylation(Maeda et al.); aberrant histone 
demethylate activity(T. Lin et al.)), post-translationally (e.g. SNAIL activation by 
glycogen synthase kinase 3β(GSK3β)-mediated phosphorylation)(B. P. Zhou et al.)) or 
through RNA processing performed by microRNAs (miRNAs). The miR-200 family of 
proteins can negatively regulate pro-EMT transcription factors (e.g. SNAIL/ZEB/bHLH), 
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primarily through binding their mRNAs and inhibiting their translation(Lamouille et al.). 
Additionally, miRNAs can also target genes that aid in defining the epithelial phenotype, 
such as miR-9 repressing E-cadherin supporting epithelial characteristics(Ma et al.), while 
miR-194 can suppress N-cadherin thereby promoting the mesenchymal phenotype(Song et 
al.; Meng et al.). Destabilization of adherins is often accompanied the by the acquisition of 
mesenchymal molecular features, e.g. fibronectin, vimentin, N-cadherin, others(Raghu 
Kalluri and Robert A. Weinberg; Yilmaz and Christofori). While the genetic switch in 
EMT between the expression of intermediate filaments (e.g. suppression of cytokeratin; 
expression of vimentin) is thought to impact intracellular transport of E-cadherin to the 
plasma membrane, as vimentin does not support E-cadherin transport while keratins do 
(Toivola et al.), coordinated vimentin expression also has roles in cell motility, possibly 
through the interactions of motor proteins and vimentin filaments(Mendez, Kojima and 
Goldman). In parallel, expression patterns of integrins and related ECM-interacting 
proteins experience significant changes also, in order to compensate for the new 
environment in which cells that undergo EMT must now interact with(Lamouille, Xu and 
Derynck). For instance, the epithelial α6β4 integrins which coordinate epithelial cell-
basement membrane interactions, is drastically downregulated in EMT(Yang et al.), while 
the α5β1 integrin expression is induced to enhance cell interactions with fibronectin, and 
is also upregulated during cell migration(Maschler et al.; Mise et al.).  Additionally, ECM 
remodeling is crucial part of EMT to permit the successful migration of transformed cells 
from either an epithelial basement membrane or from a primary tumor site, to the local 
blood vessel, to colonize distant tissues. EMTs often express the matrix metalloproteinases 
MMP2 and MMP9 at higher levels than their epithelial counterparts, which allows these 
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cells to degrade parts of the ECM enabling migration and invasion(Nistico, Bissell and 
Radisky).  
1.3.3. EMT and Cancer Stem Cells 
To complete metastasis or colonization, EMTs must not only adapt to several aspects of a 
foreign tissue but importantly contain self-renewal capacity, in order to proliferate from a 
single or group of invaded cell/s. Activation of EMT has previously been coupled to the 
acquisition of stem cell traits, in both epithelial cells and populations of carcinoma 
cells(Scheel and Weinberg). This is especially dangerous in carcinoma cells, as EMT not 
only imparts the ability of these cells to become more motile and invasive, but now also 
harbor the capacity to self-renew(Scheel and Weinberg; Heerboth et al.).  Evidence for 
EMT promoting CSC-like phenotypes has been observed in a variety of cancers such as 
breast(Maeda et al.; Morel et al.), colorectal(Brabletz et al.), pancreatic(Z. Wang et al.), 
and liver(Niu et al.). Enhanced CSC traits in cells that undergo EMT is thought to be related 
to the differences in expression profiles of miRNAs that have downstream consequences 
for proteins that regulate stem-like states(Scheel and Weinberg). For example, suppression 
of the miR-200 family during EMT removes a critical regulatory element for the polycomb 
protein Bmi-1, which promotes stem-like characteristics in cancer and embryonic stem 
cells(Shimono et al.; Wellner et al.).  
In a seminal paper by Al-Hajj and colleagues, they defined that only a small subset 
of cells from a solid breast tumor were capable of initiating and promoting tumor growth, 
and that these cells displayed unique expression patterns of cell surface markers CD24 and 
CD44 versus their bulk tumor cell counterparts(Al-Hajj et al.).  This led to waves of studies, 
further characterizing expression of cell surface markers unique to cancer stem cells. 
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Currently, there are several antibody or antibody-cytotoxic agent conjugates related 
therapies that specifically target proteins expressed on the cell surface of CSC 
populations(Chen, Huang and Chen). For example, the use of gemtuzumab ozogamicin, 
which targets CD-133, highly expressed in most AML cells(Curiel). Other CSC surface 
markers have been targeted for therapeutics, such as Anti-CD-44 conjugated antibodies 
have been employed in the treatment of breast cancer(Alkilany et al.; Marangoni et al.), 
pancreatic tumors(L. Li, X. Hao, et al.), and promising results in colorectal, lung, bladder, 
and larynx cancers(Masuko et al.; Olsson et al.). While there may be various cell surface 
markers enriched in CSC populations, potentially the most notable is CD-133(Chen, Huang 
and Chen; Dragu et al.). CD-133 has found to be widely expressed on CSCs in solid tumors 
ranging from gliomas(Singh et al.), lung(Alamgeer et al.), liver(Yamashita and Wang), and 
colorectal cancers(Vaiopoulos et al.), with most CD-133+ tumors correlating with poor 
clinical prognosis(E. H. Lin et al.).  Due to this, various antibody-related approaches to 
target CD-133 have been generated, and utilized with efficacy in breast cancer 
cells(Swaminathan et al.), sarcoma CSCs(Stratford et al.), and elimination of CD-133+ 
cells from ovarian cancer cells resulted in long-term disease free survival(Skubitz et al.).  
CSCs appear to be critically important in the genesis and progression of cancer, therefore 
warranting future study to further understand their biological and functional characteristics.  
 
1.3.4. EMT and Drug Resistance 
Increased levels of CSCs in EMT populations has also been associated with their intrinsic 
resistance to anti-cancer therapies(Shibue and Weinberg). This idea originated from the 
observation that non-neoplastic stem cells were more resistant than their differentiated 
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cellular counterparts in response to chemotherapeutic agents(Lerner and Harrison). In more 
recent studies, research has confirmed this hypothesis since CSCs from various cancerous 
tissues, survive chemotherapy and/or radiation treatments while the bulk tumor cells were 
abolished(Bao et al.; Levina et al.; Dallas et al.). This also appears to be true in context of 
molecular-targeted therapies, and has been observed in various contexts, e.g. enriched CSC 
populations following treatment with imatinib (BCR-ABL1 kinase inhibitor) in CML 
patients (S. M. Graham et al.), and EMT conferring resistance to EGFR inhibition in lung 
cancer(L. V. Sequist et al.; Z. Zhang et al.; Byers et al.). A comprehensive description of 
the many forms acquired drug resistance due to EMT, are covered here(Shibue and 
Weinberg).  While the mechanisms of precisely how EMT confers drug resistance to either 
CSCs or transformed tumor cells are incompletely understood, there have been several 
proposed mechanisms. For instance, EMT-induced expression of anti-apoptotic 
proteins(Peters, Leyvraz and Perey), and high levels of ATP-binding cassette (ABC) 
transporters, which are transmembrane proteins well known to dictate drug transport efflux 
in cancer cells(Feuerhake et al.; S. Zhou et al.). In addition to these observations, recent 
findings have also defined a unique EMT-associated gene expression signatures that 
strongly correlate with tumor responsiveness to chemotherapy regiments(Shibue and 
Weinberg), with examples in breast cancer(Farmer et al.) and lung cancer(Byers et al.). 
These and other findings support the collective importance of EMT in cancer biology. 
Further research into the associations of EMT, CSCs, acquired resistance, and the 





1.3.5. Links Between EGFR Signaling and EMT 
Interactions between EGFR and E-cadherin were initially described in 1995, where EGF 
signaling initiated the downregulation of E-cadherin in esophageal cancer cells(Shiozaki 
et al.). Shiozaki and colleagues went on to show that EGF stimulation of the E-
cadherin+/EGFR+ TE-2R cancer cell line also lead to enhanced cellular invasion and 
described for the first time that EGFR was capable of phosphorylating the E-cadherin 
complex proteins, α and β-catenin, all supporting an EMT-like cell phenotype(Shiozaki et 
al.). Later, EGFR signaling in breast cancer cells was found to dissociate actin, α-actinin, 
and vinculin from the E-cadherin/catenin complex(Hazan and Norton). Many studies since 
the late 1990s aimed to understand the mechanisms by which aberrant EGFR signaling can 
initiate or promote EMT. A landmark paper in 2007 defined that EGFR signaling 
cooperates with Signal Transducer and Activator of Transcription 3 (STAT3) to induce 
EMT, specifically through upregulation of the E-cadherin transcriptional repressor, 
TWIST(H.-W. Lo et al.). Many other reports have further characterized mechanistic 
insights to EGFR signaling promoting EMT, e.g. via glutaredoxin 3(He et al.), ionizing 
radiation(J. H. Cho et al.), SNAIL regulation(Z. C. Liu et al.), among many others. 
Paradoxically, targeted approaches to inhibit EGFR signaling have also been found to 
promote EMT or aggressive cell phenotypes. This is most well known in context of 
acquired resistance to EGFR-TKIs, although, has also been described in other scenarios. 
For example, in three independent oral squamous cell carcinoma lines, EGFR expression 
was found to be inversely related to cellular invasiveness and EMT-like features(Kimura 
et al.). Additionally, EGFR-targeted treatment (erlotinib; cetuximab) of invasive squamous 
cell carcinoma cell lines enhanced their migratory and invasive behavior, and confirmed in 
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an in vivo xenograft model(Basu et al.).  These disagreements suggest that EGFR-




1.4. Reactive Oxygen Species 
Reactive oxygen species (ROS) are defined as a group of molecules that derive from 
molecular oxygen that contain radical (superoxide or hydroxyl radical) as well as non-
radical (hydrogen peroxide) forms(Ray, Huang and Tsuji; Hayes and Knaus). Due to the 
relatively unstable nature of these species, they are particularly reactive towards a variety 
of molecular targets, such as nucleic acids, proteins, and/or lipids. Indeed, ROS 
accumulation contributes to oxidative stress, and can have broad deleterious effects. 
Oxidative stress is typically defined as an imbalance ROS production and the cellular 
response(s) to counteract their actions (Fig.1.2). It is now well understood that ROS are 
crucially used as a signaling molecule, akin to other post-translational modifications 
(PTMs) (e.g. phosphorylation, ubiquination, etc)(Reczek and Chandel). This section will 
briefly address protein cysteine thiol signaling, a reversibly oxidized amino acid residue 
gaining recognition for its role in redox signaling(Heppner, Janssen-Heininger and van der 
Vliet). Additionally, the current state of the field regarding EGFR redox regulation, 
associations with protein function, as well as addressing the gaps in knowledge. Lastly, a 





1.4.1. Cysteine Thiol Oxidation and Signaling 
 Of the various amino acids that are candidates for reversible modification by oxidation, 
cysteines are the best equip for this, since at physiological pH the sulfhydryl side chain is 
deprotonated thereby enhancing its reactivity(Paulsen and Carroll). Thiol oxidation rates 
are apparently rather variable, and not solely dependent on protein cysteine pKa, 
suggesting other confounding factors may affect oxidation rates, such as the local 
arrangement of amino acid side chains in proximity to a sulfhydryl (Nagy). The initial 
oxidation of the cysteine thiol (-SH) yields a sulfenic acid intermediate (-SOH), although 
oxidation can result in several other molecular species, e.g. sufinic acid (-SOOH), sulfonic 
acid (-SOOOH), inter- or intra-molecular disulfide bridges (-S-S-), among others described 
in more detail here (Paulsen and Carroll). Other low molecular weight thiol containing 
compounds (e.g. glutathione; GSH) can also induce the transition of a Cys-SOH species to 
a mixed disulfide, protein S-glutathionylation, catalyzed by the glutathione S-transferase 
enzymes(Hill and Bhatnagar). Moreover, disulfide bridged proteins (-S-S-) or 
glutathionylated proteins (-SSG) can be actively reduced by thioredoxins (TRXs) or 
glutaredoxins (GRXs) respectively, to restore a protein cysteine thiol back to a sulfhydryl 
state (-SH), signifying the reversibility of this process(Holmgren et al.).  In fact, 
reversibility of oxidation on cysteine thiols supports the fact that oxidation can be utilized 
as a PTM to regulate protein function. Although, defining the importance of cysteine 
oxidation and the effect it has on protein function, subcellular localization, or other protein-
regulatory roles, has been handcuffed by the limited amount of available molecular 
detection strategies(Heppner, Janssen-Heininger and van der Vliet), although, a current 
comprehensive review of the available thiol-oxidation/labeling techniques is available here 
 
24 
(Paulsen and Carroll). Despite this, numerous biological pathways across various 
organisms have been identified to be redox regulated(Poole). While this list is by no means 
comprehensive, examples exist in yeast (Le Moan et al.) and in many kinds of bacteria, as 
oxidants are sensed by transcriptional regulators through thiol biochemistry as a critical 
host defense mechanism(Antelmann and Helmann; Dubbs and Mongkolsuk; Poor et al.). 
Indeed, thiol based signaling persists to upper levels organisms such as humans, with many 
examples of thiol oxidation impacting cellular biology. Some of the first described, and 
most widely studied examples of oxidation in human cells is the oxidative inactivation of 
protein-tyrosine phosphatases (PTPs) such as PTP1B(Bae et al.; Denu and Tanner) and 
platelet derived growth factor receptor (PDGFR) associated phosphatase SHP-2(Meng, 
Fukada and Tonks; Sundaresan et al.). Oxidation-dependent inactivation of PTPs is mostly 
due to the labeling of catalytic cysteines near the enzymatic active site(Corcoran and 
Cotter), although oxidation of sensitive residues can also function as an allosteric 
modulator or initiator of protein-protein interactions (e.g. disulfide formation). A key 
example of this is found in cGMP-dependent protein kinase (PKG), where exposure to 
H2O2 initiates dimerization and coordinates its catalytic cysteine in an allosterically 
favorable position for S-nitrosylation(Burgoyne et al.).  Additionally, there have been 
suggestions that oxidation and nitrosylation act as dual ‘cross-talk’ systems, whereas S-
nitrosylation acts as an effector and oxidation functions more as an allosteric moderator, 
permitting the target protein residue to more readily respond to oxidative 
modifications(Hess et al.). It has also been proposed that oxidation initiates the formation 
of disulfide bridges between proteins to form molecular complexes. This is most notably 
observed in the Src family kinases (SFKs), where oxidation of cysteine 277 in Src promotes 
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intermolecular disulfide formation with another Src molecule(Kemble and Sun). Kemble 
and colleagues suggest this may also occur in the fibroblast growth factor receptor (FGFR), 
as the mentioned cysteine is conserved and behaves similarly to the Src residue(Kemble 
and Sun). Other examples of redox-dependent regulatory mechanisms in tyrosine kinases, 
thiol dynamics, biochemistry, and signaling, can be found in these reviews(Nagy; Paulsen 
and Carroll; Poole; Corcoran and Cotter). Feasibly, any protein containing solvent exposed 
cysteine(s) at an optimal pKa could be subject to oxidation, although as mentioned 
previously, characterizing the importance of a given reactive cysteine remains challenging. 
Regardless, redox regulation of protein cysteine thiols has been shown to significantly 
affect multiple aspects of protein biology e.g. allosterically, enzymatically(Poole), and 
likely has significant contributions to cellular function potentially as prominently as other 
PTMs e.g. phosphorylation.  
 
1.4.2. EGFR Redox Regulation 
In addition to oxidation playing a key role in the inactivation of PTPs (see above), evidence 
for direct oxidation of tyrosine kinases has accumulated in recent years(Corcoran and 
Cotter). Among the various RTKs found to be redox regulated is EGFR. Recent studies 
have indicated that a conserved cysteine near the ATP-binding site within the EGFR 
tyrosine kinase domain, C797, is susceptible to oxidation, and research by Kate Carroll and 
colleagues has indicated that oxidation of EGFR C797 to a sulfenic acid (-SOH) in 
response to ligand stimulation contributes to enhanced tyrosine kinase activity (Paulsen et 
al.; Truong and Carroll; Truong et al.). Moreover, the extent of EGFR C797 oxidation 
varied between cancer cells with WT EGFR or containing oncogenic mutants (e.g. 
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L858R/T790M, Δ746-750) with the latter showing more extensive EGFR oxidation. In 
addition to oxidation to –SOH, our recent studies show that EGFR is also subject to S-
glutathionylation, which may not necessarily affect kinase activity (Sham et al.; Heppner 
et al.; Heppner and van der Vliet) but likely impacts the efficacy of EGFR TKI that are 
covalently targeted to C797 in an attempt to overcome TKI resistance(Schwartz et al.; 
Truong et al.; Wani, Nagata and Murray). Although oxidation of EGFR C797 to –SOH 
may enhance tyrosine kinase activity (Heppner et al.; Truong et al.), the significance of 
other modifications (e.g. S-glutathionylation) for EGFR regulation is unknown, and it is 
plausible that these redox modifications might also affect kinase independent EGFR 
functions e.g. subcellular trafficking or protein-protein interactions. While significant 
advances have been made, the cellular mechanisms that mediate EGFR (and other protein) 
cysteine oxidation are not fully understood(Heppner, Janssen-Heininger and van der Vliet). 
Original studies suggested the involvement of NOX2 in the context of ligand-dependent 
stimulation, while alternative mechanisms of EGFR transactivation now involve DUOX1 
(Heppner et al.; Sirokmany et al.). Hence, the oxidative events that mediate EGFR 
oxidation, as well as its downstream consequences, could be highly context-dependent and 
are likely dysregulated in cancer biology, which may also have important consequences 
for the efficacy of EGFR-targeted therapies(Schwartz et al.; Truong et al.; Wani, Nagata 
and Murray). Intriguingly, recent studies have shown that the use of third-generation EGFR 
TKI such AZD9291(Cross et al.), designed to covalently target the redox-sensitive C797 
and to overcome TKI resistance associated with T790M mutations, leads to additional 
resistance mechanisms that are mediated mutation of C797 to serine (Kenneth S. Thress et 
al.). Thus, C797 is not essential for EGFR tyrosine kinase activity, and observations of 
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T790M/C797S mutations have spurred the development of additional fourth-generation 
EGFR inhibitors that do not target the ATP-binding site but selectively inhibit these 
mutants while not affecting WT-EGFR activity by an allosteric mechanism(Jia et al.).   
 
 
1.4.3. ROS Contributes to Pathology 
Originally considered a simple by-product of mitochondrial respiration and other metabolic 
pathways, it is now well understood that ROS can be generated by various endogenous 
cellular sources in a regulated fashion. Chief among these are the NADPH oxidases 
(NOXes), a family of enzyme complexes (NOX1-5 and DUOX1/2) that generate ROS (O2
- 
and/or H2O2) as their primary product of enzymatic activity(Lambeth; Lambeth and Neish), 
implicating the biological importance of ROS. During the past decade, extensive research 
has implicated ROS in a variety of cellular signaling pathways involved in cell 
proliferation, migration, and differentiation(Holmstrom and Finkel; Reczek and Chandel; 
Janssen-Heininger et al.), and altered ROS production or metabolism has been 
demonstrated in a variety of human pathologies such as aging(Chandrasekaran, Idelchik 
and Melendez), diabetes(Fakhruddin, Alanazi and Jackson), atherosclerosis(Forstermann, 
Xia and Li), and cancer(Galadari et al.; Landry and Cotter; Prasad, Gupta and Tyagi).  
Indeed, cancer cells are typically characterized by elevated amounts of ROS, and various 
lines of evidence indicate their ability to contribute to cancer progression(DeBerardinis and 
Chandel; Landry and Cotter; Galadari et al.). The contribution of ROS in cancer is clearly 
very complex, and likely occurs at several levels. For instance, ROS can contribute to 
genomic instability by inducing direct oxidative damage to DNA(Landry and Cotter) or by 
 
28 
promoting lipid peroxidation to generate mutagenic byproducts such as malondialdehyde 
or 4-hydroxynonenal, which can adduct DNA(Block and Gorin; Landry and Cotter) (Fig 
1.3). Furthermore, ROS can activate or inactivating cell signaling pathways that control 
proliferation, migration, differentiation, or survival, by inducing specific redox-mediated 
post translational modifications in redox-sensitive targets such as protein kinases or 
phosphatases(Block and Gorin; Roy et al.) (Fig 1.3).  
 
 
Figure 1.2 - Cellular redox homeostasis is critical for cell function. ROS generation 
from exo/endogenous sources is combatted by antioxidants to promote ROS homeostasis. 




1.4.4. Antioxidant Cancer Therapies 
Because of the presence of elevated ROS in cancer cells, which likely contributes to 
imbalanced redox-dependent cellular signaling, antioxidant approaches to minimize 
cellular ROS have been proposed as supplementation to chemotherapy regimens, such as 
vitamin C and E(Al-Tonbary et al.; Pathak et al.), N-acetyl cysteine(NAC)(Al-Tonbary et 
al.; J. Yoo et al.), and glutathione(Smyth et al.; Schmidinger et al.; Colombo et al.; Cascinu, 
Catalano, et al.; Cascinu, Cordella, et al.). However, clinical trials using antioxidant-based 
approaches have shown varying degrees of success, and in some cases, have contributed to 
worse outcomes(Galadari et al.). Indeed, recent studies in animal models of e.g. lung cancer 
or melanoma demonstrated that antioxidant supplementation (NAC, Trolox) can promote 
tumor progression and metastasis(Le Gal et al.; Sayin et al.). Opposite strategies that are 
also being explored are approaches to either inhibit antioxidant defense or enhance ROS 
generation within cancer cells, to levels that exceed their adaptive capacity and thus induce 
cancer cell death(Glasauer et al.; Wondrak). In fact, the antioxidant vitamin C may 
paradoxically act as a pro-oxidant, likely due to extracellular conversion to 
dehydroascorbic acid (DHA), thereby inducing the generation of H2O2 (Gonzalez et al.). 
High doses of intravenous vitamin C were found to significantly reduced levels of prostate-
specific antigen (PSA), an appreciated serum biomarker for prostate cancer(Keishla M 
Garcia). Pro-oxidant effects of DHA have also been explored in non-small cell lung cancer 
(NSCLC) and glioblastoma (GBM), where H2O2 induced by the extracellular conversion 
of ascorbic acid to DHA, selectively disrupted iron metabolism in cancer cells, leading to 
cytotoxic effects, and its efficacy has been demonstrated in preclinical and clinical trials 




Figure 1.3 - Biochemical reactions associated with cancer initiation and/or 
progression.  Enhanced levels of reactive oxygen species (e.g. O2
- , H2O2) promotes 
oxidation events such as direct DNA oxidation (e.g. 8-oxo-guanine) (A), or lipid 
peroxidation (B), which can both lead to genomic instability and drive tumor initiation 
and/or progression. ROS imbalance can also perturb redox dependent cellular processes 
through oxidation of sensitive amino acid residues such methionine or cysteine (C), leading 
to potential alternative protein function and/or dysregulated cell signaling. Adapted from 
Little et al., used with permission from Elsevier. 
 
1.4.5. Intracellular Sources of ROS Contribute to Cancer Etiology 
Beyond directly targeting ROS with antioxidants as a therapeutic strategy, alternative 
approaches involve strategies to inhibit major cellular sources of ROS production. The 
largest cellular source of ROS in cancer cells may be mitochondria(Saybasili et al.), due to 
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glycolytic reprogramming and upregulation of glucose metabolism leading to loss of 
regulation between glycolysis and aerobic respiration(L. Li, M. A. Fath, et al.; Vander 
Heiden, Cantley and Thompson; DeBerardinis and Chandel; Lee and Kim). Such altered 
mitochondrial metabolism in cancer cells, known as the Warburg effect, is thought to lead 
to enhanced steady-state levels of intracellular ROS which in turn may drive enhanced 
addiction to glucose to increase glycolysis and pentose phosphate cycle activity to provide 
reducing equivalents for hydroperoxide metabolism(L. Li, M. A. Fath, et al.). Indeed, 
enhanced mitochondrial-derived ROS has been implicated in pathways promoting 
oncogenic cell behavior(Weinberg et al.; DeBerardinis and Chandel), and several drugs 
that suppress mitochondrial electron transport and ROS production (e.g. complex 1 
inhibitors (metformin)(Wheaton et al.), complex III inhibitors(Orr et al.), others) have been 
utilized recently to treat cancer. Hence, alterations in mitochondrial dynamics, function, 
and regulation in cancer cells may position them as attractive targets for therapeutic 
approaches, although they may also have untoward consequences for normal cell biology.  
Although mitochondrial ROS can contribute to redox-dependent cell 
signaling(Diebold and Chandel; Murphy), the main sources of ROS involved in redox 
regulation of cell signaling pathways are thought to be the NADPH oxidases (NOXes). 
Based on growing numbers of studies indicating altered expression or activation of NOX 
family members in various cancers(Block and Gorin), they are increasingly considered as 
additional attractive targets for chemotherapeutic development in cancer(Bonner and 
Arbiser; Weyemi, Redon, et al.). For example, NOX1 and 4 have been implicated for their 
contributions to cancer, based on their roles in invadopodia formation(Diaz et al.) and 
tumorigenesis/angiogenesis(Shinohara et al.), through redox-dependent activation of 
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signaling pathways such as Akt and NF-κB (Landry and Cotter; Weyemi, Redon, et al.; 
Bonner and Arbiser; Block and Gorin). It is also worth noting that emerging evidence for 
the existence of cross-talk mechanisms between NOX enzymes and mitochondria(Dikalov; 
Shafique et al.) may imply that altered expression or activation of NOX enzymes may 
contribute to alterations in mitochondrial metabolism or, conversely, that altered 
mitochondrial metabolism in cancer cells may contribute to dysregulated NOX expression 
or activation. However, to our knowledge, the significance of such NOX-mitochondrial 
interactions for cancer biology has not been explicitly explored. Importantly, there is a 
wide variance of NOX expression and distribution across different cancers, which suggests 
that the contributions of NOX-derived ROS may be highly variable(Meitzler, Antony, et 
al.). Moreover, some NOX homologs also appear to be downregulated in cancer cells, 
primarily due to epigenetic mechanisms (Hayes and Knaus). This applies in particular to 
the dual oxidases DUOX1 and DUOX2, which are normally expressed in the thyroid and 
in epithelia of mucosal tissues(Flores et al.; Geiszt et al.; Carvalho and Dupuy; Eskalli et 
al.), and are frequently suppressed in many epithelia-derived cancers(Luxen, Belinsky and 
Knaus; S. S. Chen et al.; Little, Sham, et al.), primarily through hypermethylation of its 
promoter(Block and Gorin; Luxen, Belinsky and Knaus).  
 
1.5. NADPH Oxidases and Cancer 
The first NADPH oxidase to be described is the phagocyte oxidase flavocytochrome b558 
of which the key transmembrane heme-containing protein, gp91phox , was renamed NOX2 
after discovery of six other mammalian homologues, NOX1, NOX3, NOX4 and NOX5, 
and the dual oxidases DUOX1 and DUOX2(Landry and Cotter). All NOX enzymes are 
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transmembrane proteins that contain a C-terminus consisting of FAD and NADPH binding 
domains, and 6 transmembrane-spanning helical sequences containing two bis-his heme 
ligated by histidines located in helices III and V, which facilitate the intramolecular 
electron transfer from NADPH to O2 to generate superoxide (O2
•-)(Lambeth; Vignais). 
Cellular distribution of the NOXes varies widely, and include localization at the plasma 
membrane but also in other intracellular membranes in ER, mitochondria, nuclei, etc., 
largely dependent on cell type(Block and Gorin; Bedard and Krause). NOX1-3 each require 
assembly with various cytosolic cofactors for activation, while NOX4 only requires 
p22phox and is thought to be constitutively active (Brandes, Weissmann and Schroder). In 
contrast, NOX5 and DUOX1 and DUOX2 are activated by Ca2+ and do not require other 
cofactors(Brandes, Weissmann and Schroder). NOX proteins were initially appreciated for 
their roles in host defense(Leto and Geiszt; Lambeth) but, since their discovery in non-
phagocytic cell types, have gained recognition for their participation in other cellular 
processes, such as cell survival(Peshavariya et al.; Naughton et al.), migration(Reddy et 
al.), proliferation(Peshavariya et al.; Jeong, Jeong and Kim), and differentiation(Sardina et 
al.). Dysregulated expression and/or activation of NOX enzymes may therefore play a 
pivotal role in cancer cell behavior.  
 
1.5.1. NOX Relationships to Cancer Biology 
Table 1.1 provides a brief summary of presently established involvement of NOX 
enzymes in various cancers. The first NOX isoform that was linked to cancer biology is 
NOX1, which was originally identified as Mox1 and found to be capable of inducing 
cellular transformation and tumor growth (Suh et al.). NOX1 is primarily expressed in the 
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colon, and was found to be overexpressed in colon cancers(Laurent et al.; Banskota, Regmi 
and Kim), and in radiation induced skin cancer(Raad et al.), breast cancer (Zibara et al.), 
and oral squamous cell carcinoma(Ito et al.). Additionally, a growing number of studies 
have focused on a role for NOX4 in cancer biology. A recent meta-analysis and systematic 
review of the association between NOXes and lung cancer defined that overall NOX 
expression and activity significantly attributed to the tumorigenesis of lung cancer, and 
more specifically, NOX4, suggesting strategies to suppress it could have potential 
therapeutic benefits(Han et al.). NOX1 and 4 have been shown to contribute to 
angiogenesis, an important feature of tumor growth by promoting generation of new blood 
vessels and enhancing oxygen and nutrient supply, which may in part be associated with 
oxidation-dependent upregulation of vascular endothelial growth factor (VEGF)(Block and 
Gorin; Xia et al.). In the latter case, the effects of NOX1/4 were attenuated by 
overexpression of catalase and glutathione peroxidase(Xia et al.). Several NOX enzymes 
have also been shown to play a role in cellular invasion and metastasis (NOX1/4), redox 
based control of the Src kinase (NOX1,2, and 4) and/or NF-κB signaling (NOX1)(Block 
and Gorin). Additionally, in lung and breast epithelial cells, expression of oncogenic 
mutant p53, but not WT-p53, upregulates NOX4 expression, ROS generation, and cell 
migration(Boudreau et al.). Activation of NOX4 has also been described to promote 
pancreatic ductal adenocarcinoma (PDAC) cell growth by oxidation of NADH and 
supporting increased glycolysis(Ju et al.). Recently, overexpression of NOX4 in colorectal 
cancer was found to be significantly associated with poor prognosis and tumor 
progression(X. L. Lin et al.). The lack of NOX5 from the rodent genome has limited our 
understanding of its biological role, but several recent studies have highlighted the potential 
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importance of NOX5, based on findings of increased NOX5 expression and/or NOX5-
derived ROS in various cancers, e.g. prostate (Holl et al.; Brar et al.), hairy cell 
leukemia(Kamiguti et al.), esophageal (Fu et al.), ALK lymphoma (Carnesecchi et al.), and 
others(Antony et al.; Dho et al.). NOX2 has also been implicated in promoting the 
oncogenic phenotype in various cancers such as breast cancer(Mukawera et al.), 
myelomonocytic leukemia(Aurelius et al.), rectal cancer cells(Guo et al.), prostate(Deep et 
al.), and expression of NOX2 mRNA or protein was found to correlate with an invasive 
phenotype and poor prognosis in gastric cancer(P. Wang et al.). However, the explicit role 
for NOX-generated ROS in cancer-related outcomes is typically not demonstrated. There 
is almost no literature on NOX3, likely because of its highly-limited distribution, but a 
recent study has linked NOX3 to development of hearing loss in cancer patients receiving 




Table 1.1 - Association of the various NOX enzymes to cancer biology. Used with 
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(Diaz et al.; Suh et 
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Head/Neck Squamous Cell Carc. Invasiveness (Diaz et al.) 
Melanoma; Skin Cancer 
Invasiveness; Impaired DNA 
Repair 
(Diaz et al.; Raad 
et al.) 
Oral Squamous Cell Carcinoma  Resistance to Apoptosis (Ito et al.)  
Renal Cell Carcinoma (HRAS 
transformed cells) Invasiveness (Shinohara et al.) 
NOX2 










Correlates with Poor 
Prognosis 
(P. Wang et al.) 
Myelomonocytic Leukemia Immunosuppressive  (Aurelius et al.) 
Prostate Cancer Growth/Proliferation (Deep et al.) 
NOX4 
Breast Cancer Migration (Boudreau et al.) 
Colorectal Cancer Poor Prognosis (X. L. Lin et al.) 
Lung Cancer Migration (Boudreau et al.) 
Ovarian Cancer Angiogenesis (Xia et al.) 
Pancreatic Ductal 
Adenocarcinoma 
Glycolytic Switch (Altered 
Metabolism) 
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Prostate Cancer Angiogenesis (Xia et al.) 
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(Weyemi, Lagente-
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Leukemia Unknown (Kamiguti et al.) 
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(S. Chen et al.; 
Ling et al.; S. S. 
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Sham, et al.) 
Neuroblastoma Unknown (Damiano et al.) 
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Wang et al.; Abdul 
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Gastric Cancer Overexpressed (Qi et al.) 
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(Y. Wu, J. L. 
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Prostate Cancer Overexpressed 





Understanding the relevance of global changes in NOX expression and/or activity in cancer 
would also require insight into their subcellular localization which likely determine their 
distinct and/or unique roles in cancer biology. For example, NOX1/4 have been shown to 
localize to invadopodia and/or leading edges of invading cells, and RNAi meditated 
knockdown of NOX4 or strategies to inhibit global NOX activity effectively suppressed 
invadopodia formation(Helmcke et al.; Hilenski et al.; Díaz and Courtneidge; Diaz et al.). 
NOX enzymes typically associate with complexes at the plasma membrane, e.g. in 
caveolae or invadopodia (Masuko Ushio-Fukai; Kawahara and Lambeth; Serrander et al.; 
Donko, Peterfi, et al.), and also can be internalized to endosomal compartments (e.g. 
NOX1/2(Mumbengegwi et al.; Oakley et al.)) to enhance specificity in signaling(Spencer 
and Engelhardt). Perturbed redox signaling due to altered NOX expression and/or activity 
therefore likely impacts cell-cell communication, focal adhesions, or cellular migration 
(Masuko Ushio-Fukai; Díaz and Courtneidge; M. Ushio-Fukai). NOX4 has also been 
detected in other cell compartments, including endoplasmic reticulum where NOX4 
facilitates PTP1B (protein tyrosine phosphatase 1B) oxidation(K. Chen et al.), 
mitochondria where it supports oncogenic features (Block, Gorin and Abboud; K. A. 
Graham et al.), and nuclei where it mediates O2- generation(Spencer et al.), and thus likely 
contributes to oxidative DNA damage.  For example, in HRAS transformed thyroid cells, 
NOX4-derived H2O2 was found to enhance DNA replication rate as well as induce DNA 
damage(Weyemi, Lagente-Chevallier, et al.). NOX4 signaling in the nucleus could also 
have implications for regulation of redox sensitive transcription factors such as AP-1, NF-
κB, Nrf2, p53, among others, which have been implicated for their specific roles in cancer 
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biology(M. Ushio-Fukai).  NOX4 localized to the mitochondria may impact on 
mitochondrial DNA, which is highly vulnerable to oxidative modification since 
mitochondria do not contain histones(DeBerardinis and Chandel; Block and Gorin). 
Overall, although increased expression or activation of NOX enzymes may 
contribute to various aspects of cancer biology, the precise subcellular localization and 
contribution of the various NOXes is still incompletely understood, and published findings 
sometimes appear to be conflicting, likely due to the fact that they have diverse cell-specific 
actions in different cell types, which may have opposing consequences for tumor 
development(Block and Gorin; Roy et al.). 
 
1.5.2. Specific Roles for DUOXes in Cancer 
The most common type of cancer involves carcinomas that originate from epithelial cell 
types that are commonly exposed to environmental factors and carcinogens, such as in the 
lung, skin, or gastrointestinal tract. These mucosal surface cell types typically express high 
levels of unique NOX isoforms, the dual oxidases DUOX1 and/or DUOX2. Analogous to 
other NOXes, several studies have highlighted that DUOX2 mRNA and protein is often 
overexpressed in colorectal cancers(Qi et al.; R. Wang et al.), pancreatic adenocarcinoma 
(Y. Wu, J. L. Meitzler, et al.; Y. Wu, J. Lu, et al.), Barrett esophagus (Qi et al.), and gastric 
cancers(Qi et al.). Using a newly developed monoclonal antibody against DUOX2, 
increased immunohistochemical staining was observed in various tumor types, including 
prostate, lung, breast, and colon (Y. Wu, S. Antony, et al.). These observations suggest that 




Figure 1.4 - DUOX1 and DUOX2 display differential mRNA expression in various 
epithelial derived cancers. Dot blots represent mRNA expression of DUOX1 (A) or 
DUOX2 (B) extracted from either normal (N) healthy tissue (blue symbols), or tumor (T) 
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tissue (red symbols). Data extracted from Tissue Cancer Genome Atlas (TCGA); results 
shown as AVG ± SEM. Statistical significance determined by one-way ANOVA, n.s. = not 
significant; * p-value<0.05; ***p-value<0.001. RPKM = Reads Per Kilobase of transcript 
per Million mapped reads. Adapted from Little et al., used with permission from Elsevier.  
 
 
progression, which is supported by a recent report demonstrating that DUOX2 upregulation 
in colorectal cancer correlates with poor prognosis(Abdul Aziz et al.). Analysis of data 
available from the NIH funded Tissue Cancer Genome Atlas Project (TCGA) 
(http://cancergenome.nih.gov/) further confirms that DUOX2 is overexpressed especially 
in colon and esophageal cancers, although expression levels are highly variable and 
DUOX2 is not significantly altered in other cancers (Fig 1.4). Contrasting these findings, 
Knaus and colleagues originally reported that expression of both DUOX1 and DUOX2 is 
typically suppressed in lung cancer cell lines compared to normal epithelial cells (Luxen, 
Belinsky and Knaus), and subsequent studies confirmed that DUOX1 is frequently 
suppressed in both lung and hepatic cancers(Ling et al.; S. S. Chen et al.; Block and Gorin). 
Analysis of TCGA data confirms that DUOX1 is commonly suppressed in various cancers, 
primarily those of lung and skin, compared to adjacent healthy tissues (Fig 1.4). DUOX1 
suppression in cancers was also confirmed by immunohistochemical (IHC) analyses, as 
reported by Luxen et al. (Luxen, Belinsky and Knaus) or data deposited in the Human 
Protein Atlas (http://www.proteinatlas.org/ENSG00000137857-DUOX1/cancer), which 
indicate reduced DUOX1 protein expression in many cancers compared to expression in 
corresponding healthy tissues. Further comparison of DUOX1 mRNA expression in non-
small cell lung cancers compared to corresponding matched normal lung tissues (from the 
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TCGA repository) indicates that DUOX1 silencing is observed in both squamous cell 
carcinomas as well as adenocarcinomas, suggesting the potential broad relevance of 
DUOX1 silencing in cancer biology (Fig 1.5). Indeed, ectopic expression of DUOX1 in 
liver cancers was found to correlate strongly with overall patient survival and thus was 
proposed as a marker for patient prognosis (S. S. Chen et al.), suggests that DUOX1 
silencing may be of similar importance in progression of others cancers including NSCLCs.  
 
 
Figure 1.5 - Comparison of DUOX1 mRNA expression lung squamous cell 
carcinomas (SCC) and lung adenocarcinomas (AC) compared to corresponding 
matched controls. RNASeq data for SSC (n=50; A) and AC (n=58; B) and matched 
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controls were downloaded from the Genomic Data Commons Data Portal 
(https://portal.gdc.cancer.gov/) and converted to z-scores as described: Cheadle C, Vawter 
MP, Freed WJ, Becker KG. Analysis of Microarray Data Using Z Score Transformation. 
The Journal of molecular diagnostics : JMD. 2003;5(2):73-81. *P<0.0001 based on 
Wilcoxon matched-pairs signed rank test (Prism v7.01). Adapted from Little et al., used 
with permission from Elsevier. 
 
Observations of DUOX1 silencing in cancer are counterintuitive based on the 
common view that cancers are typically characterized by enhanced cellular ROS. Indeed, 
some studies have also suggested a contributing role for DUOX1-derived H2O2 in 
carcinogenesis. For example, ionizing radiation (IR), a strong risk factor for the 
development of thyroid cancer, was found to cause strong induction and activation of 
DUOX1 in thyrocytes and induction of genomic instability by DUOX1-derived H2O2 that 
was inhibited by pretreatment with catalase (Ameziane-El-Hassani, Talbot, et al.). 
Moreover, patients with thyroid tumors that were previously exposed to IR displayed 
elevated DUOX1 mRNA expression and immunohistochemical DUOX1 staining 
compared corresponding normal thyroid tissues(Ameziane-El-Hassani, Talbot, et al.), 
suggesting that DUOX1 may be playing an important role in radio-induced thyroid 
tumorigenesis(Ameziane-El-Hassani, Schlumberger and Dupuy). DUOX1 as well as 
DUOX2 have also been detected in human neuroblastoma cells, which were attributed to 
ROS-mediated upregulation(Damiano et al.), although relevance for brain cancer is not 
clear. Finally, although DUOX1 is often suppressed in various cancers (Fig 1.4), it was 
also found to be overexpressed in some colon and prostate cancers(Juhasz et al.). It is 
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conceivable that DUOX1 may play different roles in cancer depending on the type and 
stage of cancer, with DUOX1 playing a potential contributing role in carcinogenesis (e.g. 
by mediating ROS-induced genomic instability) whereas DUOX1 silencing in established 
cancers may be more relevant for e.g. tumor progression or metastasis, thus explaining its 
association with poor prognosis in e.g. HCC (S. S. Chen et al.). 
 
1.6. Dual Oxidase Enzymes  
To understand the potential functional consequences of DUOX1 silencing in epithelial 
cancers, it is important to first overview the known functional aspects of DUOX1 in 
epithelial biology. Below will cover basic understanding of structural information, and 
similarities and differences between DUOX1 and DUOX2. Additionally, covered here are 
mechanisms of activation, function, transcriptional regulation.  
 
1.6.1. DUOX Characterization: Structure and Expression 
DUOX1 and 2 are highly homologous (sharing more than 85% sequence identity at the 
amino acid level) and both include an internal domain with two calcium binding EF-hands, 
an additional transmembrane spanning sequence and extracellular N-terminal peroxidase 
homology (PHD) domain. Sequence alignment of the two DUOX isoforms indicates 
relatively low sequence identity within regions of their PHD, EF-hand containing domains, 
and DUOXA α-helical regions, suggesting that isoform-specific functions may largely 
depend on unique regulatory elements within these regions (Fig 1.6).  Activation of DUOX 
proteins to generate H2O2 as their primary product relies on Ca
2+ signaling. Although 
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DUOX enzymes do not require any additional co-factors for activation, other regulatory 
mechanisms have been identified (De Deken, Corvilain, et al.; Pacquelet et al.). DUOX 
proteins are expressed primarily at the apical surface of differentiated epithelial cell 
lineages, which relies largely on the co-expression of DUOX maturation factors, DUOXA1 
and DUOXA2(Carre et al.; Ueyama et al.; Grasberger and Refetoff; Luxen et al.), which 
control their transport from the endoplasmic reticulum to the  
 
Figure 1.6 - Topology of DUOX1-DUOXA1 proteins. DUOX1 utilizes reducing 
equivalents from NADPH to transfer electrons through the two heme molecules, reducing 
molecular O2 to H2O2. Regions highlighted in RED and YELLOW indicate regions with 
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relatively contain low sequence homology between DUOX1 and DUOX2 and between 
DUOXA1 and DUOXA2. Adapted from Little et al., used with permission from Elsevier. 
 
plasma membrane, resulting in a mature enzymatic complex. As will be discussed later in 
this review, alternative roles for DUOXA1 independent of DUOX1 have been described 
that may be relevant for cancer biology. Mammalian DUOX1 and 2 were first cloned from 
thyrocytes and were originally characterized as thyroid oxidase for its role in thyroid 
hormone synthesis(Dupuy et al.; De Deken, Wang, et al.), but are now known to be more 
widely expressed in various epithelial tissues in the lung, pancreas, placenta, 
gastrointestinal tract, testis, liver, prostate, salivary glands, skin, and brain(Geiszt; Leto and 
Geiszt; Choi et al.; Ling et al.; S. S. Chen et al.).  
 
1.6.2. DUOX Functions 
Based on analogous roles of phagocyte oxidase (NOX2), the main function of DUOX at 
mucosal surfaces (e.g. in the lung) is thought to be innate host defense against infection, 
by promoting direct luminal oxidative antimicrobial mechanisms catalyzed by locally 
secreted lactoperoxidase(Corcionivoschi et al.; Flores et al.; Geiszt et al.; Moskwa et al.). 
A similar concerted action of DUOX2 with thyroperoxidase in thyrocytes is responsible 
for generation of thyroid hormone(Carvalho and Dupuy). However, the precise isoform-
specific roles for DUOX1 and DUOX2 in host defense mechanisms are less well 
understood, and current evidence most strongly supports a role for DUOX2 rather than 
DUOX1 in antimicrobial or antiviral defense in the airway(Grandvaux, Mariani and Fink), 
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consistent with the high inducibility of DUOX2 in response to viral infection (Harper et 
al.; K. Fink et al.; Karin Fink et al.). Interestingly, although both DUOXes are thought to 
depend on Ca2+ signaling, studies with cultured airway epithelial cells indicate that basal 
extracellular H2O2 production under non-stimulated conditions primarily originates from 
DUOX2 (Gattas et al.; Sham et al.), whereas DUOX1 appears to be primarily responsible 
for enhanced H2O2 production in response to Ca
2+-mobilizing stimuli(Sham et al.). This 
would suggest that DUOX2 possesses basal activity and is less strictly dependent on Ca2+ 
signaling.  
Influx or intracellular mobilization of Ca2+ in response to diverse mechanical or 
biological stimuli commonly involve the initial cellular release of the cellular damage 
signal ATP(Sham et al.; van der Vliet and Janssen-Heininger; Razzell et al.; Cordeiro and 
Jacinto), which mediates critical cell responses through activation ionotropic and 
metabotropic purinergic receptors at the cell surface, as a highly conserved cellular 
mechanism in response to injury and inflammation(Cauwels et al.; van der Vliet and 
Janssen-Heininger; Cordeiro and Jacinto). Based on the known importance of ATP-
dependent purinoceptor signaling in epithelial wound responses, and the ability of ATP to 
activate DUOX1(Gattas et al.; Wesley et al.), our group considered a potential role of 
DUOX1 epithelial wound responses, and discovered that DUOX1 is indeed important in 
mediating epithelial cell migration and induction of various wound response genes (Wesley 
et al.; Sham et al.; Gorissen et al.). Subsequent studies also highlighted a role for epithelial 
DUOX1 in epithelial production of cytokines/chemokines (Hirakawa et al.; de Oliveira et 
al.; D. Y. Cho et al.; Hristova et al.) and neutrophil recruitment(Chang et al.; de Oliveira et 
al.; Habibovic et al.). DUOX1 was also found to play a potential role in T-cell receptor 
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signaling(Kwon et al.). These various actions of DUOX1 are largely mediated by H2O2-
dependent regulation of redox-dependent cell signaling pathways, through inactivation of 
protein tyrosine phosphatases(Kwon et al.) and/or direct oxidative activation of tyrosine 
kinases such as the non-receptor kinase Src and EGFR (de Oliveira et al.; Sham et al.; 
Hristova et al.; Habibovic et al.; Heppner et al.). Similar roles of DUOX in epidermal 
wound responses were subsequently also demonstrated in other organisms (Enyedi and 
Niethammer; Niethammer et al.), collectively highlighting the importance of DUOX1 in 
maintaining epithelial homeostasis. More recent studies also demonstrated the importance 
of DUOX1 in epithelial secretion of the alarmin IL-33 in response to airborne protease 
allergens or other non-microbial injurious stimuli(Hristova et al.). Epithelial secretion of 
IL-33 forms an important component of type 2 immunity as a critical host defense 
mechanism against non-microbial triggers, such as parasites, allergens, etc, which is largely 
mediated by stimulation of mucus proteins and epithelial repair pathways to enhance 
resistance or tolerance to such non-microbial insults. Moreover, allergen-induced IL-33 
secretion was also found to involve H2O2-mediated activation of the tyrosine kinases Src 
and EGFR(Hristova et al.).  Based on the notion that exaggerated type 2 responses can 
contribute to development of allergic diseases such as asthma(Hristova et al.), our group 
subsequently observed that allergic asthma is indeed associated with enhanced airway 
DUOX1 expression and that DUOX1 contributes to various critical features of asthma 




1.6.3. DUOX Transcriptional Regulation 
The transcriptional or post-transcriptional mechanisms that regulate DUOX expression are 
still poorly defined. Much of our understanding of DUOX transcriptional regulation comes 
from organisms that only harbor one DUOX gene(Bedard, Lardy and Krause; Lambeth), 
such as Drosophila melanogaster, which highlighted transcriptional regulation of DUOX 
by elements of the MAPK pathway(Buchon, Broderick and Lemaitre). The two 
mammalian DUOX genes and corresponding DUOXA genes (which encode for specific 
partner proteins, also known as DUOX maturation factors) are oriented in a head-to-head 
fashion, in tandem on chromosome 15(De Deken, Corvilain, et al.). Upon initial discovery 
of DUOX within the thyroid and its participation in thyrocyte differentiation, it was 
hypothesized that the DUOX genes were controlled by thyroid-specific transcription 
factors (TTF-1, Pax8), but this was found not to be the case(Damante, Tell and Di Lauro). 
More recent studies indicate that DUOX2 promoter activity was enhanced by Nkx2.5 and 
coactivator TAZ, transcriptional activators unrelated to thyroid-specific hormone 
production(Cardoso-Weide et al.). In lung epithelia, DUOX1 expression is also strongly 
enhanced during epithelial differentiation, and DUOX1 expression also increases strongly 
during alveolar maturation(Fischer et al.). DUOX1 expression in fetal lung cells could also 
be enhanced by hormone mixtures that promote alveolar type II differentiation, although 
the precise transcriptional mechanisms were not defined(Fischer et al.). However, other 
studies of in vitro differentiation of primary tracheobronchial epithelial cells using all-trans 
retinoic acid indicated strong induction of DUOX2 rather than DUOX1(Linderholm et al.). 
The DUOX1/DUOXA1 promoter region harbors several Sp1 binding sites, while 
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DUOX2/DUOXA2 promoter segment contains putative initiator elements (Inr) and a 
TATA box, for initiation of gene transcription(De Deken, Corvilain, et al.). Moreover, 
although such bidirectionally promoted gene pairs have a higher probability of coordinated 
expression, studies using bidirectional reporter constructs of the DUOX2/DUOXA2 
promoter revealed regulator regions necessary for bidirectional transcriptional activity, 
while other regions were found to control unidirectional activity (Xu et al.).  The 
differential regulation of DUOX1 and DUOX2 in airway epithelia is also evident from 
different responses to pro-inflammatory cytokines or environmental stimuli. Indeed, 
whereas DUOX1 is largely expressed constitutively and somewhat inducible the Th2 
cytokines such as IL-4 and IL-13, DUOX2 expression was strongly inducible by Th1 
cytokines (IL-1α, IL-1β, and IFN-γ) or viral stimuli(Harper et al.; Grandvaux, Mariani and 
Fink), suggesting unique and independent roles for DUOX1 vs DUOX2. Indeed, single 
nucleotide polymorphisms (SNPs) observed within the DUOX2/DUOXA2 promoter were 
found to significantly affect promoter activity in response to exogenous dsDNA (Xu et al.). 
The fact that DUOX2 is far more inducible by environmental or pro-inflammatory stimuli 
compared to DUOX1 would suggest that DUOX2 may be more involved in pathological 
responses, whereas DUOX1 more likely participates in more homeostatic roles within the 
epithelium (Fischer; Harper et al.), which will be discussed in more detail below.  
 Given our incomplete understanding of transcriptional and post-translational 
DUOX regulation, it is not surprising that the mechanisms involved in enhanced DUOX2 
expression in cancer are also poorly understood. Overexpression of DUOX2 and DUOX2-
dependent ROS generation in HCC has been attributed to post-transcriptional upregulation 
of DUOX2 by protein kinase C alpha (PKCα), which is also commonly overexpressed in 
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HCC and associated with poor prognosis(J. Wang et al.). Observations of DUOX2 
overexpression in pancreatic cancer are thought to be linked to pancreatitis and associated 
pro-inflammatory cytokines, and studies in pancreatic cancer cell lines indeed confirm 
induction of DUOX2 in response to bacterial lipopolysaccharide (LPS) or the inflammatory 
cytokine IFN-γ, due to concerted actions of transcription factors STAT1 and NF-κB 
(Yongzhong Wu et al.; Y. Wu, J. Lu, et al.). Similarly, pro-inflammatory cytokines IL-1α 
and IL-1β can also induce DUOX2 expression (as mentioned previously) and have 
important contributing roles in tumor progression (Apte et al.; Lewis et al.; Y. Li et al.; 
Voronov, Carmi and Apte; Voronov et al.), which could potentially involve increased 
DUOX2-dependent ROS production. DUOX2 activation has been implicated in chronic 
inflammatory diseases such as ulcerative colitis (MacFie et al.; Hayes et al.) or chronic 
airway inflammation (Joo et al.), and may thus be key in cancer development or 
progression associated with chronic inflammation. Similarly, the potential roles of IL-4/IL-
13 in tumor progression or immunosurveillance(Suzuki et al.) may be related to their ability 
to induce DUOX1 activity within the tumor microenvironment in some cases. 
 
1.7. DUOX1 Suppression in Cancer: Mechanisms and Consequences 
As previously mentioned, DUOX1 expression, both at the mRNA and protein level, is 
suppressed in many forms of epithelial cancers. This is due mostly to hypermethylation 
of its gene promotor region, first described in 2008(Luxen, Belinsky and Knaus). In this 
section, epigenetic regulation in cancer is discussed, followed by how this applies to 
DUOX regulation. Lastly, the functional consequences of DUOX suppression in cancer 
 
52 
are covered, as well as the potential for abnormalities in DUOX1-dependent EGFR 
regulation, offering insights to mechanisms of DUOX1 loss and cancer progression.  
 
1.7.1. Epigenetic Control in Cancer 
DNA hypermethylation has been well characterized as a signature mode of regulation for 
cancer cell(Paska and Hudler; F. Liu et al.; Dawson and Kouzarides; Feinberg, Koldobskiy 
and Gondor). DNA methylation typically involves methylation of cytosine within CpG-
rich regions that are prominently present in promoter regions of tumor suppressor genes 
such as cyclin-dependent kinase inhibitor 2A (CDKN2A) and BRCA1(Ting et al.; F. Liu 
et al.), and typically results in reduced expression of these genes. Conversely, DNA 
methylation is often suppressed in oncogenes and thereby permit their expression to 
promote cellular transformation(Ting et al.; Jones and Baylin). The DNA 
methyltransferases (DNMT) form a family of enzymes with isotype-specific modes of 
action, with DNMT3A/B being largely responsible for methylation of unmethylated DNA 
with important roles in development whereas DNMT1 primarily acts on hemimethylated 
DNA and participates in tissue-specific methylation patterns(Robertson). DNMTs are 
subject to regulation by e.g. phosphorylation, e.g. by cyclin-dependent kinases (CDK1/2/5) 
which stimulate their enzymatic activity (Esteve et al.). Increased expression or activation 
of DNMTs are observed as a result of oncogenic signaling programs related to constitutive 
activation of KRAS or EMT (F. Liu et al.; Jones and Baylin). Moreover, DNMT activity 
and DNA methylation status are also subject to change due to environmental factors, and 
might also occur as a result of ROS production by NOX enzymes(Hayes and Knaus; Wu 
and Ni). Therefore, the fact that NOXes can both contribute to promoting epigenetic 
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alterations, and in turn also be downregulated by such alterations, further illustrates the 
complexity of NOX biology in the context of cancer. 
Due to the strong relationship between aberrant DNA methylation and the 
progression of cancer, inhibitors of DNMT have been explored for potential anticancer 
therapy. Indeed, DNMT inhibitors such as 5’-aza-deoxycytidine (AzadC) have been FDA 
approved for the treatment of the preleukemic disorder myelodysplastic syndrome 
(Chiappinelli et al.) and have shown success treating various neoplasms, suggesting 
promise in other forms of cancer(L. Liu et al.; Qiu, Mirkin and Dwivedi; Soengas et al.). 
The precise mechanism of action of AzadC remains unclear and may also include actions 
independent of DNA methylation (Szyf). Other subsequently developed DNMT inhibitors 
such as zebularine also displays similar cytotoxic side effects, thus limiting their use 
therapeutically(Szyf). Importantly, DNA hypermethylation in cancer is also observed in 
various NOX isoforms such as NOX5 and the DUOXes (discussed below)(Hayes and 
Knaus). More intriguingly, various cancers are also characterized by increased DNA 
methylation of other genes involved in redox regulation, such as extracellular superoxide 
dismutase (SOD3), a secreted antioxidant enzyme that is highly expressed in various 
tissues and is critical for regulation of ROS-mediated alterations of extracellular matrix 
biology (M. Che et al.; Laukkanen). Indeed, SOD3 is frequently suppressed in pancreatic 
ductal adenocarcinoma (O'Leary et al.), breast cancer(Teoh-Fitzgerald, Fitzgerald, Zhong, 
et al.), and lung cancer(Teoh-Fitzgerald, Fitzgerald, Jensen, et al.), and overexpression of 
SOD3 or recovering SOD3 expression by DNMT inhibitors can suppress tumorigenic 
outcomes (Teoh-Fitzgerald, Fitzgerald, Zhong, et al.; Teoh et al.; O'Leary et al.; Teoh-
Fitzgerald, Fitzgerald, Jensen, et al.), suggesting the functional importance of SOD3 
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silencing for cancer progression. It is, however, unclear how silencing of DUOX1 as well 
as SOD3, which often occur in the same cancers, are mechanistically linked. DUOX1 
(unlike other NOX isoforms) does not generate O2
•- but only produces H2O2, which would 
therefore not be affected by superoxide dismutases such as SOD3. However, the fact that 
both DUOX and SOD3 could contribute to increased extracellular H2O2 production, might 
imply that suppression of such extracellular H2O2-generating mechanisms may be 
beneficial for tumor development.   
Countering the actions of DNMTs (which are considered to be ‘epigenetic writers’ 
able to edit the genome) are the actions of DNA demethylases (which serve as ‘epigenetic 
erasers’ and remove signatures made by the ‘writers’) (Falkenberg and Johnstone). Rao et 
al. first identified the ability of a ten eleven translocation (TET) enzyme, TET1, to catalyze 
the hydroxylation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) as a 
critical step in DNA demethylation(Tahiliani et al.; Kohli and Zhang). Two other TET 
family enzymes were subsequently identified(D. Li et al.). Interestingly, TET enzymes are 
often downregulated in various cancers by epigenetic mechanisms (Wu and Brenner; Neri 
et al.; Forloni et al.; L. Li, C. Li, et al.). Therefore, alterations of DNA methylation in cancer 
is not only mediated by altered or enhanced DNMT activity, but also appear to involve 
suppression of these ‘erasers’. A recent report demonstrated that oncogenic EGFR 
signaling represses various tumor suppressor genes through inhibition of TET1 activity, 
which could be restored by EGFR inhibition (Forloni et al.). Moreover, TET1 
overexpression inhibited tumor growth, whereas TET1 silencing enhanced resistance to 
EGFR-targeted therapies, collectively defining a unique dynamic between oncogenic 
EGFR activation and DNA methylation patterns(Forloni et al.). Recent studies also suggest 
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important consequences of metabolic alterations associated with ROS for TET enzymatic 
function. For example, ascorbate (vitamin C) is a critical co-factor for TET 
enzymes(Blaschke et al.; Minor et al.) and may be depleted in cancer cells associated with 
increased ROS levels. Moreover, alterations in cellular metabolism due to e.g. disruption 
of the tricarboxylic acid (TCA) cycle, potentially associated with ROS, can give rise to 
accumulation of so-called oncometabolites such as succinate, which can reshape 
epigenetics by competitive inhibition of e.g. TET enzymes or histone 
demethylases(Nordgren and Skildum; Sciacovelli and Frezza). 
 
1.7.2. Epigenetic Silencing of DUOX in Cancer 
Upon initial discovery of DUOX silencing in lung cancer (Luxen, Belinsky and Knaus), it 
was recognized that this is primarily due to increased DNA methylation within the DUOX 
promoter regions. The intergenic promoter regions of DUOX1/DUOXA1 and 
DUOX2/DUOXA2 were found to be rich in CpG islands, and their hypermethylation in 
cancer results in reduced expression(Luxen, Belinsky and Knaus; Little, Sham, et al.; Ling 
et al.; Wu, Mei and Brenner), likely due to interference with binding of transcription factors 
such as Sp1 and Sp3(L. Li, S. He, et al.; Zelko, Mueller and Folz). Therefore, DUOX1 has 
been considered to function as a tumor suppressor (Luxen, Belinsky and Knaus). As might 
be expected, DNMT inhibition was found to be capable of restoring expression of DUOX1 
in lung cancer cells(Luxen, Belinsky and Knaus; Little, Sham, et al.; Ling et al.), and 
suggest that the beneficial actions of DNMT inhibition might be related to recovering 
DUOX1 activity. In addition to DNA methylation, other epigenetic modifications such as 
methylation or acetylation of histones serve to control their interactions with DNA and 
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thereby regulate gene expression. The importance of histone methylation or acetylation for 
DUOX1 expression is not clear, and DUOX1 silencing in lung cancer cells could not be 
restored by the histone deacetylase (HDAC) inhibitor trichostatin A(Luxen, Belinsky and 
Knaus). Recent studies indicate that these epigenetic regulatory mechanisms can regulate 
other NOX isoforms such as NOX4(Bai et al.; Sanders et al.), and suggest that DUOX1 
expression is also subject to similar regulation by histone modifications. 
 
1.7.3. Functional Consequences of DUOX1 Loss in Cancer 
Given the observed role of DUOX1 in innate epithelial wound responses and homeostasis, 
it would seem plausible that silencing of DUOX1 in various cancers may be associated 
with loss of functional epithelial characteristics. Indeed, our recent studies, defined in 
Chapter 2, demonstrated that loss of DUOX1 in a panel lung cancer cell lines strongly 
corresponded to loss of the epithelial marker E-cadherin(Little, Sham, et al.). Subsequent 
studies showed that persistent silencing of DUOX1 using RNAi strategies, in normal 
epithelial cells or in the lung cancer cell line H292 (which maintains epithelial 
characteristics and expresses DUOX1), results in progressive loss of epithelial 
characteristics and acquisition of features representative of EMT(Little, Sham, et al.) (see 
Chapter 2). As covered in section 1.3, the process of EMT involves the loss of epithelial 
cell-cell contacts and epithelial molecular signatures (such as E-cadherin) and the gradual 
acquisition of a more motile, mesenchymal cell phenotype and expression of characteristic 
mesenchymal markers (e.g. vimentin, collagen, etc.). Our recent studies indicated that 
suppression of DUOX1 in H292 cells markedly enhanced their migratory and invasive 
capacity, both in vitro and in vivo(Little, Sham, et al.). Further supporting the functional 
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importance of DUOX1 silencing to drive features of EMT are findings that overexpression 
of DUOX1 in invasive lung cancer cell lines such as A549 or H187 (which normally lack 
DUOX1) was found to promote the reverse process of mesenchymal-to-epithelial transition 
(MET), and diminish migratory capacity and restore epithelial characteristics(Little, Sham, 
et al.). Additionally, our recent studies indicate that DUOX1 silencing in the cancer cell 
line H292 enhances the proportion of CSCs, based on analysis of CSC markers CD133 and 
ALDH(Little, Sham, et al.), and thus may suggest that DUOX1 silencing in cancers may 
pertain primarily to the most poorly differentiated cancer cells with increased CSC 
properties. This research and other details are covered comprehensively in Chapter 2.  
While our findings strongly correlate the loss of DUOX1 with EMT, the 
molecular mechanisms by which DUOX1 silencing promotes these various features are 
still unclear. On one hand, they may be related to reduced local DUOX-dependent H2O2 
production, thereby potentially modulating localized redox-dependent cellular signaling 
events that control epithelial differentiation or motility. However, since these effects of 
DUOX1 silencing were observed in the absence of known DUOX1-activating stimuli, it is 
also possible that they may point to actions of DUOX1 that are independent of its NADPH 
oxidase activity. In the next section, potential mechanistic consequences of DUOX1 
silencing will be addressed, based on known roles of DUOX1 in epithelial signaling. 
 
1.7.4. DUOX1 Loss and Altered EGFR Dynamics in Cancer 
Our studies of DUOX1-dependent redox signaling have highlighted an intricate 
relationship with the tyrosine kinases Src and EGFR as critical mediators of many of their 
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functional properties (Sham et al.; Heppner et al.; Habibovic et al.; Hristova et al.). Indeed, 
suppression of DUOX1 in cancer and the acquisition of EMT-like features may have 
connections to abnormalities in EGFR regulation. For instance, loss of epithelial polarity 
as a result of EMT diminishes this spatial control of EGFR signaling, for example by 
minimizing its interactions with E-cadherin(Qian et al.), and thus permits the unabated 
interactions between the receptor and its ligands, promoting persistent activation and 
features such as proliferation and cell migration. Therefore, loss of DUOX1 expression and 
resulting EMT features may therefore have consequences for regulation of epithelial EGFR 
signaling (Fig 1.7). Furthermore, since the process of EMT has been strongly associated 
with altered or increased ROS from multiple sources(Giannoni, Parri and Chiarugi), 
aberrant expression of the NADPH oxidases, including DUOX1 loss, could have direct 
consequences for EGFR signaling as it is highly subject to redox regulation (see section 
1.4.2). Although, little to no information is currently available regarding redox regulation 
of EGFR spatiotemporal control in normal epithelial biology or in the context of cancer.  
Cellular localization and activation of Src may also be dysregulated in cancer, which recent 
findings showing an imbalance in shuttling between caveolin-rich lipid rafts and focal 
adhesion complexes(Su et al.). Given our findings linking DUOX1 with Src in epithelial 
signaling presumably in lipid rafts (Sham et al.), DUOX1 silencing in lung cancer may 
have consequences for cellular Src distribution as well.  
As discussed previously, EMT is a critical determinant of sensitivity to EGFR-
TKIs(Thomson, Buck, et al.; Ren et al.). Moreover, our recent studies indicated that 
acquired resistance of H292 lung cancer cells to erlotinib is associated with a loss of 
DUOX1 and, conversely, that DUOX1 knockdown within H292 cells was sufficient to 
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promote resistance to erlotinib (Little, Sham, et al.) (see Chapter 2). Conceivably, these 
changes in EGFR-TKI sensitivity may be related to altered subcellular trafficking, e.g. 
towards nuclei (Singh and Coffey; T. M. Brand, M. Iida, N. Luthar, et al.; Wheeler et al.). 
In spite of the suggested association of DUOX1 silencing with EGFR TKI resistance in 
lung cancer, it is unclear whether DUOX1 status relates to the presence of activating EGFR 
mutations in lung cancers. For example, although EGFR mutations are more common in 
adenocarcinoma patients (about 30%) compared to non-adenocarcinoma NSCLC patients 
(about 2%)(Mitsudomi and Yatabe), TCGA data analysis suggests that DUOX1 silencing 
is equally common among both NSCLC types (Fig. 1.5).  
Collectively, the close relationship between DUOX1, Src, and EGFR, highlight a 
potentially dangerous triad when dysregulated in healthy epithelial cells, and is potentially 
the driving force behind DUOX1 loss and the acquisition of EMT. As modulation of 
DUOX1 expression significantly phenotypic switching between epithelial and 
mesenchymal states, without the addition of any specific exogenous cellular stimuli (e.g. 
ATP, Ca2+) (see Chapter 2), our hypothesis was directed to the notion that DUOX1 
expression may be mediating these changes in lieu of its ability to generate H2O2 
potentially through protein-protein interactions or other redox-independent processes. 
Regardless, due to the prominent roles Src and EGFR play in the progression of the cancer 
phenotype, understanding potential abnormalities in their regulation due to DUOX1 
suppression in cancer is of significant value to the basic biology of oncogenic 




Figure 1.7 - Loss of DUOX1 and local redox signaling has potential implications for 
EGFR regulation and signaling. (A) Schematic diagram of DUOX1-dependent redox 
signaling in response to epithelial stimuli. DUOX1-derived H2O2 oxidizes target protein 
cysteines (e.g. Src/EGFR) in a localized fashion near or at the plasma membrane, and 
promotes features consistent with normal epithelial redox signaling. (B) Loss of DUOX1 
in cancer removes a local oxidant source, and is associated with oncogenic EGFR 
signaling, potentially due to perturbed redox signaling mechanisms e.g. contributions from 
other NOXes or mitochondria. (C) DUOX1 suppression promotes EMT, which is 
accompanied with altered EGFR spatial distribution, although how altered redox regulation 
contributes to these consequences are unknown. (D) Associations between altered EGFR 
subcellular localization and oncogenic outcomes. Adapted from Little et al., used with 




1.8. DUOXes and their Maturation Factors: Partners or Enemies?  
As mentioned in previous sections, DUOX proteins are typically expressed in a coordinated 
manner with their maturation factors, the DUOXA proteins. Both DUOXA1 and DUOXA2 
consist of five alpha helical transmembrane regions, with extracellular loops and an 
intracellular tail (Fig. 1.6), and associate with immature DUOX within in the endoplasmic 
reticulum to promote its proper folding and glycosylation and transport to the plasma 
membrane to generate a mature, fully functional enzyme(Grasberger and Refetoff; Luxen 
et al.; Morand et al.). However, immature DUOX1 still has intrinsic catalytic activity as 
well(Ameziane-El-Hassani, Morand, et al.). Recent studies indicate that DUOX-DUOXA 
protein interactions also potentially involve intramolecular disulfide bridges between their 
extracellular regions(Carre et al.; Meitzler, Hinde, et al.). Additionally, it was recently 
recognized that the specificity of ROS release, either O2
- as an intermediate or H2O2 as its 
final product, is determined by sequences in the extracellular A loop of the DUOX proteins, 
which bind the N-termini of DUOXA proteins(Ueyama et al.). DUOXA1 is alternatively 
spliced, thereby yielding several splice variants and little is known regarding their 
individual roles(Luxen et al.). Intriguingly, it has been previously reported that certain 
splice variants of DUOXA1 can also partner with DUOX2, which permits the generation 
of H2O2 at nearly the same levels as DUOX2-DUOXA2 heterodimers, although this was 




Figure 1.8 - DUOXA1 and DUOXA2 mRNA expression in various epithelial derived 
cancers. Dot blots represent mRNA expression of DUOXA1 (A) or DUOXA2 (B) 
extracted from either normal (N) healthy tissue (blue symbols), or tumor (T) tissue (red 
symbols). Data extracted from Tissue Cancer Genome Atlas (TCGA); results shown as 
AVG ± SEM. Statistical significance determined by one-way ANOVA, n.s. = not 
 
63 
significant; * p-value<0.05; ***p-value<0.001. RPKM = Reads Per Kilobase of transcript 
per Million mapped reads. Adapted from Little et al., used with permission from Elsevier. 
 
1.8.1. Alternate DUOXA1 Functions 
In addition to partnering with corresponding DUOX proteins, DUOXA proteins may also 
have functions independent of DUOX. Indeed, DUOXA was originally identified in 
Drosophila melanogaster, as a binding partner to a master regulator of the Notch cell 
differentiation pathway, Numb, and was therefore named Numb Interacting Protein 
(NIP)(Grasberger and Refetoff; Xie et al.; Qin et al.). Sequence characteristics in the NIP 
proteins suggested they are membrane associated proteins, and as such, it was hypothesized 
that NIP regulates the subcellular localization of Numb by sequestering Numb to the 
plasma membrane during asymmetric cell division(Xie et al.). Mammalian NIP proteins 
were later recognized for their ability to regulate DUOX-dependent ROS production, and 
thus were denoted as DUOX activators, DUOXA1 and DUOXA2(Grasberger and 
Refetoff; Xie et al.). Given the importance of the Notch signaling pathway as a master 
controller of cellular differentiation, altered expression of DUOXA1 could have significant 
downstream effects on the Notch pathway, thereby leading to abnormalities in cell 
differentiation and/or tumor progression. Indeed, aberrant Notch signaling has been 
observed in a variety of cancers, with its signaling or expression either being pro- or anti- 
tumorigenic, highly dependent on the tissue and cellular context(Ostrakhovitch; Huang et 
al.; Nowell and Radtke). Interestingly, oncogenic EGFR signaling and Notch signaling 
have been considered mutual or correlative(Pancewicz-Wojtkiewicz), which could 
potentially be related to a common role for DUOX1/DUOXA1 on these processes. Beyond 
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its role as a maturation factor for DUOX1, or in regulating the Notch pathway, DUOXA1 
may also have other independent functional roles. For example, recent studies implicated 
DUOXA1 in cellular differentiation in muscle satellite cells(Sandiford et al.) and neuronal 
cells(Ostrakhovitch and Semenikhin; Kennedy et al.), which appears to involve 
interactions with p53, well-appreciated for its tumor suppressor function and its roles in 
cell cycle dynamics and differentiation(Ostrakhovitch and Semenikhin). Also, DUOXA1 
was found to harbor roles in various tissues such as the brain(Ostrakhovitch and 
Semenikhin; Kennedy et al.) and breast(Ostrakhovitch and Li), which appear unrelated to 
DUOX1. 
 
1.8.2. Independent Role for DUOXA1 in Cancer?  
Since the bidirectional promotor region of DUOX and DUOXA is rich in CpG islands, 
both DUOX and DUOXA genes were found to be suppressed in lung cancer cell lines due 
to hypermethylation(Luxen, Belinsky and Knaus). Analysis of TCGA data of DUOXA1 
mRNA expression indeed indicates that DUOXA1 is downregulated in various cancers, 
similar to DUOX1, whereas this seems to apply less to DUOX2 and DUOXA2 (Fig. 1.8). 
The functional significance of such DUOXA1 downregulation was suggested by studies in 
breast cancer cells, which showed reduced DUOXA1 expression in metastatic cell lines, 
and increased proliferation, altered cell adhesion, and susceptibility to doxorubicin after 
transient overexpression of DUOXA1, but not DUOX1 (Ostrakhovitch and Li). 
Interestingly, our recent studies in lung cancer cells indicate that overexpression of 
DUOX1, but not DUOXA1, can restore epithelial characteristics and reduce migratory and 
invasive properties (Little, Sham, et al.). Hence, the functional importance of DUOXA1 in 
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cancer still needs further clarification, but is likely independent of DUOX1. Moreover, in 
contrast to common silencing of DUOX1 appears in many cancers malignancies based on 
both TCGA data and IHC data in Human Protein Atlas, these data often show positive 
DUOXA1 protein expression in various cancer tissues (e.g. neuroendocrine, head and neck, 
testicular cancers) as well as mixed IHC protein staining in various other cancers. In 
addition, results from TCGA analysis show DUOXA1 mRNA expression is also enhanced 
in thyroid cancers (Fig. 1.8). Collectively, these observations suggest that DUOX1 and 
DUOXA1 may have independent functional properties, and alterations of DUOXA1 
expression in cancer may affect cancer biology by DUOX1-independent functions, 
potentially related to interactions with p53 or Numb/Notch pathways, in addition to 
regulating the actions of DUOX1.  
 
1.9. Dissertation Scope 
The scope of this dissertation is to characterize the functional and mechanistic 
consequences of DUOX1 suppression in lung cancer. Previous studies had highlighted that 
DUOX1 expression was silenced through promoter hypermethylation(Luxen, Belinsky and 
Knaus), a common mode of transcriptional regulation employed by cancer cells to dampen 
tumor suppressor genes. Since DUOX1 expression is coupled to epithelial differentiation, 
and has significant roles in normal epithelial maintenance, it seems plausible that 
epigenetic removal of DUOX1 could be a product of, or even promote cellular 
transformation. Initial studies aim to characterize the loss of DUOX1 in lung epithelial 
cells, while monitoring if the acquisition of oncogenic features occurs (e.g. proliferation, 
cellular invasiveness, etc). Moreover, as many lung cancer cell lines do not express 
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DUOX1, strategies to recover DUOX1 should be employed in attempt to understand if 
DUOX1 expression is a direct modulator of cellular phenotypes.  
Since DUOX1 enzymatic activity is linked to H2O2 generation, and mediates 
epithelial responses through its ability to redox activate the tyrosine kinases Src and 
EGFR(Sham et al.; Heppner et al.; Hristova et al.), investigation as to whether DUOX1 
loss in lung cancer has direct impacts for their regulation. Indeed, alterations to Src and/or 
EGFR regulation, in a redox-dependent or -independent fashion, has potentially dangerous 
oncogenic outcomes as Src and EGFR have both been well characterized for their 
individual contributions to cancer progression, warranting further examination.  
The loss of DUOX1 in cancer, is often paralleled by the loss of its maturation 
factor, DUOXA1. This is intuitive, since they share a bidirectional promoter region, 
although in some cases, DUOXA1 is expressed in lieu of DUOX1 (e.g. thyroid cancer).  
While initial discovery of the DUOXA proteins cataloged them as regulators of the Notch 
signaling pathways, they were later deemed maturation factors for DUOX1, and few 
reports since then have attempted to characterize the extraneous role of DUOXA1. Despite 
the lack of reports, a prominent example of this is the observed interactions between 
DUOXA1 and the master tumor suppressor TP53 in breast cancer cells(Ostrakhovitch and 
Li), whereas DUOX1 expression is considered to be very low and/or have minimally 
defined roles. Unraveling the dynamics between DUOX1 loss in cancer and the potential 
acquisition of extraneous DUOXA1 roles may provide insights to novel protein functions.  
 Lastly, summarizing the biological and clinical importance of the findings put 
forth in this dissertation will be addressed. Additionally, future directions and potential 
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new avenues of research are discussed, offering the capacity to enhance our knowledge of 
the importance of DUOX1 loss in cancer, and how this could be a critical event worthy of 
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Dual oxidase 1 (DUOX1) is an oxidant-generating enzyme within the airway epithelium 
that participates in innate airway host defense and epithelial homeostasis. Recent studies 
indicate that DUOX1 is suppressed in lung cancers by epigenetic silencing, although the 
importance of DUOX1 silencing in lung cancer development or progression is unknown. 
Here we show that loss of DUOX1 expression in a panel of lung cancer cell lines strongly 
associated with loss of the epithelial marker E-cadherin. Moreover, RNAi-mediated 
DUOX1 silencing in lung epithelial cells and the cancer cell line NCI-H292 was found to 
result in loss of epithelial characteristics/molecular features (altered morphology, reduced 
barrier function, loss of E-cadherin) and increased mesenchymal features (increased 
migration, anchorage-independent growth, gain of vimentin/collagen), suggesting a direct 
contribution of DUOX1 silencing to epithelial-to-mesenchymal transition (EMT), an 
important feature of metastatic cancer. Conversely, overexpression of DUOX1 in A549 
cells was capable of reversing EMT features. DUOX1 silencing in H292 cells also led to 
enhanced resistance to EGFR tyrosine kinase inhibitors such as erlotinib, and enhanced 
levels of cancer stem cell (CSC) markers CD133+ and ALDH1+. Furthermore, acquired 
resistance of H292 cells to erlotinib resulted in enhanced EMT and CSC features as well 
as loss of DUOX1. Finally, compared to control H292 cells, H292-shDUOX1 cells 
displayed enhanced invasive features in vitro and in vivo. Collectively, our findings 
indicate that DUOX1 silencing in lung epithelial cells promotes features of EMT, and may 





2.2. Materials and Methods 
 
 
Cell models and transfections - NCI-H292 cells, a human pulmonary mucoepidermoid 
carcinoma cell line (ATCC), were propagated in RPMI 1640 medium with 10% FBS/5% 
penicillin-streptomycin. DUOX1-deficient H292 cells (H292-shDUOX1) and 
corresponding vector control cells (H292-shCTL) were generated and maintained as 
previously described (Sham et al.). Three (3) separate H292-shDUOX1 clones were 
expanded and utilized in these studies. Erlotinib-resistant sub-clones of H292 cells were 
generated essentially as described by Yao et al. (Yao et al.), by culture for 30 days in the 
presence of 5 µM erlotinib followed by 60 days in the presence of 10 µM erlotinib (LC 
Laboratories, Woburn, MA). Selected resistant H292 cells (H292-E90) were maintained in 
the presence of 10 µM erlotinib and switched to regular growth media for assays. Alveolar 
adenocarcinoma cell line A549 cells (ATCC) were cultured according to ATCC guidelines, 
and grown to ~70% confluence in a 24-well dish (Costar, Corning, Corning, NY) for 
transfection with 1 μg of cDNA clone of the following vectors: pCMV6-AC-GFP control 
vector (A549-pCTL) (PS100010, Origene, Rockville, MD), pCMV-DUOXA1-GFP 
(A549-pDUOXA1) (RG206754, Origene, Rockville, MD) or pCMV-DUOX1-GFP 
(A549-pDUOX1) (RG223832, Origene, Rockville, MD). Cells were transfected 2X over 
the span of 6 days and then cultured in the presence of 250 μg/mL neomycin (G418 sulfate) 
(Calbiochem, Millipore, Billerica, MA) for 14 days. Positive transfection of DUOXA1 
and/or DUOX1 in A549-pCTL/A549-pDUOXA1/A549-pDUOX1 cell lines was verified 
by western blot and qRT-PCR analysis.  
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Other cell lines used in this study include: NHBE (normal human bronchial epithelial cells) 
maintained as described previously (Hristova et al.); HBE1 (immortalized human bronchial 
epithelial cells) maintained as described previously(Sham et al.; Hristova et al.); BEAS2B 
(human bronchial epithelial cells); Calu-3 (human lung adenocarcinoma cells); NCI-
H1975 (human lung adenocarcinoma cells); NCI-H1437 (human lung adenocarcinoma 
cells); NCI-H2170 (human lung squamous cell carcinoma cells); NCI-H82 (human lung 
carcinoma cells); NCI-H460 (human lung carcinoma cells); and NCI-H187 (human lung 
retinoblastoma cells). Unless indicated otherwise, all cell lines were obtained from ATCC 
and maintained according to established ATCC protocols, as well as surveyed for 
mycoplasma contamination.  
  
Trans-epithelial electrical resistance (TER) – Cells were seeded in transwell culture inserts 
and grown to confluency. TER was measured using an EVOMTM epithelial voltohmmeter 
(World Precision Instruments, Sarasota, FL). TER values were corrected for background 
resistance provided by the insert and/or the media. Data are represented as mean ± s.d. 
**p<0.01 were calculated by two-tailed Student’s T-test. (n=6; replicated 2x) 
 
Anchorage independent growth – Six-well culture plates were coated with 2 mL of a 50/50 
mixture of 1% agarose and 2X growth medium, and appropriate cells were harvested, 
resuspended in 50/50 mixtures of 0.67% agarose and 2X complete medium and seeded 
onto agarose-coated culture plates and placed in a 37°C incubator. After 4 weeks, plates 
were stained with a 0.005% crystal violet and imaged, and colonies were counted. Data are 
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represented as mean ± s.d. **p<0.01 were calculated by two-tailed Student’s T-test. (n=6; 
replicated 2x). 
 
In vitro assays of cell migration and invasion – Scratch wound assay - A linear scratch (~2 
mm) was generated in confluent cell monolayers in 24-well culture plates, and detached 
cells were removed with PBS and wound closure was monitored over a 24 hr period. 
Wound areas were imaged and analyzed using NIH Image J software to determine % 
wound closure as an indicator of cell migration. Data are represented as mean ± s.d. 
**p<0.01 were calculated by two-tailed Student’s T-test. (n=6; replicated 2x). Transwell 
Cell Migration Assay – Cells were seeded in Boyden-like chambers containing 10-mm 
polycarbonate membrane inserts (8 µm pore size) (Nunc International, Penfield, NY, USA) 
that were pre-coated with 10 µg/mL fibronectin (Invitrogen). Following incubation for 24 
hrs at 37°C, non-migratory cells were removed from membrane with a cotton swab, and 
migrated cells were stained with crystal violet for 30 min and extracted in 100µL of 0.2M 
sodium acetate buffer (pH 4.5) for analysis of absorbance at 570nM. Data are represented 
as mean ± s.d. *p<0.05 were calculated by two-tailed Student’s T-test. (n=6; replicated 2x). 
Donut cell migration assay – Cells were seeded inside silicone circular gaskets at 10,000 
cells/donut. Cells were maintained for ~24h in complete cell medium to reach full 
confluency. Donuts were then removed and images were taken immediately following 
donut removal and 24h later. Data was quantified using an ImageJ macro as described and 
provided previously(McKenzie, Campbell and Howe). Data are represented as mean ± s.d. 
*p<0.05 were calculated by two-tailed Student’s T-test. (n=12; replicated 2x). In vitro 
spheroid invasion assay - Invasive properties of the various cell lines were evaluated using 
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a spheroid invasion assay (Cultrex® Spheroid Invasion kit; Trevigen, Gaithersburg, MD) 
according to the manufacturer’s instructions. Images were taken on an inverted Olympus 
IX70 brightfield microscope and subsequently the images were analyzed using NIH Image 
J software in as defined in Cultrex® protocol. Data are represented as mean ± s.d. *p<0.05; 
**p<0.01 were calculated by one-way ANOVA. (n=18; replicated 2x).  
Western blot analysis – Cells cultured in 24-well culture plates were lysed using 100 μL of 
1X western solubilization lysis buffer (1% Triton, 50 mM HEPES, 250 mM NaCl, 10% 
glycerol, 1.5 mM MgCl, 1 mM PMSF, 1 mM EGTA, 2 mM Na3VO4, 10 μg/mL aprotinin, 
10 μg/mL leupeptin; pH 7.4) per well. Equal amounts of protein (20-25 μg; determined 
using BCA protein assay) were separated on Novex 10% Tris-Glycine gels (Life 
Technologies, Grand Island, NY), transferred to nitrocellulose membranes, and blotted 
using antibodies against: vimentin (#5741; 1:500; Cell Signaling, Danvers, MA), Akt 
(#9272; 1:1000; Cell Signaling, Danvers, MA), p-Akt (#4060X; 1:1000; Cell Signaling, 
Danvers, MA), β-actin (#MA5-15739; 1:10,000; Invitrogen, Waltham, MA), Collagen 
(#ab34710; 1:500; Abcam, Cambridge, MA), E-cadherin (#3195; 1:1000; Cell Signaling, 
Danvers, MA), DUOX1 (1:1000; kindly provided by F. Miot(De Deken, Wang, et al.), 
DUOXA1 (#H00090527-B01P; 1:1000; Abnova, Jhongli, Taiwan), and detected using 
enhanced chemiluminescence (Pierce, Rockfort, IL). 
Immunohistochemical analysis and morphological imaging – H292, H292-shCTL, H292-
shDUOX1 and H292-E90 cells were seeded in 8-well glass chamber slides, fixed with 4% 
PFA, and permeabilized with 0.2% Triton X-100 in 1% bovine serum albumin (BSA) in 
PBS for 15 minutes. Slides were washed 2X with 1% BSA/PBS solution, blocked with 
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10% goat serum for 1 hr, and then subjected to staining with antibodies against E-cadherin 
(1:100; Invitrogen), vimentin (1:100; Cell Signaling) or α-smooth muscle actin (1:100; Cell 
Signaling). Nuclei were counterstained with DAPI (10 μg/mL in 1% BSA/PBS). Cells were 
washed 2X with 1% BSA/PBS and mounted with glass coverslip. Images were taken on a 
Zeiss LSM 510 META laser scanning confocal microscope (Zeiss, Jena, Germany). 
Brightfield images were taken using a Zeiss Interskop phase contrast microscope interfaced 
with a digital camera (Zeiss, Jena, Germany) 
RNA interference – Cells were grown to ~70% confluence in 24-well plates and transfected 
with 0.1 μM siRNA targeted against DUOX1 mRNA (#117546, Ambion siRNA, Life 
Technologies, USA) (Accession No. NM_017434.3/NM_175940.1), DUOXA1 mRNA 
(#90527, Dharmacon, GE, Lafayette, CO) (Accession No. NM_144565.2), or 0.1 μM non-
targeting control siRNA (Dharmacon, GE, Lafayette, CO) in RPMI 1640 media (Gibco, 
Life Technologies, Grand Island, NY), and incubated 24 hours at 37°C. Media then 
replaced with complete media, and cells were incubated for an additional 48 hrs and then 
subjected to 1 or 2 successive similar transfections, and then harvested (3, 6, or 9 days after 
initial transfection for extraction of miRNA, RNA or protein.  
Analysis of cell viability and proliferation – Cells were seeded at 1x104 per well into a 96-
well black flat bottom fluorescence plates (Nunc International, Rochester, NY, USA) and 
cultured in RPMI 1640 (no FBS) in the presence of various doses of erlotinib (0.1-10 μM; 
LC Laboratories, Woburn, MA), by exchanging media ± erlotinib daily for up to 3 days, 
after which cell viability was determined using ATP TiterGlo assay reagent (Promega, 
Madison, WI) Data are represented as mean ± s.d. *p<0.05; **p<0.01 were calculated by 
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one-way ANOVA. (n=6; replicated 2x). Cell proliferation was analyzed by cell seeding at 
various densities and culture in full growth media for up to 72 hrs, using ATP TiterGlo 
reagent. Data are represented as mean ± s.d. Data did not reach significance (p<0.05) as 
tested by a two-tailed Student’s T-test (n=6; replicated 2x). Additional cell proliferation 
assays were performed by seeding cells at equal cell densities and harvested daily for 7 
days, and counted to assess proliferation. Data are represented as mean ± s.d. Data did not 
reach significance (p<0.05) as tested by a two-tailed Student’s T-test (n=6; replicated 2x). 
RNA extraction, PCR and quantitative real-time PCR – Total RNA was extracted with 
GeneJET RNA purification kit (Thermo Scientific, Waltham, MA, USA). For mature 
miRNA extraction, miRNeasy mini kit was utilized (Qiagen, Valencia, CA, USA). RNA 
extracts were reverse-transcribed and real-time PCR was performed using SYBR green 
qPCR assays. All qPCR primers were purchased from Sigma-Aldrich unless otherwise 
noted. Mature miRNA was reverse-transcribed utilizing miScript II RT Kit, and subsequent 
real-time PCR was performed with miScript SYBR Green PCR Kit and miScript Primer 
Assays (Qiagen, Valencia, CA, USA). Data are represented as mean ± s.d. *p<0.05; 
**p<0.01 were calculated by two-tailed Student’s T-test or one-way ANOVA. (n=6; 
replicated 2x) 
Evaluation of CSC characteristics – Cancer stem cell (CSC) markers were evaluated by 
multi-color flow cytometric analysis (FACS) on a BD FACS LSRII (BD Biosciences, San 
Jose, CA), after cell staining with 0.5 µg/100 µL of anti-CD24-Pacific Blue (eBioscience, 
San Diego, CA) and anti-CD44-Alexafluor 700 (Biolegend, San Diego, CA), 0.5 µg/100 
µL of anti-human-CD133-AF700 (MACS, Auburn, CA), or ALDEFLUOR reagent (0.5 
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µg/100 µL; Stem Cell Technologies, Vancouver, BC, CA) Data are represented as mean ± 
s.d. *p<0.05; **p<0.01 were calculated by two-tailed Student’s T-test. (n=6; replicated 
2x). CD24low/CD24high subpopulations of NCI-H292 cells were sorted utilizing anti-CD24-
Pacific Blue antibody, using a BD FACSAria high speed cell sorter (BD Biosciences, San 
Jose, CA). Similarly, CD133+ cells were sorted and collected in high FBS (20%) 
containing RPMI-1640 cell media (Gibco, Grand Island, NY) supplemented with 5% 
penicillin/streptomycin. Cells were centrifuged, washed 2X with 1X PBS, and resuspended 
in StemPro® mesenchymal stem cell growth media supplemented with StemPro® MSC 
SFM supplement (Gibco, Grand Island, NY) and placed in ultra-low attachment plates 
(Corning, Corning, NY) and monitored over the course of 7 days.  
In vivo tumor metastasis – Charles River CD1 nude male mice (8 wks) were injected into 
the tail vein with 1x106 of various cell lines (H292, H292-shCTL, H292-shDUOX1 (3 
separate clones), or H292-E90) in 1X sterile PBS, at random. Mice were weighed twice 
weekly and monitored for overall health up until 12 weeks post injection, after which mice 
were euthanized and tissues collected. Lung sections were cut at a thickness of 5 μm and 
stained with H&E for visual observation of lung structure. To quantify total numbers of 
neoplasias, lung tissue blocks were cut at a thickness of 5 μm and stained for H&E, then 
tissue blocks were cut into 50 μm, and another 5 μm section was isolated for H&E staining. 
This process was repeated until the tissue block was exhausted. Each tissue section was 
examined and neoplasias greater than 120 μm were counted. Neoplasia size was 
determined by measurements taken on Olympus BX-50 imaging software. Neoplasm 
quantification was not performed under blinded conditions. Data are represented as mean 
± s.d. *p<0.05; ***p<0.001 were calculated by two-tailed Student’s T-test. (for H292; 
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H292-E90; H292-shCTL; n=3 each; for H292-shDUOX1 n=7). Genomic DNA from 
mouse lungs was isolated utilizing phenol-chloroform extraction method and 30 ng of 
DNA was further amplified by qPCR for human ALU DNA sequences (Munoz et al.). All 
animal experiments were performed in compliance with IACUC regulations and 
guidelines.   
Analysis of DUOX1 activity – DUOX1 activity was evaluated by extracellular H2O2 
production in response to cell stimulation with 100 μM ATP (Sigma, USA), as described 
previously (Sham et al.). Data are represented as mean ± s.d. **p<0.01 were calculated by 
two-tailed Student’s T-test. (n=6; replicated 2x) 
Analysis of EGFR mutations – To determine potential acquisition of EGFR mutations in 
various engineered cell lines, cDNA was PCR amplified for EGFR exon 18 
(GCTGAGGTGACCCTTGTCTC (F) ACAGCTTGCAAGGACTCTGG (R)), EGFR 
exon 19 (GCTGGTAACATCCACCCAGA (F) GAGAAAAGGTGGGCCTGAG (R)), 
EGFR exon 20 (CCTCCTTCTGGCCACCATGCG (F) CATGTGAGGATCCTGGCTCC 
(R)) and EGFR exon 21 (CGGATGCAGAGCTTCTTCCC (F) 
AGGCAGCCTGGTCCCTGGTG (R)), purified and prepared for Sanger sequencing 
utilizing the forward (F) primers listed above. Samples were analyzed on an ABI Prism 
3130xl Genetic Analyzer (Thermo Scientific, Waltham, MA) at the University of Vermont 
DNA Analysis Core Facility. 
Statistical Analysis – All experimental procedures are reported with ≥4 individual 
replicates and replicated experimentally at a minimum of 2 times.  All data are subjected 
to either students two tailed t-test or a one way ANOVA for the determination of statistical 
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significance based on the set being analyzed. P-values < 0.05 (*), p-values < 0.01 (**). 
Correction for multiple comparisons were made using either Welch’s correction or the 
Holm-Sidak method depending on the data set. All data were calculated in Microsoft Excel 




The NADPH oxidase DUOX1 is highly expressed in differentiated airway and alveolar 
epithelia and generates H2O2 in response to various environmental triggers as part of innate 
protective response against challenges to the airway(Leto and Geiszt; Fischer). Activation 
of airway DUOX1 mediates epithelial production of inflammatory mediators and mucus 
proteins, and promotes cell migration, as critical events in mucosal host defense and 
maintenance of airway epithelial integrity(Fischer; Gorissen et al.; Wesley et al.; Hristova 
et al.), events that largely depend on redox-dependent activation of cell signaling 
mechanisms involving Src family tyrosine kinases(S. K. Yoo et al.; Sham et al.) and 
epidermal growth factor receptor (EGFR)-dependent pathways(Sham et al.; Gorissen et al.; 
Koff et al.). Since increased expression and/or activation of Src and EGFR are well-known 
features of lung cancer(Reungwetwattana and Dy; Summy and Gallick; Kim, Song and 
Haura), it is plausible that lung cancer may also be associated with increased expression or 
activation of DUOX1. Indeed, production of reactive oxygen species (ROS) from NADPH 
oxidases (NOX) including DUOX1 have been reported to promote genomic instability and 
alter signaling pathways involved in carcinogenesis(Meitzler, Antony, et al.; Ameziane-
El-Hassani, Talbot, et al.; Block and Gorin), and cancer cells commonly produce elevated 
levels of ROS as potential mediators of mitogenic signaling and metastasis(Kamata; Gius 
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and Spitz; Trachootham, Alexandre and Huang). Furthermore, expression of certain NOX 
isoforms is often increased in various cancers, although the distribution and expression 
levels are highly diverse across cancers and the biological roles of different NOX isoforms 
in cancer development and progression is still poorly understood(Block and Gorin; 
Meitzler, Antony, et al.).  
In apparent contrast with these concepts, several recent studies demonstrated that 
DUOX1, as well as its maturation factor, DUOXA1, is frequently silenced in various 
epithelial cancers, including lung cancer, due to DNA hypermethylation within their 
promoter regions(Luxen, Belinsky and Knaus; Wu, Mei and Brenner; Juhasz et al.; Ling et 
al.).  The significance of DUOX1/DUOXA1 silencing in cancer is unclear, and might 
suggest a role for DUOX1 and/or DUOXA1 as a potential tumor suppressor, potentially by 
mediating ROS-dependent inhibition of cytokinesis(Takahashi et al.). DUOX1 suppression 
may also be relevant for maintenance of cancer stem cells (CSC), which typically contain 
reduced ROS levels as an essential feature for maintaining quiescence and self-
renewal(Ogasawara and Zhang; Zhou, Shao and Spitz). Furthermore, since DUOX1 
activation participates in epithelial Src/EGFR-mediated signaling(Sham et al.; Koff et al.; 
S. K. Yoo et al.), DUOX1 silencing might result in altered regulation of these kinases, with 
potential consequences for development of resistance against tyrosine kinase inhibitors 
(TKI). In this regard, responsiveness of non-small cell lung cancers to EGFR TKI is 
strongly related to epithelial phenotype(Ren et al.; Thomson, Buck, et al.; Yauch et al.) and 
acquired resistance to EGFR TKI has been associated with epithelial-to-mesenchymal 
transition (EMT), a critical feature of invasive and metastatic cancers that is associated 
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with poor prognosis in lung cancer(Xiao and He; Nurwidya et al.; Thomson, Buck, et al.; 
Yao et al.).  
The present studies were conducted to address the potential association of DUOX1 
silencing in lung cancer with development of EMT and EGFR TKI resistance. Indeed, our 
results demonstrate that RNAi-mediated DUOX1 silencing in lung epithelial cells and the 
lung cancer cell line H292 induces loss of epithelial characteristics, increases features of 
EMT, and promotes invasive properties. Conversely, DUOX1 overexpression in lung 
cancer cells was able to reverse EMT features and enhance epithelial characteristics. 
DUOX1 silencing was also found to promote EGFR TKI resistance and enhance features 
of cancer stem cells (CSC), suggesting the significance of DUOX1 silencing in lung cancer 
as a possible indicator of lung cancers with poor prognosis or lack of responsiveness to 




DUOX1 silencing induces features of EMT 
We evaluated a panel of non-cancer airway epithelial cells and various lung cancer cell 
lines for mRNA expression of DUOX1 and DUOX2, and observed a general loss of 
DUOX1 and DUOX2 in most lung cancer cell lines tested (Fig 2.1A, 2.2A), with the 
exception of the pulmonary epidermoid adenocarcinoma cell line H292 and the lung 
adenocarcinoma cell line Calu-3, two cancer-derived cell lines that maintain many normal 
airway epithelial features(Shen et al.; Koff et al.) and maintain DUOX1 expression. We 
therefore hypothesized that epithelial DUOX1 expression may associate with epithelial 
characteristics. Indeed, DUOX1 expression status in a panel of lung cancer cell lines 
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strongly correlated with expression of the epithelial marker E-cadherin (Fig. 2.1A), 
suggesting that DUOX1 silencing in lung cancer is associated with loss of epithelial 
characteristics. To explore this further, we silenced DUOX1 in the DUOX1-expressing cell 
line H292, by stable transfection with DUOX1-targeted shRNA(Sham et al.), and selected 
3 individual clones for use in subsequent studies. We observed that H292-shDUOX1 cells 
display altered morphological features compared to normal or control transfected H292 
cells (Fig. 2.1B), with loss of cobblestone appearance and intercellular junctions and a 
more fibroblast-like cell morphology. Functional analysis also indicated a loss of epithelial 
characteristics of H292-shDUOX1 cells, with markedly reduced transepithelial electrical 
resistance (TER) (Fig. 2.1C), reflecting loss of epithelial barrier function due to loss of 
epithelial adherens junctions that are maintained by E-cadherin. H292-shDUOX1 cells also 
display increased migratory ability, as measured using a recently developed “donut” cell 
migration assay(McKenzie, Campbell and Howe) (Fig.2.1D; 2.2F), and using a scratch 
wound assay and a TranswellTM migration assay(Wesley et al.) (Fig. 2.2C/D). In contrast, 
DUOX1 deletion did not significantly affect proliferation (Fig. 2.1E; 2.2E). Moreover, 
H292-shDUOX1 cells also demonstrated markedly increased ability of anchorage-
independent growth on soft agar (Fig.2.1F). These findings were consistent across the 3 
separate H292-shDUOX1 clones. Together, these findings suggest that DUOX1, 
suppression can initiate the process of epithelial-to-mesenchymal transition (EMT).  
Analysis of various molecular features characteristic of EMT(R. Kalluri and R. 
A. Weinberg) revealed that H292-shDUOX1 cells showed markedly reduced expression 
of E-cadherin, and upregulation of the mesenchymal markers vimentin, collagen, and 
smooth muscle actin, compared to corresponding controls (Fig. 2.1G, 2.2B). Moreover, 
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H292-shDUOX1 cells also displayed constitutive activation of Akt, an important common 
hallmark of EMT(Larue and Bellacosa; Lamouille and Derynck) (Fig 2.2B), as well as 
markedly reduced levels of miR-200b, miR-200c and miR-205, and enhanced mRNA 
expression of EMT-promoting transcription factors ZEB1 and ZEB2 (Fig. 2.1H), 
additional common molecular features of EMT(Brabletz and Brabletz; Wellner et al.). To 
confirm the association of DUOX1 silencing with EMT in multiple epithelial cell lines, we 
performed similar analyses after repetitive siRNA-mediated DUOX1 silencing over a 
period of 9 days in both H292 cells and the non-cancer bronchial epithelial cell line HBE1, 
which revealed a similar gradual loss of E-cadherin and induction of mesenchymal markers 
in both cell models (Fig. 2.3A/B). Since DUOX1 silencing also resulted in reduced 
expression of the DUOX1 maturation factor DUOXA1, we determined whether silencing 
of DUOXA1 itself was able to cause features of EMT. However, similar siRNA targeted 
suppression of DUOXA1 did not induce loss of E-cadherin although it did enhance 
vimentin expression (Fig. 2.3C). Finally, induction of EMT features by DUOX1 silencing 
could be reversed by treatment with the DNA methyltransferase inhibitor 5-aza-
deoxycytidine (aza), suggesting that DUOX1 suppression promotes EMT by an epigenetic 
mechanism (Fig. 2.4). Collectively, these findings indicate that loss of DUOX1 expression 
in lung epithelial cells directly induces loss of epithelial characteristics and promotes 
development of EMT.  
 
DUOX1 suppression is associated with resistance to EGFR-TKI 
The process of EMT has been associated with acquired resistance of lung cancers to 
chemotherapeutic drugs and to tyrosine kinase inhibitors (TKI) of the epidermal growth 
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factor receptor (EGFR)(Shien et al.; Thomson, Petti, et al.). Because of the close 
relationship between DUOX1 and EGFR-dependent signaling(Sham et al.; Koff et al.), we 
explored the association between DUOX1 silencing, EMT and sensitivity to the EGFR TKI 
erlotinib. First, we cultured H292 cells for prolonged periods of time in the presence of 
erlotinib to select subpopulations with acquired erlotinib resistance (H292-E90). 
Consistent with earlier reports(Yao et al.), thus cultured erlotinib-resistant cells displayed 
morphological and molecular features of EMT (Fig. 2.5A,B), which were partly reversible 
by treatment with aza (Fig. 2.3). Importantly, compared to normal H292 cells, H292-E90 
cells also displayed dramatic loss of DUOX1 protein and mRNA expression (Fig. 2.5B), 
and loss of functional DUOX1 activity (Fig. 2.5C), further supporting a close association 
between DUOX1 silencing and EMT. Also, while normal H292 cells showed impaired 
growth in the presence of erlotinib, both H292-E90 and H292-shDUOX1 cells displayed 
marked resistance to erlotinib up to 10 µM (Fig. 2.5D), indicating that DUOX1 suppression 
may be an important determinant of acquired erlotinib resistance in lung cancers. 
Importantly, to rule out the possibility that enhanced erlotinib resistance may be related to 
acquired activating mutations in EGFR in our engineered cell lines, we verified by DNA 
sequencing that neither H292-E90 and H292-shDUOX1 cells contained the following 
detectable EGFR point mutations at exon 19 D761Y, V769L and N771T or exon 20 T790M 
or any insertion mutations on exon 19 (D770_N771) (Fig. 2.6).  
DUOX1 silencing leads to enhanced CSC characteristics 
One characteristic feature of EMT is altered expression of cell surface markers such as 
CD44 and CD24, typically involving increased CD44 expression and reduced CD24 
expression(Singh and Settleman; Yao et al.). Since established cancer cell lines are known 
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to display heterogeneity with respect to CD44/CD24 expression, and contain 
CD44high/CD24low subpopulations that are typically more mesenchymal in nature(Singh 
and Settleman; Yao et al.), we used FACS high speed cell sorting to isolate 
CD24low/CD44high subpopulations from H292 cells (Fig 2.7A; 2.8A) and confirmed that 
this subpopulation demonstrated enhanced EMT characteristics compared to 
CD24high/CD44low cells. Moreover, CD24low/CD44high H292 sub-populations demonstrated 
marked suppression of DUOX1 mRNA and protein (Fig. 2.7B,C; 2.8B), confirming the 
close relationship between loss of DUOX1 expression and EMT features. Conversely, 
analysis of H292-shDUOX1 cells as well as H292-E90 cells for mRNA levels and cell 
surface expression of CD24 and CD44, revealed that both H292-shDUOX1 and H292-E90 
cells displayed reduced mRNA expression and cell surface levels of CD24, and enhanced 
mRNA and surface expression of CD44, compared to corresponding controls (Fig.2.9A,B; 
2.8C), consistent with a shift toward a more mesenchymal phenotype in both cases.  
The process of EMT is strongly associated with increased characteristics of cancer 
stem cells (CSCs) and CD24low/CD44high sub-populations are thought to display increased 
CSC features(Eramo et al.), suggesting that DUOX1 silencing in lung cancer may also be 
associated with increased CSC characteristics. To address this, H292-E90 cells and H292-
shDUOX1 cells were analyzed for the expression of two commonly accepted lung CSC 
markers, CD133 and ALDH1(Eramo et al.; F. Jiang et al.; Sarvi et al.), using flow 
cytometry (Fig. 2.10). Indeed, both H292-shDUOX1 and H292-E90 cells were found to 
contain significantly increased populations of CD133+ cells compared to corresponding 
controls (6.61 ± 0.72% vs 3.25 ±  0.70% and 7.52 ± 0.85% vs 2.41 ± 0.16%, respectively) 
(Fig. 2.9C). Similarly, H292-shDUOX1 cells also displayed an increased fraction of 
 
108 
ALDH1+ cells compared to H292-shCTL cells (23.1 ± 5.2% vs 12.5 ± 0.6%), although no 
significant increase was observed in H292-E90 cells (Fig. 4D). Finally, culturing of FACS-
sorted CD133+ subpopulations in ultra-low attachment plates in stem cell media revealed 
enhanced growth of CD133+ cells from H292-shDUOX1 or H292-E90 cells compared to 
their control counterparts (Fig. 2.11). Together, these findings demonstrate that DUOX1 
silencing in lung cancer is associated with increased CSC properties.  
DUOX1 overexpression reverses EMT features 
Although our results indicate that DUOX1 silencing in lung epithelial cells promotes EMT 
and CSC features, the question remains whether these features can also be reversed by 
DUOX1 overexpression. To address this, we used the alveolar adenocarcinoma cell line 
A549, which displays low DUOX1 and E-cadherin expression and high levels of vimentin, 
and transfected them with DUOX1 cDNA (A549-pDUOX1; Fig. 2.12).  Since DUOX1 
silencing was also associated with suppression of its maturation factor DUOXA1 (Fig. 
2.3A), we similarly transfected A549 cells with DUOXA1 cDNA (A549-pDUOXA1) for 
comparison. Remarkably, compared to control A549 cells or A549-pDUOXA1 cells, 
A549-pDUOX1 cells displayed enhanced epithelial morphology with tight cell-cell 
contacts and increased cobblestone appearance (Fig. 2.13A). Accordingly, DUOX1 
overexpression enhanced protein expression of E-cadherin and suppressed expression of 
the mesenchymal marker vimentin, as visualized by immunofluorescence and Western blot 
analysis (Fig. 2.13A,B). DUOX1 overexpression in A549 cells also enhanced E-cadherin 
and reduced vimentin mRNA expression (Fig. 2.14).  Overexpression of DUOX1 but not 
DUOXA1 also inhibited migratory capacity of A549 cells in a donut migration assay (Fig 
2.13C; 2.14E) and in a scratch wound assay (Fig 2.12C). Finally, DUOX1 overexpression 
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in A549 cells significantly suppressed their ability to form colonies in soft agar (Fig. 
2.13D). Similar reversal of EMT features were observed after overexpression of DUOX1, 
but not DUOXA1, in the metastatic lung cancer cell line NCI-H187 (Fig. 2.15) in which 
DUOX1 is also silenced (Fig. 2.2). Collectively, these findings indicate that DUOX1 
overexpression in lung cancer cells can indeed reverse molecular and functional features 
of EMT. 
DUOX silencing promotes tumor invasiveness 
 Since the process of EMT is strongly linked with increased invasive or metastatic potential 
of lung cancer cells(R. Kalluri and R. A. Weinberg), we evaluated whether DUOX1 
silencing was associated with increased invasive/metastatic behavior. First, H292-
shDUOX1 cells and corresponding controls were evaluated in a spheroid invasion assay, 
which indeed demonstrated significantly increased invasiveness of H292-shDUOX1 cells 
into the surrounding extracellular matrix, compared to H292-shCTL cells or untransfected 
control H292 cells (Fig. 2.16A). To address in vivo invasiveness, we injected 3 clones of 
H292-shDUOX1 cells, as well as H292-E90 and corresponding control cells, into the tail 
vein of male CD-1 nude mice and harvested major organs after 12 weeks for analysis. 
Indeed, lung tissues of mice injected with H292-shDUOX1 cells or the EMT cell line 
H292-E90 displayed altered lung architecture with hyper-cellularity (Fig. 2.16B) and 
regions of atypical hyperplasia or small localized neoplasias (Fig. 2.16C; lower panels). 
No significant abnormalities were observed in livers or spleens (not shown). To evaluate 
quantitative differences in neoplasias or metastatic lesions within the lung, we sectioned 
the entire left lung lobe of each animal and examined series of sections separated by about 
50 μm for the presence of neoplasias with diameter >120 μm (Fig. 2.17). Total numbers of 
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counted neoplasias are summarized in Fig. 2.16D, and indicate that injection of H292-E90 
or H292-shDUOX1 (average of all 3 H292-shDUOX1 clones) resulted in significantly 
greater numbers of neoplasias compared to their respective controls. Because our 
histological analysis does not identify the cellular origin of these lung lesions, invasion or 
engraftment of injected human tumor cells was also evaluated by qPCR analysis of human 
ALU (hALU) repeat sequences, a DNA element not found in murine tissues. Indeed, mouse 
lung tissues with altered lung architecture and regions of hyperplasia also contained 
enhanced levels of hALU DNA (Table 2.1). While injection of normal H292 or H292-
shCTL cells did not induce significant increases in hALU DNA in mouse lungs compared 
to naïve mice (n=3), >5-fold increases in hALU DNA were detected in lung tissues after 
injection of H292-shDUOX1 cells in 4 out of 7 cases, and after injection of H292-E90 (2 
out of 3 cases). Overall, these findings indicate that DUOX1 silencing in H292 lung cancer 




The main finding of the present studies is that they establish the potential significance of 
frequent observations of epigenetic silencing of the NADPH oxidase DUOX1 in lung 
cancer and in other epithelial-derived cancers(Juhasz et al.; Ling et al.; Luxen, Belinsky 
and Knaus; S. S. Chen et al.), and indicate that DUOX1 silencing is causally linked with 
the development or progression of EMT, and promotes invasive properties as well as CSC 
features and resistance to EGFR tyrosine kinase inhibitors. Our findings may be highly 
relevant for lung cancer, since the process of EMT is a critical determinant of tumor 
invasiveness and metastatic potential, and has been frequently linked with poor 
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prognosis(R. Kalluri and R. A. Weinberg; Nurwidya et al.). Furthermore, associations of 
DUOX1 silencing with increased CSC properties and resistance to EGFR inhibitors has 
important implications for anticancer therapies and suggest that development of 
approaches aimed at preventing or reversing DUOX1 silencing may be clinically useful in 
targeting invasive or metastatic lung cancer. Moreover, although EGFR inhibitors are 
typically not recommended for use in treatment of lung cancers expressing wild-type 
EGFR, some patients with wild-type EGFR may also benefit and identification of 
biomarkers to identify such patients would be desirable(Laurie and Goss). In this regard, 
our studies suggest that lung cancers with wild-type EGFR and positive DUOX1 
expression may benefit for EGFR inhibitor therapy. The clinical relevance of DUOX1 
suppression in lung cancer is also supported by a recent study of patients with 
hepatocellular carcinoma, which indicated that higher DUOX1 expression strongly 
correlated with disease free survival(S. S. Chen et al.). However, since our various 
observations were based on experimental cell models, the clinical relevance of our findings 
with respect to e.g. tumor stage or progression is still unclear. 
Our present findings appear to contrast previous findings by us and others(Sham 
et al.; S. K. Yoo et al.) which indicated that inhibition of DUOX1 in epithelial cells 
attenuates cell migration in the context of epithelial wound injury responses, which involve 
the activation of DUOX1 by wound-derived signals such as ATP. The present findings, 
however, highlight a different scenario related to more gradual changes in epithelial 
biology and gene expression due to persistent loss of DUOX1, which leads to cell 
transformation with enhanced intrinsic cell motility, even though cells are less responsive 
to ATP-mediated wound responses(Sham et al.).  
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In addition to silencing of DUOX1, lung cancers were also found to display 
silencing of DUOXA1(Luxen, Belinsky and Knaus), a maturation factor for DUOX1 which 
aids in its trafficking to the plasma membrane to function as a competent NADPH 
oxidase(Fischer). Indeed, our findings indicate that RNAi-dependent silencing of DUOX1 
also leads to suppression of DUOXA1 (Fig.2.4A), which might contribute to observed 
EMT phenomena (e.g. Fig. 2.7). Intriguingly, DUOXA1 was originally described as Numb 
interacting protein (NIP). Numb is a negative regulator of the Notch signaling pathway, 
which plays an important role in airway basal cell differentiation(Rock et al.). Uncontrolled 
Notch signaling has been associated with metastatic and aggressive epithelial derived 
carcinomas, and nearly half of non-small cell lung cancers display elevated Notch 
expression/signaling, often associated with suppressed Numb expression(Westhoff et al.). 
DUOXA1/NIP expression often mimics the expression status of Numb and loss of Numb 
has been associated with disruption of the epithelial phenotype(Ostrakhovitch). In addition 
to regulating Numb, NIP/DUOXA1 also plays an important role in e.g. in myogenesis, with 
overexpression of NIP/DUOXA1 inhibiting differentiation and promoting apoptosis 
through enhanced DUOX1-dependent ROS production(Sandiford et al.). To address the 
potential involvement of DUOXA1, we used either direct siRNA silencing or 
overexpression of DUOXA1, which did not significantly affect EMT (Fig. 2.3C, Fig. 2.13). 
Therefore, although some molecular alterations associated with DUOX1 silencing may 
have resulted from indirect changes in e.g. Notch/Numb status due to suppression of 




The mechanism(s) by which DUOX1 silencing results in increased EMT still 
remain to be determined. It is plausible that a loss of DUOX1 activation and H2O2-
dependent redox signaling might impact on regulation of Src activation and EGFR-
dependent signaling pathways, based on recent studies linking DUOX1 and Src/EGFR 
activation in epithelial wound responses(Sham et al.; Gorissen et al.). Indeed, expression 
and activation of Src and EGFR are often increased in lung cancer and form a common 
therapeutic target in many lung cancers(Reungwetwattana and Dy; Kim, Song and Haura), 
and acquired resistance to EGFR tyrosine kinase inhibitors may be associated with 
increased nuclear localization of EGFR(C. Li et al.; T. M. Brand, M. Iida, N. Luthar, et 
al.). However, our studies did not indicate significant differences in overall ROS 
production in either DUOX1-deficient H292 cells(Sham et al.) or in DUOX1-
overexpressing A549 cells under basal conditions (Fig. 2.12C), unless DUOX1 was 
activated by external stimuli such as extracellular ATP. Although we cannot rule out a 
potential impact of basal DUOX1-derived H2O2 production in determining cellular 
outcomes, it is also possible that DUOX1 expression may control cell fate by redox-
independent mechanisms, e.g. by acting as a scaffold for EGFR or Src, similar to the 
recently described role of AKAP12(Su et al.). In addition, it is also plausible that altered 
DUOX1 status affects cellular redox-dependent mechanisms by more indirect effects, e.g. 
by altered expression of other NOX isozymes. However, although DUOX1 loss or 
overexpression resulted in some modest alterations in mRNA expression of NOX1, 2, or 4 
(Fig. 2.18), we did not observe consistent alterations that would point to a major role of 
other NOX isoforms in our observed outcomes. Future mechanistic studies will be required 






In summary, our findings indicate that DUOX1 silencing, a common finding in epithelial 
cancers including lung cancer(Ling et al.; Juhasz et al.; Meitzler, Antony, et al.), may be a 
strong determinant of increased invasive or metastatic potential, as well as resistance to 
conventional anti-cancer therapies.  At this stage, it is unknown how DUOX1 silencing 
relates to different types of lung cancer or with specific mutations in EGFR, KRAS, etc. 
Also, our findings appear to contrast with recent findings indicating a role for DUOX1-
derived H2O2 as a cause of oxidative DNA damage and genomic instability in response to 
ionizing radiation (IR) of the thyroid, as a potential mechanism of development of thyroid 
cancer(Ameziane-El-Hassani, Talbot, et al.). However, it is plausible initiation of lung 
carcinogenesis by oxidative events related to DUOX1 may be followed by subsequent 
epigenetic DUOX1 silencing in established tumors, which in turn may serve to promote 
invasiveness or metastatic potential. Also, the observed association between DUOX1 
expression and sensitivity to EGFR TKI may suggest that positive DUOX1 expression 
status in lung cancers may be suitable for therapeutic management with EGFR TKI, even 
if they express wild-type EGFR. Future studies are warranted to further decipher the 
mechanism(s) involved in epithelial DUOX1 expression and its relation to epithelial 
phenotype or development of EMT, which would allow for alternative approaches to 
therapeutically control DUOX1 expression as a potential treatment strategy in established 
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Figure 2.1 - DUOX1 silencing displays functional mesenchymal features. (A) 
Evaluation of DUOX1 and E-cadherin (CDH1) mRNA expression in normal non-cancer 
airway epithelial cells (black dots) and a panel of lung cancer cell lines (red dots). (B) 
Phase contrast brightfield microscope images taken of host cell line H292, H292 cells 
transfected with an empty vector (H292-shCTL) and H292 cells transfected with short 
hairpin RNA targeted against DUOX1 (H292-shDUOX1). (C) Trans-epithelial resistance 
(ohms) characterization of each cell model. (D) Cell migration as measured by Donut cell 
migration assay. (E) Cells were seeded at various densities and allowed to grow in culture 
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for 72hrs. Post 72hrs, cell viability via ATP production was determined in a luminescence 
assay. (F) Cells were grown on soft agar and colonies counted to assess anchorage 
independent growth. (G) Fluorescent images of EMT markers; (SMA) smooth muscle 
actin. (H) Quantitative real-time PCR results of miR-200 family and transcriptional 





Figure 2.2 - DUOX1 silencing promotes features of EMT. (A) Evaluation of DUOX1 
and DUOX2 mRNA expression in normal airway epithelial cells and a panel of lung cancer 
cell lines. (B) Western blot analysis of molecular features of EMT in H292 cells after 
constitutive silencing of DUOX1 (H292-shDUOX1). (C,D) Analysis of cell migration of 
H292-shDUOX1 and corresponding controls in a scratch wound assay (n=6) (C) and in a 
Transwell migration assay (n=6) (D). (E) Evaluation of cell proliferation after cell seeding 
at 50,000/well (n=6). (F) Representative images from donut cell migration assay. Migrated 
cells (right most panel), represent total migrated cells 24hrs post removal of the silicon 
gasket (donut) (24hrs image – 0hrs image = migrated cells). Results are expressed as mean 





Figure 2.3 - Transient siRNA targeting of DUOX1 promotes features of EMT. (A) 
H292 cells were transfected with DUOX1-targeted siRNA or control siRNA 3X over the 
course of 9 days, and alterations in DUOX1, DUOXA1, E-cadherin, vimentin, or miR200 
members were analyzed by RT-PCR (n=4 per group). (B) RT-PCR or Western blot analysis 
of DUOX1 and DUOX2 and EMT markers of after repeated siRNA-dependent silencing 
of DUOX1 in HBE1 cells . (C) H292 cells were transfected with DUOXA1 siRNA 3X 
over the course of 9 days, and DUOX1, DUOXA1, E-cadherin or vimentin were analyzed 
by qPCR (n=4 per group). Data are represented as mean ± SD *p<0.05, **p<0.01 were 





Figure 2.4 - DUOX1 silencing-induced EMT is mediated by epigenetic mechanisms. 
Control H292 cells (H292-shCTL), DUOX1-silenced cells (H292-shDUOX1) and 
erlotinib-resistant H292 cells (H292-E90) were incubated in the absence or presence of 5-
azadoxycytidine (aza) for 4 days and mRNA levels of E-cadherin or vimentin were 





Figure 2.5 - DUOX1 silencing is associated with acquired resistance to the EGFR TKI, 
erlotinib. (A) Brightfield and fluorescent confocal imaging of host cell line H292 and 
erlotinib resistant H292 cell model (H292-E90) displaying features of EMT. (B) Protein 
and RNA analysis of EMT markers. (C) HPLC H2O2 measurements of ATP stimulated 
H292 and H292-E90 cell lines. (D) Percentage of viable cells post treatment of 






Figure 2.6 - Acquired resistance to erlotinib or DUOX1 silencing does not promote 
the acquisition of EGFR-TKI resistance point mutations. We confirmed by DNA 
Sanger sequencing that the host cell line H292 (A), erlotinib resistant H292-E90 cell model 
(B), H292-shCTL (C), or the H292-shDUOX1 (D) cell lines did not display point mutations 






Figure 2.7 - EMT features and loss of DUOX1 in the H292 CD24Low subpopulation. 
(A) FACS gating strategy displaying H292 cell subpopulations were sorted based on their 
expression of surface antigen CD24/CD44. (B) Quantitative Real-Time PCR and western 
blot (C) results displaying CD24low H292 subpopulations display features of EMT and 





Figure 2.8 – Gating strategy and isolation of cancer stem cell populations. (A) FACS 
gating strategy for H292 cells against CD24 and CD44. (B) Characterization of FACS 
sorted CD24high and CD24low subpopulations of H292 cells for CD24 and DUOX1 mRNA 
expression by RT-PCR. (C) Analysis of CD24 and CD44 mRNA by RT-PCR in H292-E90 







Figure 2.9 - DUOX1 silencing enhances proportions of EMT-like CD24low/CD44high 
cell populations and elevates expression of CSC markers CD-133 and ALDH1. (A/B) 
FACS results of relative percent change of surface antigen CD24 and CD44 (left/right 
respectively) versus their unstained controls. (C) FACS results of %CD-133+ cells as 
compared to their individual controls. (D) FACS results of %ALDH1+ cells as compared 




Figure 2.10 - FACS gating strategy for evaluation of surface expression of CD133 in 
H292-shCTL and H292-shDUOX1 cells (A) and in H292 and H292-E90 cells (C). (B,D) 
FACS gating strategy employed to monitor the expression of intracellular ALDH activity 





Figure 2.11 - Evaluation of CD133+ subpopulations of various cell lines for stem cell 
properties. CD133+ subpopulations were obtained by high speed FACS cell sorting and 
cultured in ultra-low attachment plates in mesenchymal stem cell growth media. Images 





Figure 2.12 - Characterization of A549 cells transfected with DUOX1 or DUOXA1 
cDNA. Performed by qRT-PCR analysis of DUOXA1 mRNA (A) or DUOX1 mRNA (B) 
(n=4 per group), and by HPLC analysis of DUOX-dependent H2O2 production in response 
to cell stimulation with ATP (100 μM) (n=6). H292 cells were analyzed for comparison. 
Data are represented as mean ± SD *p<0.05, **p<0.01 were calculated by one-way 






Figure 2.13 Overexpression of DUOX1 in A549 cells promotes epithelial signatures. 
(A) Brightfield microscopy reveals DUOX1 overexpressing cells display an epithelial cell 
morphology. Confocal imaging of epithelial marker, E-cadherin and mesenchymal protein, 
vimentin. (B) Western blot analysis shows DUOX1 overexpression promotes features of 
the mesenchymal to epithelial transition (MET). (C) Donut cell migration assay displaying 
slower migration in DUOX1 overexpressing cells. (D) DUOX1 overexpression inhibits 




Figure 2.14 - Effect of overexpression DUOX1 or DUOXA1 on EMT features in A549 
cells. Control or transfected A549 cells were analyzed for mRNA levels of the epithelial 
marker E-cadherin (A) and the mesenchymal protein vimentin (B) by qRT-PCR (n=4 per 
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group). Control or transfected A549 cells (A549-pDUOX1) were analyzed for cell 
migration in a scratch wound assay (C) and in a Transwell migration assay (D). Results are 
expressed as mean ± SD (n=4).  (E) Representative images from donut cell migration assay. 
Migrated cells (right most panel), represent total migrated cells 24hrs post removal of the 
silicon gasket (donut) (24hrs image – 0hrs image = migrated cells). *p<0.05, **p<0.01 
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Figure 2.15 - Effect of DUOXA1 or DUOX1 overexpression on EMT features in H187 
cells. Control or DUOX1/DUOXA1-transfected A549 cells were analyzed for mRNA 
expression levels of the epithelial marker E-cadherin and the mesenchymal protein 
vimentin by qRT-PCR. Results are expressed as mean ± SD (n=4) *p<0.05, **p<0.01 were 






Figure 2.16 - DUOX1 silencing displays enhanced invasive properties. (A) H292-
shDUOX1 cell spheroids display invasion into surrounding ECM-like matrix after 4 days, 
arrows display cellular invasion into mock ECM gel matrix. Right panel shows average 
percent change in pixel area quantified over the course of multiple experiments. *p<0.05, 
**p<0.01. (B) H&E stained lung sections of H292-shDUOX1 or H292-E90 injected mice 
present significantly altered lung architecture. (C) Localized areas of neoplasias or small 
engrafted tumors in H292-shDUOX1 injected mouse lungs. (D) Quantification of counted 
lung neoplasias >120μM in diameter for animals injected with various cell models 




Figure 2.17 - Analysis of neoplasm size in lung tissues after tail vein injection of tumor 
cell lines. (A,B) Representative lung tissue sections (H&E) and identification of neoplastic 





Figure 2.18 - Effect of DUOX1 silencing or overexpression on expression of NOX1,2 
4. H292-shCTL, H292-shDUOX1, A549-pCTL and A549-pDUOX1 cell RNA extracts 
were analyzed for NOX1, NOX2, or NOX4 mRNA expression by qRT-PCR. Results are 






Table 2.1 - Evaluation of tumor cell engraftment into lung tissues by qPCR analysis 
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Dual oxidase 1 (DUOX1) is an H2O2 producing enzyme located in the airway epithelium 
with key roles in epithelial homeostasis. Prior findings indicate that DUOX1-dependent 
redox regulation of the epidermal growth factor receptor (EGFR), is critical for its function 
in normal epithelial responses. Recent studies indicate that DUOX1 is silenced in lung 
cancer, and our previous report displays DUOX1 loss promotes the epithelial-to-
mesenchymal transition (EMT). Because of the well characterized role of EGFR in cancer 
biology, we hypothesized that DUOX1 loss in lung cancer may have impacts for its 
regulation. In this study, we have uncovered that DUOX1 suppression in lung cancer cells 
significantly alters EGFR redox dynamics, both under basal and stimulatory conditions. 
Our observations indicate that EGFR undergoes rapid turnover of oxidized cysteines 
following EGF-stimulation in DUOX1-depleted cells but not in control cells. Interestingly, 
changes in EGFR redox-status respective to DUOX1 expression, correlated with aberrant 
EGFR subcellular trafficking, with nuclear targeting. Indeed, we find many oncogenic 
features of nuclear EGFR (nEGFR) in DUOX1-lacking cells but minimally in control cells. 
Lastly, in DUOX1-depleted cells, we find nEGFR is in part reliant on the enzymatic 





3.2. Materials and Methods 
 
Cell models and transfections - NCI-H292 cells, a human pulmonary mucoepidermoid 
carcinoma cell line (ATCC), were propagated in RPMI 1640 medium with 10% FBS/5% 
penicillin-streptomycin. DUOX1-deficient H292 cells (H292-shDUOX1) and 
corresponding empty vector cells (H292-shCTL) were generated and maintained as 
previously described(Sham et al.). Alveolar adenocarcinoma cell models, either transfected 
with empty vector (A549-pCTL) or DUOX1-expression vector (A549-pDUOX1) were 
generated as previously described(Little, Sham, et al.) and maintained in DMEM-F12 
media supplemented with neomycin. Likewise, NCI-H187 human lung retinoblastoma 
cells transfected with empty vector (H187-pCTL) or DUOX1 cDNA (H187-pDUOX1) 
were generated as previously described(Little, Sham, et al.). Other cell lines utilized in this 
study include HBE1 (immortalized human bronchial epithelial cells) and NCI-H187/NCI-
H460 (human lung carcinoma cells) maintained as described previously(Hristova et al.; 
Little, Sham, et al.).   
Immunofluorescence, immuno-electron microscopy, and data processing –  H292, H292-
shCTL, H292-shDUOX1, A549, A549-pCTL, A549-pDUOX1, H187, cells were seeded 
in 8-well glass chamber slides, treated with EGF ligand (100ng/mL) (Millipore, MA, US) 
or mock, fixed with 4% PFA, and permeabilized with 0.2% Triton X-100 in 1% bovine 
serum albumin (BSA) in PBS for 15 minutes. Slides were washed 2X with 1% BSA/PBS 
solution, blocked with 10% goat serum for 1 hr, and then subjected to staining with 
antibodies against Src (1:100; Cell Signaling, Danvers, MA), pSrc-416 (1:100; Millipore), 
or EGFR 1:100; Cell Signaling) overnight at 4°C. Nuclei were counterstained with DAPI 
 
143 
(10 μg/mL in 1% BSA/PBS). Cells were washed 2X with 1% BSA/PBS and mounted with 
glass coverslip. Images were taken on a Zeiss LSM 510 META laser scanning confocal 
microscope (Zeiss, Jena, Germany). Brightfield images were taken using a Zeiss Interskop 
phase contrast microscope interfaced with a digital camera (Zeiss, Jena, Germany). Post 
image nuclear mask processing of pSrc-416 or EGFR was performed as previously 
described(Noursadeghi et al.), utilizing NIH ImageJ.  
RNA interference and chemical inhibitors – Cells were grown to ~70% confluence in 24-
well plates and transfected with 0.1 μM siRNA targeted against DUOX1 mRNA (#117546, 
Ambion siRNA, Life Technologies, USA), 0.1 μM siRNA targeted against GSTP1 
(Dharmacon SmartPool siRNA # L-011179-00-0005, GE, Lafayette, CO) siALOX5 
(Dharmacon SmartPool siRNA #L004530-00-0005, GE) or 0.1 μM non-targeting control 
siRNA (Dharmacon, GE, Lafayette, CO) in RPMI 1640 (H292 or H187 cells) or DMEM-
F12 media (A549 cells) (Gibco, Life Technologies, Grand Island, NY), and incubated 24 
hours at 37°C. Media then replaced with complete media, and cells were incubated for an 
additional 24 hrs prior to experimentation. To diminish ROS from mitochondria (mtROS), 
cells were pretreated in serum-free media for 60 minutes with the mtROS scavenger, 
MitoQ (1µM) or the NADPH oxidase inhibitor, DPI (1µM) (Sigma Aldrich, #D2926). 
Total cell protein was then isolated per experimental requirements.  
RNA extraction, PCR and quantitative real-time PCR – Total RNA was extracted with 
GeneJET RNA purification kit (Thermo Scientific, Waltham, MA, USA). RNA extracts 
were reverse-transcribed and real-time PCR was performed using SYBR green qPCR 
assays. All qPCR primers (Supplemental Table 1) were purchased from Sigma-Aldrich. 
 
144 
Data are represented as mean ± s.d. *p<0.05; **p<0.01 were calculated by one-way 
ANOVA. (n=4; replicated 2x) 
Determination of Cellular ROS – Cell models were seeded in 96 well plates and pretreated 
with 5µM final concentration of H2DCFDA (#D399, Thermo) for 30 min at 37°C. 
Fluorescence was monitored on a Bio-Tek Synergy HT fluorescent plate reader (Bio-Tek, 
Winooski, VT) in accordance with manufacturers protocol. Additionally, intracellular ROS 
levels were confirmed with the H2O2 sensitive probe, CellRox Deep Red Reagent 
(#C10422, Thermo). Cells were seeded on 8-well chamber slides (mentioned previously), 
pretreated with 5µM final concentration solution for 30 minutes at 37°C, and then subjected 
to paraformaldehyde fixation (4%) for 30 minutes at RT, coverslip applied, and imaged on 
a Zeiss LSM 510 META laser scanning confocal microscope (Zeiss). Quantification of 
CellRox signal was performed on ImageJ (NIH), from at least 2 independent experiments.  
Protein isolation, subcellular fractionation, protein cysteine oxidation, and western blot 
analysis – Cells cultured in 24-well culture plates were lysed using 100 μL of 1X western 
solubilization lysis buffer (1% Triton, 50 mM HEPES, 250 mM NaCl, 10% glycerol, 1.5 
mM MgCl, 1 mM PMSF, 1 mM EGTA, 2 mM Na3VO4, 10 μg/mL aprotinin, 10 μg/mL 
leupeptin; pH 7.4) per well. Subcellular protein isolation was performed with the 
Subcellular Protein Fractionation Kit (#78840; Thermo Scientific, Waltham, MA, USA) in 
accordance with manufacturers protocol. To determine protein cysteine sulfenylation (-
SOH), cells were serum starved overnight, and media changed the following day, 1hr prior 
to treatment. Cells were then treated with either 4, 20, or 100ng/mL EGF at various time 
points. Cells were then lysed in Western solubilization buffer containing 1 mM DCP-bio1 
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(Kerafast, Boston, MA), 200 units/ml catalase (Worthington, Lakewood, NJ), and 10 
mM N-ethylmaleimide (Sigma) and incubated for 1 h on ice. Excess DCP-bio1 reagent was 
removed by 6 successive washes with 20 mM Tris-HCl (pH 7.4) on Amicon Ultra-0.5 
Centrifugal Filter Devices (Millipore). Biotin-tagged proteins were collected with high 
capacity NeutrAvidin-agarose beads (50 μl of a 50/50 slurry; Pierce) and biotin-
precipitated proteins were then subjected standard western blotting techniques. To identify 
protein S-gluathionylation (-SSG), this was achieved after cell loading with biotinylated 
glutathione ethyl ester (BioGEE) which was prepared by reacting 0.5 M glutathione ethyl 
ester (Sigma) with 0.5 M EZ-link sulfo-NHS-biotin (Pierce) in 50 mM NaHCO3 (pH 8.5) 
and added to cells at a final concentration of 250 μM for 1 h before cell treatment. Excess 
BioGEE was removed using G25 columns (GE Healthcare) and isolated using 
NeutrAvidin-agarose beads. To identify reduced protein cysteine content (-SH), cells were 
lysed in deoxygenated Western solubilization buffer containing 100 μmol/L EZ-link 
Iodoacetyl-LC-biotin (Pierce, Rockford, Ill) and 20 U/mL catalase in an N2 atmosphere to 
avoid artificial cysteine oxidation during processing and incubated for 90 minutes at 37°C. 
Excess reagent was removed in the same fashion as previously described for cysteine 
oxidation (-SOH), and isolated via NeutrAvidin-agarose beads. For Western blotting, equal 
amounts of protein (20-25 μg; determined using BCA protein assay) were separated on 
Novex 10% or 12% Tris-Glycine gels (Life Technologies, Grand Island, NY), transferred 
to nitrocellulose membranes, and blotted using antibodies against: EGFR (1: 1000; Cell 
Signaling), pEGFR-1068 (1:1000; Cell Signaling), pEGFR-1101 (1:500; Abcam, 
Cambridge, MA), Src (1: 1000; Cell Signaling), Histone H3 (1:2000; Cell Signaling), 
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GAPDH (1:1000; Origene, Rockville, MD) and detected using enhanced 
chemiluminescence (Pierce, Rockfort, IL).  
Analysis of resistance to EGFR-mAb, proliferation, and migration – Cells were seeded at 
1x104 per well into a 96-well black wall-flat bottom fluorescence plates (Nunc 
International, Rochester, NY, USA) and cultured in complete media in the presence of 
15µg/mL of neutralizing EGFR mAb (#05-101, Millipore) or IgG isotype control Ab for 
72hrs, with fresh supplemented media provided daily. Cells viability was then determined 
using ATP TiterGlo assay reagent (Promega, Madison, WI).  Data are represented as mean 
± s.d. *p<0.05; **p<0.01 were calculated by one-way ANOVA. (n=8; replicated 2x). To 
analyze cell proliferation, cells were seeded at 1x104 per well into a 96-well black wall-flat 
bottom fluorescence plates, and media supplemented with 100ng/mL EGF for 24hrs, 48hrs, 
or 72hrs. Percentage of viable cells were analyzed with ATP Cell TiterGlo reagent. To 
determine the migratory capacity, we employed a scratch wound assay. A linear scratch 
(~2 mm) was generated in confluent cell monolayers in 24-well culture plates, and detached 
cells were removed with PBS, and given either RPMI-1640 (no serum) or DMEM-F12 (no 
serum) supplemented with either 100ng/mL EGF or mock.  Wound closure was monitored 
over a 24 hr period. Wound areas were imaged and analyzed using NIH Image J software 
to determine % wound closure as an indicator of cell migration. Data are represented as 
mean ± s.d. **p<0.01 were calculated by a one-way ANOVA (n=4; replicated 2x).  
in vivo urethane model of chemically induced lung cancer – C57BL/6 wild type (WT) 
(n=6) or DUOX1-/- (DX1-KO) (n=6) mice were injected intraperitoneally (IP) with 1g/kg 
body weight, urethane, in 100µL sterile-saline or a saline control. Mice were monitored 
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and weighed 3X weekly, over 18 weeks. Following 18 weeks, mice were euthanized and 
major organs harvested. For immunohistochemical and immunofluorescent analysis, lung 
lobes were embedded in paraffin wax resin and serial sectioned for neoplasm quantification 
(H&E staining) as described here(Little, Sham, et al.). Data are represented as mean ± s.d. 
*p<0.05 (t-test). Additionally, 5µm lung sections were stained for Ki67 (#9129; 1:400; Cell 
Signaling), neoplasms were size matched (WT n=13; DX1-KO n=16), and Ki67 
fluorescence intensity was quantified using MetaMorph image analysis software. Data are 




Lung cancer remains to be the leading cause of cancer-related mortality annually, 
claiming roughly 1.69 million lives worldwide and nearly 150,000 alone in the United 
States(Gridelli et al.; Miller et al.). In non-small cell lung cancer (NSCLC), which 
comprises roughly 80% of all lung cancers(Gridelli et al.), epidermal growth factor 
receptor (EGFR) activating mutations (e.g. L858R, exon 20 del, others) and/or its elevated 
expression are common molecular signatures and thereby promote oncogenic features e.g. 
enhanced cell proliferation and/or resistance to apoptosis(Dayde et al.; T. M. Brand, M. 
Iida, N. Luthar, et al.). This has made EGFR a popular target in the design of molecular 
based therapeutics, with many variations of inhibitors currently clinically available(Neel 
and Bivona; Camidge, Pao and Sequist). However, most patients will experience acquired 
resistance to these therapies due to mutations or other causes e.g. epithelial-to-
mesenchymal transition (EMT)(Neel and Bivona; Camidge, Pao and Sequist). This speaks 
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to the need for more precise, effective, molecular approaches to target EGFR in 
chemotherapy, thereby warranting further study to better understand EGFR regulatory 
mechanisms.  
EGFR is expressed in many tissues in the body, and EGFR signaling is involved in 
a vast number of cellular processes(Citri and Yarden). In the airway epithelium, EGFR 
signaling contributes to cellular functions such as epithelial wound repair(Sham et al.), 
type-2 immune responses(Hristova et al.), inflammation(Habibovic et al.), mucus 
production(Takezawa et al.), among others. One of the critical regulators of EGFR 
signaling in the lung epithelium is the NADPH oxidase homolog, dual oxidase 1 (DUOX1). 
DUOX1 is an H2O2 generating enzyme, localized to the plasma membrane on the apical 
surface of lung epithelial cells, with critical roles in host defense and epithelial wound 
closure(Little, Sulovari, et al.). Various studies from our lab have demonstrated that 
DUOX1-dependent signaling in innate responses to epithelial injury, is mediated by redox-
dependent activation of EGFR(Wesley et al.; Sham et al.). In EGFR, this is most likely 
mediated by the oxidation of a reactive cysteine to a sulfenic acid (EGFR-SOH) near the 
ATP-binding site within the EGFR tyrosine kinase domain (cysteine 797; C797), which 
has been shown to contribute to enhanced tyrosine kinase activity following ligand 
stimulation(Paulsen et al.; Truong and Carroll; Truong et al.). While EGFR cysteine 
oxidation to a sulfenic acid is thought to enhance kinase activity, the biological significance 
of other oxidative modifications (e.g. S-glutathionylation; sulfonic acid -SOOH; sulfinic 
acid -SOOOH) for EGFR regulation remain incompletely understood. Interestingly, recent 
reports have described that activated EGFR can phosphorylate glutathione S-transferase pi 
1 (GSTP1)(Tatsunori Okamura et al.; T. Okamura et al.), the enzyme that catalyzes the 
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reaction of an sulfenic acid (-SOH) to a glutathionylated protein (-SSG), suggesting a role 
for EGFR signaling in the regulation of cysteine oxidation.  
 Currently, there is very little information is available regarding EGFR redox 
regulation in cancer. This understudied aspect of EGFR regulation is indeed surprising, as 
many cancers are well characterized to harbor elevated levels of reactive oxygen species 
(ROS). Intriguingly, H2O2 producing DUOX1 is epigenetically suppressed in the vast 
majority of epithelial derived cancers, including lung cancer(Luxen, Belinsky and Knaus; 
Little, Sulovari, et al.; Little, Sham, et al.). Our initial studies characterizing the loss of 
DUOX1 in lung cancer uncovered DUOX1 suppression promotes features of EMT in lung 
cancer cells(Little, Sham, et al.), a key signature of metastatic and aggressive 
cancers(Polyak and Weinberg). DUOX1 loss also enhanced levels of cancer stem cell 
surface markers, cellular invasiveness, and resistance to the EGFR tyrosine kinase inhibitor 
(TKI), erlotinib(Little, Sham, et al.). Due to the close relationship between DUOX1 and 
EGFR signaling, coupled to the finding of DUOX1 suppression promotes EGFR-TKI 
resistance, we hypothesized DUOX1 loss may significant impacts for EGFR regulation in 
cancer.  
The goal of the present study was to further understand the mechanistic 
consequences of DUOX1 suppression in cancer, more specifically to expose potential 
irregularities in EGFR regulation. Our findings display that lung cancer cells which lack 
DUOX1, have significantly greater levels of EGFR cysteine oxidation under basal 
conditions, and kinetically enhanced cysteine oxidation-reduction biochemistry following 
EGF stimulation. In parallel, we find that cells lacking DUOX1 have significantly altered 
EGFR internalization and trafficking post EGF-ligand stimulation, specifically with 
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enhanced nuclear targeting. Indeed, we observe many features of nuclear EGFR in 
DUOX1-suppressed cells, and minimally in DUOX1-expressing control cells. Lastly, we 
find that blocking enzymatic resolution of oxidized cysteines, by RNAi-mediated 
knockdown of glutathione S-transferase pi 1 (GSTP1) or glutaredoxin 3 (GRX3), 
suppressed levels of nuclear EGFR in DUOX1 lacking cells, but not in control cells.  
Collectively, this report highlights unique, DUOX1-dependent differences in EGFR redox 
dynamics that may be related to its spatiotemporal regulation. Enhancing our 
understanding of intrinsic changes in EGFR redox-regulation in cancer could potentially 
lead to the development of novel therapeutic approaches.  
 
3.4. Results 
Lung cancer cells with suppressed DUOX1 expression have altered EGFR redox 
regulation 
Initially, we aimed to determine if DUOX1 expression status had any effect on basal EGFR 
cysteine oxidation, since oxidation is often coupled to kinase activation. To our surprise, 
we observed that DUOX1 depleted cells harbor oxidized EGFR cysteines and low levels 
of Y1068 phosphorylation at resting state (long exposure of pEGFR-1068 blot), under non-
stimulatory conditions (Fig. 3.1A). To assess the cause of the observed elevated cysteine 
oxidation, we employed DCFDA and CellRox assays to determine if intracellular ROS 
levels were different in our various cell models. Intriguingly, no difference in intracellular 
ROS accumulation was observed in our various cell models (Fig. 3.2). Since total ROS 
levels were not different among our cell lines, we hypothesized that basal levels of EGFR 
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oxidation may be from an intracellular source of ROS in a transient and/or local fashion, 
which would explain why no differences were observed globally. In attempt to block ROS 
from intracellular sources, we treated cells with inhibitors of either NADPH oxidases (DPI) 
or mitochondrial function (MitoQ), and utilized RNAi-mediated knockdown of 5-
lipoxygenase. In all three cases, we did not observe any suppression of basal EGFR 
oxidation at baseline (Fig. 3.3). In parallel with enhanced cysteine oxidation at baseline in 
cells lacking DUOX1, the observation of low basal levels of Y1068 phosphorylation (blot 
displays long exposure of pEGFR-1068; Fig. 3.1A) suggested the possibility that EGFR 
ligands were being produced and could serve as the potential reason for 
activation/oxidation of the receptor. Indeed, we find enhanced expression of epiregulin 
(EREG) in A549 and H187 cells, but not H292 cells (Fig. 3.1B). Enhanced EREG was 
observed in H292 DUOX1 knockdown cells, but DUOX1 overexpression in A549 or H187 
cells did not have an effect (Fig. 3.4).  
Since we observed elevated oxidation of EGFR at baseline in cells lacking DUOX1, 
we hypothesized that stimulation with EGF ligand may induce even greater oxidation, 
based on previous reports describing EGF ligand stimulation inducing EGFR oxidation 
through various mechanisms(Truong et al.; Heppner et al.). We did not observe any 
changes in EGFR sulfenylation in our H292 DUOX1 knockdown cells as compared to the 
H292 host controls, at baseline or following EGF stimulation (Fig. 3.5A). Interestingly, 
A549 control cells again display elevated cysteine oxidation that is depleted following EGF 
stimulation (Fig. 3.5B). In stark contrast, our DUOX1-expressing A549 cell model displays 
low levels of EGFR sulfenylation at baseline, and EGF stimulation promotes robust EGFR 
oxidation (Fig. 3.5B), mimicking our observations in H292 cells. We observed similar loss 
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of EGFR sulfenylation in the DUOX1-null H187 (Fig. 2C) and H460 lung cancer cells 
(Fig. 3.6A).  To address whether these altered EGFR redox states in A549 and H187 cells 
was a function of kinetics (e.g. EGFR oxidation occurring sooner and resolving at 20 
minutes post stimulation), we stimulated A549 and H187 cell over 20 minutes and 
monitored EGFR cysteine oxidation. Indeed, diminished EGFR sulfenic acid species 
occurs as quickly as 5 minutes post EGF-ligand stimulation, while EGFR activation 
increases (Fig. 3.5D/E). Rapid reduction in cysteine oxidation following direct ligand 
stimulation suggested potentially higher oxidation species formation (e.g. -SOOH; -
SOOOH), or basally oxidized cysteines were undergoing protein S-glutathionylation 
and/or reduction to a free thiol form (EGFR-SH). To exclude the possibility that loss of 
EGFR oxidation was potentially an artifact or related to high EGF concentrations, we 
stimulated A549 or H187 cells with lower doses of EGF ligand (4 or 20ng/mL), and 
observed a similar loss of EGFR-oxidation as seen initially (e.g. 100ng/mL EGF) (Fig. 
3.6B). Surprisingly, we observe high levels of EGFR S-glutathionylation (EGFR-SSG) 
under basal conditions in the A549 and H187 cell lines, but not H292 cells (Fig. 3.7A), 
suggesting a mixed population of oxidized EGFR species. Furthermore, following EGF 
ligand stimulation, we observe a loss of EGFR-SSG, as soon as 5 minutes’ post EGF 
treatment in both the A549 and H187 cells (Fig. 3.7B). This directly contrasts DUOX1-
expressing H292 cells, where increases in EGFR-SSG track with increases in EGFR 
activation (Fig. 3.7B). We then asked whether the oxidized EGFR cysteines were being 
reduced to a free-thiol form, rather than being further oxidized to a higher cysteine 
oxidation state (e.g. -SOOH; -SOOOH). Indeed, results from iodoacetyl-LC-biotin labeling 
experiments show that A549 and H187 cells harbor higher levels of reduced EGFR cysteine 
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thiols (EGFR-SH), following EGF stimulation, while the opposite is observed in H292 
cells (Fig. 3.7C, Fig. 3.8). These findings suggest that EGFR cysteine oxidation/reduction 
biochemistry is kinetically enhanced in the A549 and H187 cell models, with preferential 
reduction of oxidized EGFR cysteines (EGFR-SOH) back to their reduced state (EGFR-
SH). Collectively, these findings characterize unique changes in EGFR redox regulation, 
respective to DUOX1 expression. Kinetically enhanced cysteine oxidation-reduction in 
cells lacking DUOX1 could be indicative of a novel feature of EGFR redox regulation in 
aggressive cancer cells.  
 
 
DUOX1 suppression alters EGFR subcellular localization, trafficking mechanisms, and 
phosphorylation of the nuclear translocation signal, EGFR-Y1101  
Our observations of reduced EGFR cysteine sulfenylation following EGF-ligand 
stimulation contrasts enhancements in pEGFR-1068 levels, suggests that oxidation may 
have regulatory roles outside of supporting kinase activation e.g. receptor endocytosis; 
subcellular endosomal sorting. This is compounded to the fact that EGFR subcellular 
localization and intracellular trafficking mechanisms are altered in cells which have 
undergone EMT(Tanos and Rodriguez-Boulan). Therefore, we aimed to determine if 
modulation of DUOX1 expression had any effect on EGFR spatiotemporal control. Under 
non-stimulatory conditions, the EGFR is mainly localized to the plasma membrane in H292 
cells expressing DUOX1, and in A549 and H187 cells lacking DUOX1 (Fig. 3.9A ‘Mock’). 
EGFR plasma membrane localization is also seen in our DUOX1 knockdown cells (H292-
shDUOX1) and our DUOX1 overexpressing cells (A549-pDUOX1) (Fig. 3.9B ‘Mock’). 
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Surprisingly, following EGF stimulation (100ng/mL 20min), internalized EGFR appears 
to be more localized to the nuclear or perinuclear space in A549 and H187 cells 
(low/undetectable DUOX1) while the EGFR following stimulation appears to be more 
dispersed throughout the cell in the H292 cell model (high DUOX1) (Fig. 3.9A). 
Additionally, DUOX1 knockdown cells display enhanced intracellular EGFR as compared 
to their controls (Fig. 3.9B), while the DUOX1 overexpressing A549 cells appear to display 
dispersed staining patterns, similar to the H292 cell model (Fig. 3.9B). Collectively, these 
observations implicate DUOX1 as a mediator of EGFR internalization and/or trafficking 
dynamics.  
 Beyond the EGFR harboring nuclear translocation signals in its C-terminal tail(S.-
C. Wang et al.; H. W. Lo et al.), Src-dependent phosphorylation of EGFR tyrosine 1101 
has emerged as a critical mediator of nuclear transport(Iida et al.; T. M. Brand, M. Iida, N. 
Luthar, et al.; T. M. Brand, M. Iida, C. Li, et al.).  Based on our previous findings pinning 
DUOX1 as a critical mediator of both Src and EGFR, we aimed to determine if DUOX1 
expression status had any effect on EGFR-Y1101 phosphorylation. Indeed, we observed 
significantly greater EGFR-Y1101 phosphorylation in H292-shDUOX1 cells (shDX1) 
(Fig. 3.10A/C) than the host H292 control (shCTL). Our results show the opposite finding 
in A549 cells overexpressing DUOX1, whereas a decrease in EGFR-Y1101 
phosphorylation is occurring (Fig. 3.10B/C). Since DUOX1 activation by exogenous ATP 
stimulation is required for the transactivation of the EGFR through Src oxidation, and cell 
surface EGFR ligand shedding(Sham et al.), we utilized ATP stimulation as a positive 
control for DUOX1-dependent EGFR activation, as well as to determine if direct activation 
of DUOX1 was required for EGFR-Y1101 phosphorylation. Consequently, we observed 
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EGFR activation, as measured by its autophosphorylation of tyrosine 1068, following ATP 
stimulation in H292-shCTL cells, but not in H292 cells lacking DUOX1 (shDX1) (Fig. 
3.10A), confirming our previous findings(Sham et al.). Although, ATP stimulation did not 
induce changes in EGFR-Y1101 phosphorylation, suggesting DUOX1-dependent 
transactivation of the EGFR is not a requirement (Fig. 3.10A/B). Additionally, we observed 
suppression of EGFR-Y1101 phosphorylation in our H187 lung cancer cells 
overexpressing DUOX1, further supporting the role of DUOX1 in this event (Fig. 3.11). 
Moreover, EGFR-Y1101 phosphorylation appears to be a rapidly occurring event, as host 
A549 control cells quickly induce phosphorylation of this residue, as soon as 1 minute 
following EGF stimulation, and gradually increase the pY1101 signal over 30 minutes, 
while A549 cells overexpressing DUOX1 display slower phosphorylation kinetics, and 
pY1101 levels are significantly lower compared to the A549 host cells (Fig. 3.12). The 
kinetics of this phosphorylation event are significant, as this could be ‘priming’ the EGFR 
for nuclear transport following internalization, which occurs around 8-10 minutes’ post 
ligand stimulation. Next, we employed subcellular fractionation techniques to determine 
EGFR protein levels in nuclear vs membrane and cytosolic extracts. In parallel with levels 
of pEGFR-Y1101 in whole cell extracts, we find enhanced levels of EGFR, pEGFR-
Y1068, and pEGFR-Y1101 in the nuclear preparations of H292-shDUOX1 cells vs the 
host H292 control cells, following EGF stimulation (Fig. 3.10D). In contrast, we observe 
that DUOX1 overexpression in A549 cells suppresses nuclear levels of EGFR, pEGFR-
Y1068, and pEGFR-Y1101 (Fig. 3.10E). These results indicate that cells lacking DUOX1 
display altered EGFR internalization and recycling dynamics, with potentially enhanced 
nuclear targeting, in part due to elevated phosphorylation of EGFR-Y1101, which provide 
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interesting correlations between cancer aggressiveness, DUOX1 status, and EGFR 
subcellular spatial organization.  
DUOX1 suppression enhances oncogenic features of nuclear EGFR 
Interestingly, previous reports have defined that nuclear EGFR can act as a transcriptional 
co-activator to genes related to proliferation and cell cycle progression(Lo and Hung; T. 
M. Brand, M. Iida, N. Luthar, et al.). As our initial findings demonstrated enhanced nuclear 
EGFR following EGF stimulation, in cells lacking DUOX1, we asked whether nEGFR 
related gene expression was also elevated. Indeed, we observed increased mRNA 
expression of Aurora kinase (AURKA), cell cycle dependent kinase 1 (CCND1) and 
STAT1 in H292 DUOX1 knockdown cells, following EGF stimulation (Fig. 3.13A). In 
parallel, we found that DUOX1 overexpression in A549 cells, suppressed the gene 
induction of AURKA, CCND1, STAT1, MYC, and iNOS, post EGF stimulation (Fig. 
3.13B). Next, we asked whether DUOX1 suppression would support EGF-induced cell 
proliferation. EGF-stimulation of DUOX1 lacking cells trend toward higher proliferations 
rates versus their DUOX1 expressing counterparts, although the data were not statistically 
significant (Fig. 3.13C). Previous reports have connected nEGFR with poor clinical 
outcome(Traynor et al.; C. F. Li et al.), and acquired resistance to cetuximab(C. Li et al.; 
Wheeler et al.), a monoclonal antibody based therapy utilized to block EGFR signaling. 
Based on this, we hypothesized that DUOX1-lacking cells would display resistance to this 
mode of treatment. Indeed, we find that DUOX1-expressing cells were sensitive to an 
EGFR-blocking antibody, while DUOX1 silenced cells are more resistant (Fig. 3.13D; Fig. 
3.14). We then sought to determine if EGF could enhance cellular invasiveness or 
migration, as our previous report shows that cellular transformation due to constitutive 
 
157 
DUOX1 suppression, induces EMT, enhanced migratory and invasive capacity(Little, 
Sham, et al.). Cell medium supplemented with EGF promoted significant cell migration in 
a linear scratch wound assay in DUOX1 lacking cells, as compared to their DUOX1-
expressing counterparts (Fig. 3.13E/F; Fig. 3.15). Collectively, these findings highlight that 
enhanced nuclear EGFR in DUOX1 knockdown cells, contributes to cell proliferation, 
migratory capacity, and resistance to EGFR antibody-based inhibition, further implicating 
DUOX1 as a key mediator or indicator of nEGFR and/or its functional consequences. 
 
Chemically induced lung neoplasms are enhanced in DUOX1-deficient mice 
Since our previous findings show DUOX1 loss is associated with EMT, and our current 
studies are coupling DUOX1 loss with oncogenic features of nuclear EGFR, we asked 
whether DUOX1 suppression could alter tumor or neoplastic formation/growth, in vivo. To 
address this, we utilized intraperitoneal (IP) injections of urethane (1mg per gram body 
weight) in C57BL6 wild type (WT) or DUOX1-/-  (DX1-KO) mice, as a chemically-induced 
model of lung cancer(Kellar, Egan and Morris; de Seranno and Meuwissen). Based on 
previous findings, we hypothesized that DUOX1-KO mouse would in fact develop greater 
numbers of neoplasms versus their WT counterparts, due in part to the inability of the DX1-
KO mice to effectively mitigate epithelial wound responses(Wesley et al.) as well as 
DUOX1 loss being associated with aggressive and invasive cellular behavior(Sham et al.; 
Little, Sham, et al.). Indeed, examination of lung histological sections show that the overall 
observed area and predicted volume (based on histological stereology) of the neoplasms, 
were not different between WT and DX1-KO mice (Fig. 3.16A/B). Moreover, significantly 
greater numbers of neoplastic growths were measured in the lungs of DX1-KO mice versus 
 
158 
their WT control mice (Fig. 3.16C). Since our cell based findings suggest that DUOX1 loss 
is associated with enhanced levels of nuclear EGFR and aggressive cell behavior, we 
stained size-matched neoplasms for the proliferation marker, Ki67. Intriguingly, neoplasms 
in DUOX1-deficient mice stain significantly higher for Ki67, suggesting small tumor 
formation in DUOX1-lacking mice may show a more aggressive phenotype (Fig. 3.16D/E). 
Collectively, these finding support the notion that DUOX1 suppression in cancer associates 
with a negative outcome, and may be a critical mediator of tumor cell behavior.  
 
Inhibition of EGFR cysteine redox cycling suppresses levels of nuclear EGFR 
To address whether EGFR redox regulation was imperative for intracellular trafficking 
following stimulation, we utilized RNAi-mediated knockdown of glutathione S-transferase 
Pi (GSTP1), followed by EGF stimulation and nuclear EGFR identification by western 
blot. To adequately address this, we first determined if knockdown of GSTP1, was 
sufficient to inhibit the catalysis of a glutathionylated EGFR thiol (EGFR-SSG) from a 
sulfenylated species (EGFR-SOH). Indeed, RNAi-mediated knockdown of GSTP1 
attenuated the loss of EGFR sulfenic acid following EGF stimulation in both A549 and 
H187 cells, while no changes were observed in EGFR activation (pEGFR-1068; Fig. 
3.17A; Fig. 3.18). We then asked whether oxidation was important for EGFR nuclear 
localization. Indeed, RNAi-mediated knockdown of GSTP1 in A549 cells, but not H292 
cells, suppressed levels of nuclear EGFR at resting state and following EGF treatment (Fig. 
3.17B; Quantified in Fig. 3.17C). These data suggest that EGFR oxidation may be a critical 
mediator or determinant of intracellular trafficking. Collectively, these results show that 
DUOX1-lacking cells present with enhanced basal EGFR cysteine oxidation and S-
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glutathionylation, and promptly reduce oxidized cysteines to their free-thiol form (-SH) 
post EGF stimulation and blocking this enzymatic process suppressed levels of nuclear 
EGFR. These results implicate that EGFR cysteine oxidation may be a regulatory 
mechanism to coordinate post endocytic processing and nuclear transport. 
3.5. Discussion 
It has been well established in several instances that direct ligand stimulation with EGF 
rapidly induces EGFR activation and cysteine sulfenylation(Heppner et al.; Paulsen et al.; 
Truong and Carroll). Therefore, it was surprising to find that following EGF stimulation in 
lung cancer cells lacking DUOX1, EGFR cysteine sulfenylation appeared to resolve. In 
contrast, EGF stimulation promoted oxidation in DUOX1-expressing cells, supporting 
results attained from previously performed studies. Intriguingly, following EGF 
stimulation, resolution of EGFR cysteine oxidation to a reduced state occurs rapidly (e.g. 
5 min post EGF stimulation) in A549 and H187 cell models, despite EGFR enhanced 
activation that persisted over 20 minutes. These findings suggest an uncoupling of EGFR 
oxidation and activation, leading to two potential hypotheses. First, since EGFR undergoes 
dynamic regulation following ligand stimulation, we hypothesized that oxidation may in 
fact harbor regulatory roles outside of supporting EGFR kinase activation, e.g. intracellular 
trafficking, protein-protein interactions, etc. Secondly, EGFR cysteine oxidation, and 
kinase activation may still be occurring in unison, although at a kinetically enhanced rate 
versus DUOX1-expressing cells. In fact, kinetically enhanced EGFR redox cycling may be 
a feature of transformed cells, based on prior studies suggesting enhanced expression of 
redox enzymes GSTP1(Stavrinou et al.; Rybarova et al.; Grimminger et al.) and GRX3(Cha 
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and Kim), coupled to the fact that DUOX1 loss is associated with EMT and invasive 
cellular phenotypes(Little, Sham, et al.). Although, additional experimentation in other cell 
models would be required to support this hypothesis. Regardless, our findings imply EGFR 
redox regulation is potentially more dynamic than previously considered. Moreover, a key 
consideration is that cancer cells have been previously characterized to support EGFR 
dimer and/or oligomer formation in lieu of ligand (Kovacs et al.), and basal cysteine 
sulfenylation could be the driving force to support kinase activation, which in this context 
could explain our observations of elevated EGFR cysteine oxidation under resting 
conditions. The rapid depletion of EGFR sulfenylation following EGF ligand stimulation 
could be that a considerable proportion of the EGFR sulfenylated species is reduced to 
promote the classical mode of ligand-receptor activation mechanisms, and cysteine 
oxidation is thereby resolved. This argument may be refuted by recent reports which have 
shown acquired resistance to the third-generation EGFR-TKI, AZD9291, designed to 
target EGFR-C797, is mediated by a cysteine to serine mutation (C797S), therefore 
bypassing the need for cysteine oxidation and kinase activation(Cross et al.; K. S. Thress 
et al.; Jia et al.; Little, Sulovari, et al.).  Collectively implying that EGFR redox regulation 
remains incompletely understood.  
Interestingly, in addition to regulating EGFR signaling, DUOX1-dependent redox 
regulation of the non-receptor tyrosine kinase, Src, is a critical event in mediating lung 
epithelial responses(Wesley et al.; Gorissen et al.; Sham et al.). Recent literature from 
Wheeler and colleagues describe the close relationship between the SFKs (Src family 
kinases) and their ability to promote EGFR nuclear translocation in cancer cells, primarily 
through phosphorylation of EGFR tyrosine 1101(C. Li et al.; Wheeler et al.; T. M. Brand, 
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M. Iida, C. Li, et al.; T. M. Brand, M. Iida, N. Luthar, et al.; Iida et al.; T. M. Brand, M. 
Iida, K. L. Corrigan, et al.). Indeed, EGFR spatial regulation is drastically perturbed in 
cancer cells, and previous reports have highlighted some of the negative consequences 
associated with this outcome(Traynor et al.; T. M. Brand, M. Iida, N. Luthar, et al.; T. M. 
Brand, M. Iida, C. Li, et al.; T. M. Brand, M. Iida, K. L. Corrigan, et al.). Therefore, we 
sought to explore if DUOX1 suppression had impacts for this process. Indeed, our data 
clearly identifies DUOX1 loss elevates levels of pEGFR-Y1101, potentially through 
enhanced activation of the Src kinase, although the direct mechanism by which this occurs 
remains unclear. Additionally, DUOX1 suppression associates with enhanced levels of 
nuclear EGFR, as well as some of its functional features. Since we observed such drastic 
differences in EGFR redox regulation, as well as altered levels of nuclear EGFR in 
DUOX1-lacking cells, we hypothesized that EGFR redox regulation may be a contributing 
factor to EGFR spatiotemporal control. Blocking the enzymatic turnover of EGFR cysteine 
sulfenic acids, by GSTP1-knockdown, blunted EGFR nuclear abundance in A549 cells, 
but not in H292 cells. These results imply that oxidation is potentially impacting EGFR 
trafficking in aggressive cancer cells. While this is the first report to associate EGFR redox 
regulation and spatiotemporal control, further characterization is required and could be 
critically important in the development of novel therapeutics.  
Attenuation of EGFR signaling is a tightly controlled process, and as mentioned 
previously, achieved primarily through internalization of EGFR via clathrin-dependent 
(CDE) or -independent (CIE) endocytosis, and endosomal processing towards receptor 
recycling, organelle trafficking, or lysosomal degradation(Madshus and Stang; Casaletto 
and McClatchey). While both endocytic pathways (e.g. CDE & CIE) have been shown to 
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process internalized EGFR to various destinations, and often times both endocytic 
pathways have the capacity to coordinate similar EGFR outcomes (e.g. recycling; 
degradation), there have been attempts to characterize fates of internalized EGFR more 
associated with either clathrin or non-clathrin mediated endocytosis(Myromslien et al.).  
For instance, clathrin-mediated EGFR endocytosis has been previously linked to recycling 
mechanisms, and prolonged signaling(Sigismund, Argenzio, et al.; Eden et al.; Ibach et al.; 
Alejandra Tomas, Clare E. Futter and Emily R. Eden). Furthermore, internalized EGFR in 
a clathrin-dependent fashion has also been shown to be critical for chemotactic 
invasion(Mutch et al.), and specific intracellular EGFR trafficking to the nucleus(De 
Angelis Campos et al.). Meanwhile, clathrin-independent EGFR endocytosis has been 
associated with receptor ubiquination and lysosomal degradation(Sigismund, Argenzio, et 
al.). While there is some controversy over the mechanisms that govern CIE, a recent report 
has identified the endoplasmic reticulum as a key mediator of EGFR CIE(G. Caldieri et 
al.). Additionally, the authors show that this ER-dependent EGFR CIE mechanism is reliant 
on calcium(G. Caldieri et al.), which directly poses the question whether this process is 
associated with DUOX1 activation and redox signaling. It is plausible, that DUOX1-
expressing cells, EGFR internalization is governed by both CDE and CIE at an equilibrium, 
dependent on local ligand concentration. Providing normal epithelial cells the means to 
attenuate signaling and control EGFR spatial organization, while in cancer cells which lack 
DUOX1, this process may be shunted towards EGFR CDE, promoting prolonged EGFR 
signaling, migration, and/or enhanced nuclear transport. This hypothesis also offers 
alternative explanations as to the mechanism of EGFR nuclear transport in cells that lack 
or harbor DUOX1. For instance, precisely whether EGFR is internalized and processed in 
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a clathrin-dependent fashion in DUOX1-lacking cells or directly transported to the ER 
(CIE) in DUOX1-expressing cells, in route to the nucleus, while a possibility, remains 
unknown. Regardless, future study is needed to fully address these outstanding research 
questions, and further investigation as to whether oxidation of EGFR (or other RTKs) is 





In conclusion, we display that EGFR redox regulation is significantly altered in 
DUOX1-lacking lung cancer cells, which may be linked to aggressive or invasive cell 
phenotypes. Additionally, our results demonstrate that DUOX1 suppression is associated 
with enhanced nuclear EGFR and its functional features. Lastly, we show that nuclear 
EGFR is in part dependent on cysteine redox cycling in DUOX1-lacking lung cancer cells, 
proposing that EGFR redox regulation is a potentially novel regulatory intracellular 
trafficking mechanism in cancer. Collectively, these findings support the concept that 
DUOX1 expression could serve as a useful biomarker for epithelial cell phenotypes and 
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Figure 3.1 – EGFR cysteine oxidation and activation are altered in DUOX1-lacking 
lung cancer cells at baseline. (A) Basal oxidation (EGFR-SOH) and activation (pEGFR-
1068) are observed in lung cancer cell lines H292, A549, H187 cell lines. (B) A549 and 
H187 cells express significantly greater EGFR ligand, epiregulin (EREG) than H292 cells. 





Figure 3.2 - Basal rates of ROS accumulation are unchanged with respect to DUOX1 
expression. Results from DCFDA assay (left) display similar intracellular rates of ROS 
accumulation in H292, H187, A549, and H460 cell models. Modulation of DUOX1 
expression does not change basal ROS levels as determined by CellRox DeepRed assay. 







Figure 3.3 - NOXes, Mitochondria, or 5-Lipoxygenase do not contribute to basal 
EGFR cysteine oxidation. In both A549 and H187 cell models, inhibitors of mitochondria 
(MItoQ) or NADPH oxidases (DPI) do not suppress basal levels of EGFR cysteine 
oxidation (A).  Additionally, RNAi-mediated knockdown of 5-lipoxygenase (ALOX5) also 





Figure 3.4 - Modulation of DUOX1 expression has a variable effect on EGFR ligand, 
epiregulin (EREG) expression. Constitutive DUOX1 knockdown (H292-shDUOX1) 
enhanced epiregulin (EREG) mRNA expression, while overexpression of DUOX1 in A549 







Figure 3.5 - EGFR cysteine oxidation following EGF stimulation is altered in cells 
with low DUOX1 expression (A) DUOX1 expression status does not affect EGFR 
cysteine oxidation in H292 cells. (B) EGFR sulfenylation is suppressed following EGF 
stimulation in A549 host cells, although in DUOX1 expressing A549 cells (A549-pDX1) 
display lower basal oxidation, and EGF stimulation promotes EGFR sulfenylation. (C) 
EGFR-SOH levels drop following EGF stimulation in the DUOX1-lacking H187 cells. 
(D/E) Loss of EGFR-SOH occurs rapidly following EGF-stimulation in A549 and H187 





Figure 3.6 - Lung cancer cell model H460 also displays loss of EGFR oxidation 
following EGF stimulation, and loss of oxidation also occurs at lower EGF 
concentrations. (A) DUOX1-lacking H460 lung cancer cells lose EGFR oxidation 
following 100ng/mL EGF stimulation (20 min). (B) Loss of EGFR cysteine oxidation is 
observed upon cell stimulation with either 4 or 20ng/mL EGF ligand. Western blot results 





Figure 3.7 - DUOX1-low expressing cells recover free cysteine thiols (R-SH) following 
EGF stimulation. (A) A549 and H187 cells harbor basal levels of EGFR-S-
glutathionylation. (B) EGFR-SSG levels increase following EGF stimulation in H292 cells, 
while a loss of EGFR S-gluathionylation is observed in both A549 and H187 cells (C) 
EGFR cysteine thiols are reduced to their free thiolate state (EGFR-SH) in A549 and H187 
cells following EGF stimulation (see Supplemental Fig. S5 for western blots) *p<0.05, 





Figure 3.8 - EGF stimulation induces reduction of oxidized cysteine to a free thiol. 
Western blot results from additional iodoacetyl-LC-biotin labeling experiments showing 
cells that lack DUOX1 (e.g. A549/H187) recover a reduced EGFR thiol (EGFR-SH) 20 
minutes’ post EGF stimulation. While DUOX1 expressing H292 cells have a diminished 






Figure 3.9 - EGF-dependent EGFR intracellular trafficking is altered in DUOX1 
expressing cells. (A) EGFR (green) is localized to the plasma membrane in mock treated 
cells. EGF-treated (100ng/mL 20min) cells display internalized EGFR. (B) DUOX1 
expressing cells (H292-shCTL/A549-pDUOX1) display greater plasma membrane 
staining following EGF (100ng/mL 20min) stimulation while their DUOX1-lacking 
counterparts (H292-shDUOX1/A549-pCTL) display elevated levels of internalized EGFR. 





Figure 3.10 - DUOX1 expression alters levels of nuclear EGFR and the EGF-
dependent phosphorylation of the EGFR nuclear translocation signal, tyrosine 1101. 
(A/B) DUOX1 expressing cells display less EGF-induced EGFR-Y1101 phosphorylation 
than their counterpart cell models; pEGFR-1101 quantification over multiple experiments 
(C) (**p<0.01; n=4; t-test). (D) Results from subcellular fractionation display H292-
shDUOX1 cells harbor greater nuclear EGFR (quantified-middle right) (*p<0.05; n=4; t-
test), following EGF stimulation, than their H292 controls, while we observe opposing 
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results in our DUOX1-expressing A549 cell model (quantified-lower right) (*p<0.05; n=4; 




Figure 3.11 - DUOX1-overexpression in H187 cells suppresses EGF-induced EGFR-
Y1101 phosphorylation. H187 empty vector cells (H187-pCTL) or H187 cells 
overexpressing DUOX1 (H187-pDUOX1), were treated with EGF ligand (100ng/mL) for 
20 minutes and examined for EGFR phosphorylation events.  Western blot image is 





Figure 3.12 - EGFR tyrosine 1101 phosphorylation occurs rapidly in A549 cells but 
not in A549 cells overexpressing DUOX1. Results from western blot analysis display 
levels of EGFR-Y1101 phosphorylation following cell stimulation with 100ng/mL EGF 






Figure 3.13 - DUOX1 loss promotes features consistent with nuclear EGFR. (A) H292-
shDUOX1 cells when stimulated with EGF promote induction of genes related to nEGFR, 
but not in the H292 control cells (*denotes significance to same-cell model unstimulated 
control; # denotes significance to EGF stimulated opposing cell model; */#p<0.05; 
***/###p<0.001; n=4; one-way ANOVA). (B) EGF-stimulation induces nEGFR related 
gene expression in A549 cells but is suppressed in DUOX1-expressing A549 cells 
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(*denotes significance to same-cell model unstimulated control; # denotes significance to 
EGF stimulated opposing cell model; */#p<0.05; **/##p<0.01; ***/###p<0.001; n=4; one-
way ANOVA). (C) EGF-induced cell proliferation is greater in cells lacking DUOX1. (D) 
DUOX1 expression correlates with sensitivity to EGFR-antibody based inhibition 
(**p<0.01; ***p<0.001; n=8; t-test). (E/F) EGF stimulation promotes wound closure in 






Figure 3.14 - DUOX1-overexpressing H187 lung cancer cells are sensitized to EGFR 
mAb inhibition. H187 control or DUOX1 overxpressing cells were treated with 15ng/mL 
EGFR blocking antibody for 72h and cell viability determined with ATP-Cell-Titer-Glo 
reagent. Results are an average of 2 separate experiments; n=8, **p<0.01; as determined 





Figure 3.15 - EGF supplementation promotes wound closure in DUOX1-lacking cells. 
In DUOX1 lacking cells (H292-shDUOX1; A549-pCTL), significant wound closure is 
observed following 100ng/mL EGF treatment in serum-free media. Images are 





Figure 3.16 - Chemically induced lung neoplasms in DUOX1 knockout mice are more 
abundant and present elevated levels of the proliferation marker, Ki67. Intraperitoneal 
urethane injections in C57BL6 wild type (WT) or DUOX1 knockout (DX1-KO) mice 
result in the formation of lung neoplasms. No significant differences were observed in 
tumor size, either area (A) or predicted volume (B).  DUOX1 knockout mice display higher 
numbers of lung neoplasms versus their wild type control (C) (*p<0.05; n=6 mice per 
group; t-test). Quantified data from immunofluorescent staining of lung sections display 
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that neoplasms (size matched vs WT controls) in DUOX1 knockout mice also display 





Figure 3.17 - GSTP1 knockdown suppresses nuclear EGFR in DUOX1-lacking cells. 
(A) RNAi-mediated knockdown of GSTP1 attenuates the reduction of EGFR cysteine 
oxidation following EGF stimulation. (B) Results from subcellular fractionation 
experiments show GSTP1 knockdown suppresses nuclear EGFR in A549 cells (lower 
right) but not in H292 cells (upper right). (C) Quantified results from multiple experiments. 





Figure 3.18 - RNAi-mediated knockdown of GSTP1 moderately attenuates loss of 
sulfenylated EGFR species in H187 cells. Western blot results showing levels of oxidized 
















CHAPTER 4: DUOX1-DUOXA1: EXPLORING NOVEL DYNAMIC 
INTERACTIONS AND IMPLICATIONS FOR CANCER BIOLOGY 
4.1 Abstract 
Dual oxidase maturation factor 1 (DUOXA1) was first described as numb interacting 
protein (NIP) for its participation in the regulation of the Notch signaling pathway. Later, 
NIP was described to support dual oxidase 1 (DUOX1) transport from the endoplasmic 
reticulum to the plasma membrane, forming a mature enzymatic complex and thereby 
renamed DUOXA1. Since then, additional extraneous roles for DUOXA1 have been shown 
e.g. interactions with p53; among others. In epithelial cancers, DUOXA1 expression is 
often downregulated in tandem with DUOX1, although not to the same extent, and in some 
cases expressed in lieu of DUOX1 (e.g. thyroid cancer). This suggests that DUOXA1 may 
have other roles in cancer not previously studied, supporting the fact that DUOXA1 
biology is incompletely understood. Here we generated a complete DUOX1-DUOXA1 
enzymatic system in A549 cells, with fluorogenic and molecular protein tags, to better 
study these dynamics. Our results show DUOX1-DUOXA1 interactions are subject to 
dissociation following ATP stimulation which correspond with resolution of DUOX1 
enzymatic activity. Furthermore, we find that DUOXA1 is potentially localized to the 
nucleus post ATP stimulation. While the functional outcomes of these findings are 
unknown and need additional experimental evidence, this supports the need to better 
understand DUOXA1 functions as it may have significant impacts for normal epithelial 





4.2 Materials and Methods 
Cell lines, DUOX1-DUOXA1 construct generation, and ATP stimulation – NCI-A549 cells 
(ATCC) were transfected (Turbofect reagent; #R0531; ThermoFisher) with 1µg of 
pCMV6-AC-DUOX1-GFP-DDK cDNA and pCMV6-AC-DUOXA1-RFP-HIS (Origene; 
(see (Little, Sham, et al.) for details regarding original expression vectors). Original cDNA 
constructs (pCMV6-AC-DUOX1-GFP; pCMV6-AC-DUOXA1-RFP) were modified with 
site-directed mutagenesis to add either DDK (FLAG) or HIS epitope tail, by Dr. Sheryl 
White of the University of Vermont Advanced Genomics Core Facility. Modified cDNA 
construct sequences were confirmed by the University of Vermont Cancer Center DNA 
Sequencing Facility (data not shown). Following transfection, cells were subjected to dual 
selection of 3.5 µg/mL neomycin (G418) (ThermoFisher; #10131035) and 1.5µg/mL 
puromycin (ThermoFisher; A1113802) for ~20 days. Resistant populations were then 
expanded for use in cell studies and maintained in DMEM-F12 complete media (10% fetal 
bovine serum, 5% penicillin-streptomycin) supplemented with both neomycin and 
puromycin.  To monitor cellular responses to ATP, cells were seeded either in 12- or 24-
well flat bottom, cell culture grade polystyrene dishes, and allowed to reach ~70% 
confuluence. Cells were serum starved overnight, and subjected to 100µM ATP treatment 
for varying times. Following treatment, cells were washed with 1X phosphate-buffered 
saline (PBS) and either RNA or protein were isolated as described below. HPLC 




RNA, Protein isolation and antibodies – Information regarding standard isolation of RNA 
and whole protein lysates, as well as DUOX1/DUOXA1 qPCR primers, are described in 
detail here(Little, Sham, et al.). Antibodies utilized in this study are as follows: GFP 1:1000 
(Origene; #TA150041), RFP 1:1000(Origene; #TA150061), DUOXA1 (NIP) 1:300 
(Novus, Littleton, CO, USA; #NBP1-79883). To analyze subcellular protein fractions, 
cells were subjected ATP stimulation, and isolated accordingly per manufacturers protocol 
(ThermoFisher; #78840).  
 
Live-cell immunofluorescence – Cells were seeded on MatTek live-cell culture dishes 
(provided by University of Vermont Microscopy Imaging Center) and allowed to reach 
~70% confluence. Cells were serum starved overnight, and stimulated the following day 
with either 100µM ATP or control. Prior to ATP stimulation, cells were preloaded with 
1µg/mL Hoechst dye to stain nuclei (ThermoFisher; #62249). Immediately following cell 
stimulation, MatTek dishes were placed into a 37°C, 5% CO2, live-cell imaging chamber 
and imaged for GFP, RFP, and/or Hoechst fluorescence, respectively. All images were 
taken on a Zeiss LSM 510 META laser scanning confocal microscope either 20X or 63X 
objectives (Zeiss, Germany). 
 
4.3 Introduction 
Dual Oxidase 1, an NADPH oxidase homologue, is an H2O2 producing enzyme highly 
expressed in developing tissues and subsequently expressed in many terminally 
differentiated epithelial lineages(Fischer). Upon proper folding and processing in the 
endoplasmic reticulum, DUOX1 is partnered to dual oxidase maturation factor 1 
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(DUOXA1), which must occur for transport to the plasma membrane and proper enzymatic 
function(Morand et al.). DUOXA1 was first described as Numb interacting protein (NIP), 
for its ability to bind numb and recruit it to the plasma membrane(Qin et al.).  Numb is a 
negative regulator of the Notch signaling pathway, a master molecular switch of cellular 
differentiation and have both been heavily implicated for their respective roles in 
cancer(Stylianou, Clarke and Brennan; Ostrakhovitch; Z. Wang et al.; Pancewicz-
Wojtkiewicz; Nowell and Radtke). The landmark report describing DUOXA1 or NIP, 
defined that it binds Numb through its PTB domain and displays asymmetric localization 
with Numb in proliferating neuronal cells(Qin et al.). This led to the notion that NIP played 
a role in the polarized recruitment of Numb. Later, a very similar observation was made in 
the maturation of the DUOXes(Grasberger and Refetoff), thus NIP was renamed 
DUOXA1.  
 Notch signaling is widely considered for its participation in cellular 
differentiation, but also has roles in development, lineage commitment, cell cycle 
progression, and stem cell properties (Wilson and Radtke; J. Liu et al.). Due to this, Notch 
signaling is highly context dependent, even in the same tissue(Wilson and Radtke; J. Liu 
et al.). This has made defining a singular role of Notch signaling in cancer challenging, as 
it sometimes promotes both oncogenic and tumor suppressive outcomes(Nowell and 
Radtke). For instance, Notch signaling is confirmed to be oncogenic in T-cell acute 
lymphoblastic leukemia (T-ALL) (Koch and Radtke), while Notch signaling has shown to 
be tumor suppressive in various cancers (e.g. breast(Reedijk), brain(Teodorczyk and 
Schmidt), lung(Galluzzo and Bocchetta), others).  This dichotomy appears to be present in 
non-small cell lung cancer (NSCLC) as well, as roughly half present with enhanced Notch 
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signaling, which appears to be due in part to loss of Numb expression(Westhoff et al.). The 
primary function of Numb is to bind the cleaved intracellular portion of Notch (ICN) and 
promote its degradation, preventing ICN to translocate to the nucleus where it acts as a 
transcriptional gene promoter (reviewed comprehensively here (Kopan and Ilagan; Bray)). 
Clearly, loss of Numb expression would permit unabated Notch signaling and could have 
significant effects on downstream pathways. Intrudingly, loss of Numb expression strongly 
correlates with the loss of DUOX1/DUOXA1 expression, and may be coupled to poorly 
differentiated tumor cell populations. Supporting this, DUOXA1 expression was highest 
in the well differentiated breast cancer cell line MCF-7, compared to the poorly 
differentiated MDA-MB-231 cell line which harbor in activated or mutated 
p53(Ostrakhovitch and Li; O'Neill et al.).  
The extraneous roles of DUOXA1/NIP, such as DUOXA1-p53 interactions, while 
incompletely understood, could be due in part to the fact that DUOXA1 has previously 
been reported to express three splice variants(Luxen et al.), and their individual roles have 
not been fully characterized. These variants are categorized as the short isoform (298aa) 
which lacks two of the three N-glycosylation sites, full length (343aa), and a long isoform 
(483aa) which contains an extended C-terminus(Luxen et al.). Each of the three isoforms 
support DUOX1 activation although each with differing levels of potency. Additionally, 
alternative splicing could be the reason why DUOXA1 expression levels do not fully 
correspond with DUOX1 levels in epithelial cancers (e.g. thyroid cancer)(Little, Sulovari, 
et al.), as transcriptional regulation of the variants versus the full length transcript could be 
altered in the context of cancer, potentially to support non-traditional DUOXA1 functions. 
Alternatively, loss of DUOX1 in cancer may permit a gain-of-function phenotype for 
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DUOXA1, although additional experimentation is needed to support this hypothesis. 
Collectively, DUOXA1 biology is poorly understood and further study is needed to address 
potential roles independent of DUOX1 maturation.  
  In this pilot study, we utilize previously generated genetic tools to examine the 
relationship between DUOX1 and DUOXA1. We have uncovered that following DUOX1 
activation, the DUOX1-DUOXA1 relationship is more dynamic than previously 
considered. Furthermore, we observe nuclear localization of DUOXA1 which appears to 
be bound to chromatin or interacting with a chromatin bound protein. The functional 
outcomes of this cellular event remain unknown, although these findings define a 
potentially novel dynamic DUOX1-DUOXA1 dissociation event that could have impacts 
for epithelial and cancer cell biology.   
 
4.4 Results  
Generation of DUOX1-DUOXA1 dual expression system 
To study the interactions of DUOX1 and DUOXA1, we created a novel dual expression 
system in A549 cells, with additional fluorogenic and protein isolation molecular tags. We 
overexpressed a vector encoding for DUOX1 cDNA, tagged with green fluorescent protein 
(GFP) for optimum visualization and a FLAG epitope C-terminal tail to enhance protein 
isolation from cell extracts and/or lysates. In the same cells, we overexpressed a vector 
encoding for DUOXA1 cDNA, tagged with red fluorescent protein (RFP) and a histidine 
repeat C-terminal tag (HIS-tag), to specifically visualize and isolate DUOXA1. 
Additionally, we modified these individual constructs to express different antibiotic 
resistance markers (DUOX1-neomycin; DUOXA1-puromycin) to properly select for dual 
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expressing cells. These constructs were initially purchased from Origene Technologies but 
modified in house to fit the needs of this project (see materials and methods for additional 
information). Following ~30 days selection post transfection, we confirmed the expression 
levels of DUOX1-GFP and DUOXA1-RFP in our cell models via western blot (Fig. 4.1). 
Additionally, we utilized confocal microscopy to visualize the subcellular localization of 
DUOX1 (GFP; green) and DUOXA1 (RFP; red) (Fig. 4.2). Under non-stimulatory 
conditions, DUOX1 and DUOXA1 show strong co-localization at the plasma membrane 
(Fig. 4.2). 
DUOX1-DUOXA1 display dynamic characteristics  
 To ensure our dual expression system was a fully functional enzymatic complex, 
we utilized ATP stimulation to activate DUOX1 and measured levels of extracellular H2O2 
(Fig. 4.3). Indeed, H2O2 generation was observed following ATP stimulation, with optimal 
enzymatic activity 10 minutes’ post stimulation with resolution back to basal levels around 
25 minutes’ post ATP stimulation (Fig.  4.3). Furthermore, we confirmed that 100µM ATP 
to be the optimal concentration of stimulus to activate DUOX1 (Fig. 4.3). These data 
support previous findings and confirm that the DUOX1-DUOXA1 complex is a fully 
functional system, expressed at the plasma membrane.  
 Mature DUOX1 localization is primarily to the plasma membrane, although, there 
is no literature that has examined direct DUOX1 activation and monitored with live-cell 
fluorescence microscopy if there are changes to its spatial organization. Furthermore, since 
other NOXes (e.g. NOX1/2) which are expressed and active at the plasma membrane can 
be internalized to redox-active endosomes (e.g. redoxosomes)(Oakley et al.; Spencer and 
Engelhardt), we aimed to characterize the spatiotemporal dynamics of DUOX1-DUOXA1 
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during enzymatic activation. Initially, we observe significant colocalization of DUOX1-
DUOXA1 during ATP stimulation, although, over 20 minutes, DUOXA1 signal appears 
to deplete and dissociate from DUOX1 (Fig. 4.4; 4.5). DUOX1-DUOXA1 dissociation 
appears to follow similar kinetics as the enzymatic activity, offering potential insight to a 
novel mode of regulation, although significantly more experimentation is needed to support 
these preliminary findings.   
Evidence for nuclear DUOXA1 
 Our preliminary studies examining the DUOX1-DUOXA1 spatial dynamics 
revealed some suggestion that following ATP-dependent DUOX1-DUOXA1 dissociation, 
DUOXA1 may be traversing to the nucleus (data not shown). Due to prior reports 
supporting a role for nuclear DUOXA1(Sandiford et al.; Ostrakhovitch and Semenikhin; 
Ostrakhovitch and Li), we utilized confocal microscopy and subcellular fractionation to 
determine if this occurs in lung epithelial cells. Interestingly, following ATP stimulation, 
we observed DUOXA1 seemingly binding to regions of nuclear chromatin or perhaps 
interacting with a DNA-binding protein (Fig. 4.6A). Furthermore, preliminary results from 
subcellular fractionation western blots displaying DUOXA1 in the nucleus as well as 
precipitating in the insoluble or chromatin bound fraction (Fig. 4.6B). While these 
preliminary findings must be confirmed with follow up studies, these data are the first to 





Since our observations of DUOX1-DUOXA1 dissociation are following enzymatic 
activation of DUOX1, this is suggestive of a role for oxidation and/or modification of 
reactive cysteines, potentially promoting their uncoupling. Indeed, a recent report 
described that the interactions between DUOX2 and DUOXA2 are governed by 
intramolecular disulfides(Carre et al.), and this is likely the case with DUOX1, as DUOX1 
and DUOX2 share significant sequence homology(Little, Sulovari, et al.). While calcium-
dependent activation of DUOX1 is often associated with oxidation of downstream target 
proteins which are characterized to contain reactive cysteines that regulate their function 
(e.g. Src, PTPs, EGFR, etc), it is plausible that DUOX1 could oxidize itself or DUOXA1 
in a similar fashion, as a mode of negative regulation, potentially in a concentration 
dependent manner. In fact, there is some degree of experimental evidence for this, as our 
recent publication shows that following treatment of cells with reactive electrophiles, 
DUOX1 is subject to cysteine modification and/or alkylation/carbonylation which 
inhibited enzymatic activity(Danyal et al.), although did not address this effect on DUOX1-
DUOXA1 dynamics. Moreover, resolution of an intermolecular DUOX1-DUOXA1 
disulfide directly by H2O2 and dissociation of the enzymatic complex in this fashion is 
improbable due to unfavorable biochemical kinetics. Although, DUOX1 contains several 
extracellular cysteines that are not involved in disulfide linkages with DUOXA1 and 
therefore could be subject to oxidation by DUOX1-derived H2O2. Oxidation of 
extracellular DUOX1 cysteine residues, not involved in DUOX1-DUOXA1 intermolecular 
disulfides, to a sulfenic acid species (or other oxidized species) could promote disulfide 
exchange chemistry of these cysteines with the disulfides that link DUOX1-DUOXA1, 
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forming an intramolecular disulfide in DUOX1, permitting the separation of DUOXA1 
from DUOX1. This may be accompanied by shifts in protein conformation during calcium 
and/or NADPH binding, a feature of the calcium-binding NOX5, recently observed in the 
first report of a resolved NADPH oxidase crystal structure(Magnani et al.). Regadless, 
these speculations need significantly greater experimental evidence, although could 
provide novel insights to the potentially dynamic DUOX1-DUOXA1 relationship.  
 As mentioned previously, high levels of DUOX1-DUOXA1 expression has been 
previously observed in developing tissues and terminally differentiated epithelia(Fischer 
et al.). The intriguing links between DUOXA1, Notch, and p53, are suggestive of a role in 
differentiation and tissue development, although if dysregulated, could have significant 
impacts for cancer biology. It is plausible that DUOXA1 contributes to tumor 
differentiation as well, supporting a more well-differentiated state, and as cancers lose 
DUOX1 and DUOXA1, this checkpoint no longer exists, transitioning tumors into a 
malignant state.  Although, this does not offer an explanation as to why DUOXA1, in some 
cancers is still expressed independently of DUOX1. Dramatic loss of DUOX1 in cancer 
could promote a gain-of-function phenotype for DUOXA1, and enhanced interactions with 
the Notch signaling pathway and/or p53, could undoubtedly have impacts on cancer cell 
characteristics. Furthermore, little to nothing is known regarding the role or expression 
levels of DUOXA1 splice variants in cancer. Variants of DUOXA1 could have primary 
functions outside of DUOX1 maturation, and further experimentation is needed to fully 
understand their roles. Regardless, DUOXA1 biology remains incompletely understood, 
and new studies should aim to explore these novel dynamics and relationships as they may 




In summary, DUOX1 and DUOXA1 show a dynamic relationship following enzymatic 
activation, not previously described. While the functional relevance and mechanism(s) 
remain unknown, dissociation of DUOXA1 from DUOX1 could provide insights to novel 
protein function or a regulatory mechanism to turn off the active enzymatic complex. Our 
observations of nuclear DUOXA1 suggest a role for p53 interaction in lung epithelial cells, 
as this has been observed in other cells types. Nuclear DUOXA1 warrants further 
examination, as the biological importance is also unclear, harboring the potential to be both 
pro- or anti-tumorigenic. Collectively, this study generated unique molecular/genetic tools 
which ultimately lead to the unexpected finding of dynamic, extraneous roles of DUOXA1 
following DUOX1 activation, an observation not previously described. Coupled with the 
newly generated resources, our results offer the opportunity to explore DUOXA1 biology 
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Figure 4.1 – DUOX1-GFP and DUOXA1-RFP protein detection in dual expression 
system. Results from western blot analysis of A549 cells transfected with either empty 





Figure 4.2 -  DUOXA1 and DUOX1 signals overlap under normal growth conditions. 
DUOXA1 signal (RFP; red) and DUOX1 (GFP; green) show colocalization under non-






Figure 4.3 – Characterization of DUOX1-DUOXA1 dual expression system in A549 
cells. Treatment of A549-pDUOXA1-pDUOX1 cells with 100µM ATP generates the 
strongest H2O2 generation (A). Cells stimulated with 100µM ATP generate H2O2 over the 






Figure 4.4 – DUOX1 and DUOXA1 show signal divergence following ATP 
stimulation. Images taken from live cell confocal microscopy shows 20 minutes’ post 
100µM ATP stimulation, less colocalization of DUOX1 (green) and DUOXA1 (red) 







Figure 4.5 – Higher magnification shows DUOX1-DUOXA1 dissociation post ATP 
stimulation. Images obtained from live-cell confocal microscopy at 63X magnification 
show DUOX1 (green) and DUOXA1 (red) signal diverge following ATP stimulation. 







Figure 4.6 – DUOXA1 potentially translocates to the nucleus following ATP 
stimulation. Results from live-cell confocal microscopy show DUOXA1 (red) focal 
interactions with nuclear regions (Hoechst dye; blue) (A). Subcellular fractionation results 
show potential DUOXA1 in the nuclear and chromatin bound fractions post ATP 








CHAPTER 5: SUMMARY, PERSPECTIVES, AND FUTURE DIRECTIONS 
Characterization of DUOX1 suppression in cancer remains in its early stages of 
development. In this chapter, brief summaries of each chapter are provided, in context with 
their clinical relevance and individual future directions are proposed. Lastly, a conclusion 
to this dissertation is given, providing a global summary of DUOX1 loss and oncogenic 
outcomes.  
5.1 Chapter 2: DUOX1 Silencing and EMT 
While the role of ROS in cancer biology is still incompletely understood, and various NOX 
enzymes are variably overexpressed in cancer, common observations of DUOX1 silencing 
in many carcinomas suggest that it may represent an important prognostic marker. Indeed, 
DUOX1 expression levels has been successfully linked with positive prognosis in patients 
with hepatocellular carcinoma (S. S. Chen et al.), although it is presently unclear whether 
this is also true for other epithelial-derived cancers. However, our studies highlighting a 
direct link between DUOX1 loss and EMT, CSC characteristics and resistance of EGFR-
targeted therapy (Little, Sham, et al.) suggests that DUOX1 expression status may also be 
an important prognostic indicator in lung cancer. Furthermore, it is also currently unknown 
whether the loss of DUOX1 precedes and initiates the EMT program, or if DUOX1 
suppression occurs as a result of EMT. Regardless, our studies have defined that directly 
knocking down DUOX1 induces EMT, and overexpressing DUOX1 in A549 cells 
promotes MET, supporting the prior hypothesis. This suggests that DUOX1 potentially 
supports the epithelial phenotype, although the mechanism by which this occurs remains 
unknown. In fact, maintenance of the epithelial program could be mediated through 
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DUOX1-dependent interactions with E-cadherin or its complex of proteins that support its 
function e.g. catenins, p120. Reports from the late 1990s defined that oxidative stress was 
sufficient to promote the dissociation of E-cadherin from the catenin cell adhesion 
complex(Parrish et al.) Furthermore, β-catenin has been found to be redox regulated in 
context of Wnt signaling(S. Jiang et al.; Korswagen). Regardless, these hypotheses would 
require experimental evidence and further study.  
 The fact that some, mostly non-invasive, lung cancer cell lines retain expression 
of DUOX1 may support the notion that DUOX1 expression promotes a more differentiated 
state regarding tumor classification. In fact, this may be supported by previous work which 
demonstrated that DUOX1 is highly expressed in developing tissues as well as many 
terminally differentiated epithelial cell lineages (see section 1.6.). Loss of DUOX1 
expression in a benign tumor may be an initiating factor in the transition to a poorly 
differentiated, more malignant cancer. Indeed, our experimental findings demonstrated loss 
of DUOX1 promotes the acquisition of invasive cell characteristics, which may coincide 
with tumor malignancy. Albeit, exploration of DUOX1 status and tumor dynamics has 
been hampered by the lack of available mouse models. Therefore, future studies should 
attempt to utilize some of the newly designed genetic tools to generate DUOX1-transgenic 
mouse models.  This suggestion is in part due to our lab recently acquiring loxP-DUOX1-
loxP mice, which could be exploited in various settings to characterize DUOX1 
suppression in lung tumors, in vivo.  To enhance specificity, initially our floxed DUOX1 
mouse would require crossing with a transgenic mouse expressing Cre-recombinase on a 
lung epithelial specific promoter, club cell secretory protein (CCSP), yielding a conditional 
lung epithelial DUOX1-knockout. Following successful generation of this transgenic 
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mouse model, various strategies could be employed to study DUOX1 loss and lung cancer. 
For instance, it has been well characterized that mice conditionally expressing the 
oncogenic KRASG12D mutant develop lung tumors rapidly and consistently, which crossed 
with the floxed DUOX1 mouse could be utilized as a genetically induced model of lung 
cancer. Moreover, other modes of developing lung cancer in the floxed DUOX1 mouse 
could be utilized e.g. chemically induced; urethane, others.  
 Alternatively, approaches to conditionally overexpress DUOX1 in preformed 
tumors in animal models would be useful to further address the relevance of DUOX1 
silencing for cancer progression or responses to anticancer therapies. Since DUOX1 
suppression in cancer is primarily dictated by hypermethylation of its promoter(Luxen, 
Belinsky and Knaus; Ling et al.; Little, Sham, et al.; Wu, Mei and Brenner), attempts to 
recover DUOX1 expression would need to revolve around inhibition of DNA 
methyltransferases (DNMTs) or potentially approaches to minimize TET suppression. 
Clinical trials have been performed attempting to target DNMTs and have shown some 
efficacy(Fahy, Jeltsch and Arimondo), although specific recovery of DUOX1 by DNMT 
inhibition in a pre-clinical or clinical setting has not been explicitly examined. Additional 
insights are needed into other epigenetic modifications, such as histone acetylation or 
methylation patterns, that may regulate DUOX1 and may offer additional strategies to 
restore DUOX1 expression in the context of cancer. Moreover, since Th2 cytokines such 
as IL-4 and IL-13 can enhance DUOX1 expression and/or activity(Harper et al.; Rada et 
al.; Eskalli et al.), they could potentially be exploited as an alternative therapeutic approach 
to recover DUOX1.  
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Another important gap in this field is the lack of information regarding existing 
DUOX1 polymorphisms and lung cancer. Whereas abundant literature has connected 
DUOX2 SNPs to hypothyroidism(Donko, Morand, et al.; S. Liu et al.), and several reports 
suggest that the development of hypothyroidism is a risk factor for the onset of cancer(Park 
et al.; Mu et al.; Tseng et al.), information on DUOX1 SNPs are scarce, with only one 
report identifying two SNPs on exons 27 and 28, although no association with lung disease 
was observed(P. L. Lee et al.). Potential associations of DUOX1 SNPs with increased 
cancer incidence or progression could offer important additional insights into the overall 
importance of DUOX1 in cancer biology.  Additionally, there is very little structural 
information gleaned from crystallographic studies regarding the NOX enzymes, which has 
significantly hindered the design of antibodies, inhibitors, and/or mutagenic studies to 
understand precisely how these family of enzymes function. Just recently, a landmark 
paper in PNAS, solved the crystal structure of NOX5, the first of any of the 
NOXes(Magnani et al.). These structural insights provide information on how electrons are 
transferred from the intracellular NADPH binding domain to the extracellular oxygen, 
generating a superoxide anion. Since NOX5 is the structurally closest to the DUOXes of 
any of the other NOXes, this information could potentially be extended into the DUOXes, 
and offer the unique capacity to synthesize mutants that are incapable of producing ROS, 
or ‘redox-dead’ variants. This becomes increasingly important, as our studies defined in 
Chapter 2 demonstrate that overexpression of DUOX1, in absence of an activating stimuli, 
is sufficient to recover the epithelial phenotype in mesenchymal lung cancer cells, 
suggesting DUOX1-dependent redox processes may not be the critical factor. 
Overexpression of ‘redox-dead’ DUOX1 in various lung cancer cells that have silenced its 
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expression, will allow us to explore if DUOX1-dependent ROS production is the primary 
reason for epithelial-mesenchymal phenotypic switching.  
 
5.2 Chapter 3: DUOX1 Loss and Altered EGFR Regulation 
Dysregulated EGFR signaling has long been recognized for its role in cancer progression. 
As stated in the introduction, our prior studies defined that ATP stimulation, which 
activates DUOX1, promoted cysteine oxidation of EGFR and was found to be a critical 
regulator of many of its downstream processes including epithelial wound closure and 
innate immune responses (see section 1.2.3 and 1.7.4). Based on the closely defined 
relationship between DUOX1 and EGFR, it was intuitive to explore if DUOX1 loss in 
cancer had impacts for EGFR regulation. Indeed, our initial observations of altered EGFR 
redox status in lung cancer cells that either harbor or lack DUOX1 expression was quite 
staggering. Our studies demonstrate that lung cancer cells lacking DUOX1 have high levels 
of basal cysteine oxidation and following stimulation with the EGFR ligand, EGF, these 
cells resolved oxidation at a significantly greater rate than cells with DUOX1. Loss of 
EGFR cysteine oxidation following EGF stimulation occurred in contrast to the enhanced 
levels of EGFR autophosphorylation, indicating EGFR kinase activity remained high. 
Initially, this finding was perplexing and counterintuitive to the previously defined notion 
that oxidation of EGFR enhanced its kinetic activity(Paulsen et al.; Truong et al.; Truong 
and Carroll; Heppner et al.). These results were suggestive that EGFR oxidation may be 
participating in regulatory roles outside of kinase activation e.g. EGFR 
internalization/trafficking.  Indeed, we found that cells lacking DUOX1 had significantly 
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different EGFR internalization and subcellular trafficking behavior following EGF 
stimulation, with targeting toward the nuclear region of the cell. Indeed, our results 
demonstrate higher levels of nuclear EGFR and nuclear EGFR oncogenic features (e.g. 
enhanced migration, resistance to EGFR-blocking antibody) in DUOX1-lacking lung 
cancer cells. Lastly, RNAi-mediated knockdown of GSTP1, effectively blocking the 
resolution of oxidized EGFR cysteines, blunted levels of nuclear EGFR in A549 cells. 
These findings demonstrate that cysteine oxidation may be participating in regulatory roles 
outside of kinase activation, warranting further examination. 
Indeed, further characterization as to the role of EGFR oxidation in subcellular 
trafficking should be performed, as this may offer significant insights to EGFR regulation. 
As described in Chapter 3 section 3.5, EGFR endocytosis is performed in clathrin-
dependent (CDE) and independent fashions (CIE), with the latter in part being a calcium 
reliant process regulated by the endoplasmic reticulum(Giusi Caldieri et al.). CIE of EGFR 
is considered to primarily sort/direct EGFR for degradation, while CDE of EGFR have 
been recognized to traffic EGFR to intracellular organelles and promote its recycling back 
to the cell surface(Tan et al.; A. Tomas, C. E. Futter and E. R. Eden). DUOX1-dependent 
regulation of EGFR could be an imperative regulator of CIE and promote its degradation 
in normal epithelial cells, while in cancer cells, this regulatory mechanism is removed, 
enhancing EGFR signaling and prolonging its activity. This may be critically important in 
EGFR mutant (e.g. T790M; L858R; Ex19del; C797S) cell lines and/or tumors, all lacking 
DUOX1. Additionally, exploring EGFR redox dynamics in EGFR-mutated cell models 
may also offer unique insights to their regulation, offering potential new druggable targets. 
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Collectively, enhancing our understanding of EGFR redox regulation in cancer could offer 
novel avenues in the development of chemotherapeutics.   
DUOX1-dependent oxidation of EGFR in allergic airways disease, initiates the 
prompt release of interleukin-33 from airway epithelial cells, activating the type-2 immune 
response(Hristova et al.; Habibovic et al.). Indeed, loss of DUOX1 in cancer certainly has 
impacts for EGFR regulation, and could be critically important for immune responses in 
the tumor microenvironment. Tumor immunity research has gained significant recognition 
over the last 5 years, and there are a growing number of reports attempting to characterize 
the role of IL-33 in cancer. IL-33, a member of the IL-1 family, is known for its various 
roles in cellular immunity, although, the role of IL-33 in cancer has been somewhat 
controversial, with conflicting reports detailing both pro- and anti-tumorigenic potential(J. 
Y. Kim et al.; Liew, Girard and Turnquist; Villarreal et al.; C. Wang et al.). The argument 
for IL-33 aiding in cancer progression, lends to its ability to signal for cellular growth, 
which has been observed in several contexts such as chronic myeloid leukemia(Levescot 
et al.), myeloproliferative neoplasms(Mager et al.), and NSCLC(C. Wang et al.). While 
these reports highlight the oncogenic role of IL-33, other literature supports an opposite 
claim, that IL-33 can serve as a tumor suppressor, and its functionality could be of further 
use in cancer immunotherapies. For instance, IL-33 administration as a chemotherapy 
adjuvant enhanced anti-tumor CD4+ and CD8+ T-cell responses(Villarreal et al.). 
Additionally, IL-33 tumor infiltration has been characterized to strongly correlate with 
patient survival in HCC(Brunner et al.), and other anti-tumor responses in various forms 
of cancer(X. Gao et al.; K. Gao et al.).  These conflicting reports suggest that tumor 





Figure 5.1 – Interleukin-33 mRNA expression is suppressed in several epithelial 
cancers.  Dot blots represent mRNA expression of IL-33 extracted from either normal (N) 
healthy tissue (blue symbols), or tumor (T) tissue (red symbols). Data extracted from 
Tissue Cancer Genome Atlas (TCGA); results shown as AVG ± SEM. Statistical 
significance determined by one-way ANOVA, n.s. = not significant; ***p-value<0.001. 





Interestingly, results from data extracted from TCGA demonstrate that IL-33 
mRNA expression is suppressed in many forms of epithelial cancers (Fig. 5.1), in a similar 
fashion as DUOX1 (Fig. 1.4A). Loss of DUOX1 in epithelial derived cancers, is potentially 
a key mechanism by which transformed cells are no longer able to signal for the release of 
IL-33, together with its downregulation, removes a key mediator of tumor immune 
surveillance. This notion also may be important for cancers driven by chronic inflammation 
and/or faulty epithelial wound repair, as IL-33 is an important DAMP released from 
wounded or dead epithelial cells, to signal for type-2 immune responses(Liew, Girard and 
Turnquist). It is plausible that loss of IL-33 in this context could contribute to failed wound 
repair mechanisms coupled with chronic inflammation which are well appreciated in the 
development and progression of cancer(Coussens and Werb; Elinav et al.).  Regardless, 
due to the complex nature of tumor immunity, the proposed studies would require in vivo 
lung cancer models, genetically or chemically induced as described above. Indeed, in vivo 
IL-33 adjuvant studies could be performed in tandem with approaches to recover DUOX1 
in a lung tumor, either by administration of IL-4/13, DNMT inhibition, or both. These 
studies should attempt to characterize if DUOX1 restoration and/or IL-33 treatment impair 
tumor growth or metastatic spread. Collectively, the connection between DUOX1, EGFR, 
IL-33, and tumor biology requires a significant amount of experimental data to effectively 
text these hypothesis, although could help define and characterize another detrimental 





5.3 Chapter 4: DUOX1-DUOXA1 Dynamics 
Our observations of DUOX1 and DUOXA1 diverging following DUOX1 activation by 
ATP suggests a potentially dynamic relationship. Indeed, in normal epithelial cells this 
may be a regulatory mechanism to halt ROS production, since DUOX1-DUOXA1 
dissociation kinetics tracks with resolution of DUOX1 enzymatic activity. As mentioned 
in the discussion of Chapter 4, high levels of local ROS produced by DUOX1, could in fact 
be promoting intramolecular disulfide formation in DUOX1, releasing DUOXA1. 
Regardless, these hypotheses are based molecular modeling and predictive positioning of 
extracellular cysteines, as there is no available crystal structure for DUOX1 or DUOXA1. 
Although, studies could be performed with ‘redox-dead’ DUOX1-DUOXA1 dual 
expression systems, to address if the generation of ROS is the purpose for their 
dissociation. Alternatively, exogenous addition of H2O2 could be utilized to monitor a 
similar outcome.  
 The more surprising finding from this exploratory project, was our observations 
of nuclear DUOXA1 following ATP stimulation. The DUOXA1-RFP signal appeared to 
colocalize with the Hoechst dye, suggesting an interaction with either chromatin directly 
or indirectly through protein-protein-DNA interactions. This hypothesis was founded 
based on prior observations of DUOXA1-p53 partnerships, described in more detail in 
Chapter 4. Since DUOX1 and DUOXA1 are highly expressed in developing tissues, 
coupled to the fact that DUOXA1 was initially described to regulate the Notch signaling 
pathway, DUOXA1-dependent p53 regulation could have impacts for airway basal cell 
differentiation. Additionally, DUOXA1 could have impacts for p53-dependent regulation 
of cell proliferation in the context of cancer.  Regardless, much more experimentation is 
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needed to support these hypotheses and our initial preliminary findings. Future studies 
should first aim to explore our observations of DUOXA1-DNA interactions. This could be 
performed by chromatin immunoprecipitation (ChiP) techniques or DNA electrophoretic 
mobility shift assays (EMSA). Additionally, studies should also address whether DUOXA1 
is co-localizing and/or interacting with p53 following ATP stimulation, by confocal 
microscopy and immunoprecipitation assays. These experiments will provide initial 
information regarding DUOXA1 and nuclear interactions, potentially launching a new 
avenue of research, not previously examined in lung epithelial or cancer cells.  
Collectively, preliminary findings suggest DUOX1 and DUOXA1 show a 
dynamic partnership, with potential roles for nuclear DUOXA1. Enhancing our 
understanding of DUOX1-DUOXA1 biology, may shed light on DUOX1 regulatory 
functions, airway basal cell differentiation, and/or other extraneous roles for DUOXA1 
independent of DUOX1.  
 
5.4 Conclusions and Closing Remarks 
Loss of an ROS generating enzyme in cancer is remarkably paradoxical to the observations 
of enhanced levels of oxidants in tumorigenic environments. Suppression of DUOX1 
across many cancers is highly suggestive that DUOX1 plays a tumor suppressive role, 
supported by the fact that patients that retain DUOX1 expression in liver cancer have 
greater overall survival. Indeed, surveying of DUOX1 expression in various epithelial 
tumors may be a useful indicator of not only survival, but responsiveness to EGFR-targeted 
therapies. Our studies demonstrate that DUOX1 expression maintains the epithelial 
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phenotype in lung cells, and its suppression promotes transformation and aggressive 
cellular behavior. While our initial studies did not address mechanisms or mechanistic 
consequences of DUOX1 suppression in cancer, our latter studies uncovered that DUOX1 
suppression has profound impacts for EGFR redox regulation and spatiotemporal 
dynamics. These findings have pinned DUOX1 as a critical mediator of the epithelial 
phenotype. Furthermore, this also supports the notion that redox regulation is a tightly 
controlled, highly regulated, dynamic signaling system, which is significantly altered in 
cancerous cells. While it remains unknown whether DUOX1 loss promotes the genesis of 
cancer or if it is simply a byproduct of tumor development, it is undoubtedly a pivot point 
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